TOHOKU UNIVERSITY Researchers

Details of the Researcher

Home

日本語 English

Eisaku Miyauchi

Section

Tohoku University Hospital

Job title

Assistant Professor

Degree

博士（医学）（東北大学）

researchmap

https://researchmap.jp/emiyauchi

J-GLOBAL ID

201801006858295641

ORCID

https://orcid.org/0000-0002-6837-6392

Research History 11

2021/07 - Present

Tohoku University Hospital　Departmemt of Respiratory Medicine　Assistant Professor/ Hospital Lecture
2018/10 - 2021/06

東北大学病院　呼吸器内科　助教
2017/10 - 2018/09

University of Chicago　Department of Hematology/ Oncology　Visiting Scholar
2016/03 - 2017/09

Tohoku University Hospital　Department of Respiratory Medicine　Assistant Professor
2015/10 - 2016/03

気仙沼市立病院　呼吸器科　科長
2013/10 - 2015/09

Tohoku University　Graduate School of Medicine
2011/04 - 2013/09

Cancer Institute, Japanese Foundation for Cancer Research　Department of Pathology　Research student
2010/04 - 2011/03

Tohoku University　Graduate School of Medicine
2007/04 - 2010/03

Cancer Institute Hospital, Japanese Foundation for Cancer Research　Department of Respiratory Medicine　Resident
2006/04 - 2007/03

秋田県厚生連平鹿総合病院　後期臨床研修医
2004/04 - 2006/03

秋田県厚生連平鹿総合病院　初期臨床研修医

Show all Show first 5

Education 2

東北大学大学院　医学系研究科　呼吸器内科学分野

2010/04 - 2014/03
Yamagata University　Faculty of Medicine　School of Medicine

1998/04 - 2004/03

Committee Memberships 10

Japan Lung Cancer Society　Academic-Industrial Collaboration Subcommittee

2024/11 - Present
Japan Lung Cancer Society　Japan Lung Cancer Society, Committee Member of Biomarker Committee

2024/11 - Present
Japan Lung Cancer Society　Japan Lung Cancer Society, International Committee Member

2024/11 - Present
日本呼吸器内視鏡学会　評議員

2023 - Present
Global Oncology Trials Japan　member

2021/12 - Present
宮城県生活習慣病検診管理指導協議会　肺癌部会委員

2019/01 - Present
リレー・フォー・ライフ・ジャパンみやぎ実行委員会　実行委員

2018/12 - Present
特定非営利活動法人North East Japan Study Group（NEJSG）　正会員、臨床判断部会委員

2017/04 - Present
北日本肺癌臨床研究会　運営委員、事務局

2017 - Present
日本肺癌学会　ガイドライン検討委員会薬物療法及び集学的治療小委員会委員

2018/12 - 2024/11

Show all ︎Show first 5

Professional Memberships 10

ESMO
THE JAPAN SOCIETY FOR RESPIRATORY ENDOSCOPY
International Association for the Study of Lung Cancer（IASLC）
American society of clinical oncology (ASCO)
日本臨床細胞学会
THE JAPANESE CANCER ASSOCIATION
THE JAPAN LUNG CANCER SOCIETY
日本臨床腫瘍学会
THE JAPANESE RESPIRATORY SOCIETY
THE JAPANESE SOCIETY OF INTERNAL MEDICINE

︎Show all ︎Show first 5

Research Interests 8

EGFR
Liquid biopsy
Cytology
Chemotherapy
Immunotherapy
Clinical Trials
Lung Cancer
Thoracic Oncology

Research Areas 2

Life sciences / Tumor diagnostics and therapeutics /
Life sciences / Respiratory medicine /

Awards 3

Best Presentation Award

2023/03
若手リーダー研究者海外派遣プログラム

2017　東北大学
マイ・オンコロジー・ドリーム奨励賞

2017　公益財団法人日本対がん協会

Papers 108

Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors. International-journal

J Nicholas Bodor, Jonathan Dowell, Joseph Treat, Janakiraman Subramanian, Nihal Abdulla, Eric Lee, Kamlesh Sankhala, Chun-Hui Lee, Go Makimoto, Eisaku Miyauchi, Kartik Konduri, Hajime Asahina, Shuji Murakami, Yueh-Feng Wen, Yung-Hung Luo, Shan Yueh Chang, Reginald Ewesuedo, Jianli Zhou, Yasushi Goto

Clinical lung cancer　2025/05/28

DOI： 10.1016/j.cllc.2025.05.013 　

More details Close

INTRODUCTION: Most patients with non-small cell lung cancer (NSCLC) who have never smoked possess tumors bearing tyrosine kinase oncogenes. While such tumors may exhibit robust responses to front-line tyrosine inhibitors (TKIs), disease progression is inevitable. Subsequent available therapies confer limited benefit, thus developing effective treatments for these patients remains a critical need. LP-300 is a novel compound that enhances chemotherapy sensitivity and inhibits the activity of tyrosine kinase oncogenes. Retrospective subset analyses of prior phase III studies found females and never-smokers, groups likely to have oncogene-driven tumors, obtained a considerable survival advantage with LP-300 combined with platinum-based chemotherapy as compared to chemotherapy alone. Prospective validation of these findings in patients with oncogene-driven NSCLC is needed. METHODS: The HARMONIC clinical trial, which is currently in progress, is a global, randomized, phase II study (NCT05456256) evaluating the 3-drug regimen of LP-300 with pemetrexed and carboplatin versus pemetrexed and carboplatin alone in 90 patients with advanced primary lung adenocarcinoma bearing tyrosine kinase oncogenes. Patient randomization is stratified by gender and favors the LP-300 containing arm (2-1). Patients must have tumors bearing tyrosine kinase actionable alterations (i.e. EGFR, ALK, ROS1, MET, RET, BRAF, or NTRK) and have prior TKI progression or intolerance. Primary endpoints are progression-free survival (PFS) and overall survival (OS). Secondary endpoints include objective response rate, duration of objective response, clinical benefit rate, and incidence of adverse events. CONCLUSION: This phase II trial is accruing patients at sites in the U.S, Japan, and Taiwan. Patient accrual is expected to be completed in the Fall of 2026.
Durvalumab after concurrent chemoradiotherapy for sensitizing epidermal growth factor receptor-mutant stage III non-small cell lung cancer: A Japanese Real-World data analysis. International-journal

Toshiya Fujisaki, Eisaku Miyauchi, Gen Kida, Yu Miura, Kana Watanabe, Hironori Ashinuma, Motohiro Tamiya, Hajime Kikuchi, Daisuke Arai, Satoshi Takahashi, Ken Masuda, Ayako Takigami, Yoshiaki Nagai, Taichi Miyawaki, Yukari Tsubata, Akira Nakao, Ken Masubuchi, Kazuhiro Nishiyama, Satoshi Watanabe, Satoshi Morita, Makoto Maemondo

Lung cancer (Amsterdam, Netherlands)　205　108597-108597　2025/05/27

DOI： 10.1016/j.lungcan.2025.108597 　

More details Close

INTRODUCTION: In locally advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), the efficacy and safety of durvalumab after concurrent chemoradiotherapy (CCRT) remain controversial. METHODS: In this retrospective cohort study, we analyzed treatment outcomes in patients with unresectable stage III sensitizing EGFR-mutant NSCLC who underwent and completed CCRT without progression between July 2015 and June 2022 from 48 institutions in Japan. Patients with confirmed EGFR mutations after recurrence were excluded. Comparisons between groups were conducted using a cohort extracted through propensity score matching (PSM). The primary outcome was progression-free survival (PFS). The secondary outcomes were overall survival (OS) and safety of EGFR-tyrosine kinase inhibitor (TKIs) after durvalumab treatment. RESULTS: Out of 162 eligible patients, 106 received consolidation durvalumab following CCRT and 56 did not. After PSM, 56 patients were matched to the durvalumab and CCRT alone groups. The median PFS was significantly longer in patients treated with durvalumab than in those treated with CCRT alone (26.8 months [95 % confidence interval [CI], 13.9-NA] vs. 11.1 months [95 % CI, 9.0-18.2]; hazard ratio [HR], 0.52 [95 % CI, 0.33-0.83]; p = 0.005). While early osimertinib administration following durvalumab tended to increase Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 3 pneumonitis, there was no significant difference in the frequency of CTCAE grade ≥ 3 adverse events with EGFR-TKIs between the groups (23.5 % vs. 20.8 %). CONCLUSIONS: Durvalumab administration following CCRT prolongs PFS in patients with locally advanced EGFR-mutant NSCLC. Durvalumab can be safely administered if the timing of subsequent osimertinib is carefully managed.
Phase 2 Trial of Combination Radiotherapy and Pembrolizumab Plus Chemotherapy in Patients With Previously Untreated Metastatic NSCLC: NJLCG 1902. International-journal

Yoko Tsukita, Rei Umezawa, Taku Nakagawa, Akira Anbai, Tomonori Makiguchi, Hisashi Tanaka, Yosuke Horii, Aya Suzuki, Ryo Morita, Hitomi Nogawa, Hiroshi Yokouchi, Nozomu Kimura, Keiichi Jingu, Akira Inoue, Hisatoshi Sugiura, Eisaku Miyauchi

JTO clinical and research reports　6　(5)　100817-100817　2025/05

DOI： 10.1016/j.jtocrr.2025.100817 　

More details Close

INTRODUCTION: Treatment strategies that enhance the efficacy of immunotherapy are desired. Radiotherapy can enhance immunity, but the utility of adding radiotherapy to immunotherapy plus platinum-doubled chemotherapy in patients with metastatic NSCLC has not been explored. METHODS: This multicenter, single-arm phase 2 trial evaluated the efficacy and safety of combining radiotherapy with pembrolizumab plus chemotherapy in patients with previously untreated metastatic NSCLC. Patients begin receiving pembrolizumab plus platinum-doublet chemotherapy within 1 week of starting radiotherapy (30 Gy in 10 fractions). The primary end point was the 12-month progression-free survival (PFS) rate. The secondary end points included PFS, overall survival, and toxicity profiles. RESULTS: Forty patients were enrolled. In total, 37 and 38 patients were analyzed for efficacy and safety, respectively. The 12-month PFS rate was 44.3% (90% confidence interval [CI]: 30.3-57.3), which met the primary end point. The median PFS was 8.4 months (95% CI: 5.7-22.2), and the median overall survival was 30.1 months (95% CI: 22.3-not reached). Grade 3 or 4 adverse events occurred in 25 patients (65.8%), and one treatment-related death was reported. Pneumonitis was reported in 10 patients (26.3%), including two cases of grade 3 pneumonitis and one case of grade 5. CONCLUSIONS: Adding radiotherapy to pembrolizumab plus platinum-doublet chemotherapy led to promising efficacy in patients with previously untreated metastatic NSCLC. Although caution should be exercised with regard to pneumonitis, adverse events were tolerable. Further research is needed to confirm the efficacy and safety of this strategy.
Regional Differences in the Frequency of BRCA1 and BRCA2 Variants in Northeastern Japan: A Cohort Study. International-journal

Hidekazu Shirota, Akimitsu Miyake, Maako Kawamura, Shuhei Suzuki, Kensuke Saito, Jun Yasuda, Hiroyuki Shibata, Motonobu Saito, Takeshi Iwaya, Hiroshi Tada, Muneaki Shimada, Naoki Kawamorita, Masayuki Kanamori, Eisaku Miyauchi, Hidetaka Niizuma, Tomoyuki Iwasaki, Yuki Kasahara, Hiroo Imai, Ken Saijo, Keigo Komine, Masanobu Takahashi, Tetsuya Niihori, Yoko Aoki, Toru Furukawa, Gen Tamiya, Chikashi Ishioka

Cancer medicine　14　(8)　e70443　2025/04

DOI： 10.1002/cam4.70443 　

More details Close

BACKGROUND: Germline mutations in BRCA1/2 are known to cause hereditary tumors in the breast, ovary, and other organs. With the widespread adoption of comprehensive diagnostics, including comprehensive genomic profiling (CGP) tests for solid tumors, many patients with BRCA1/2 variants have been identified. METHODS: In this study, we extracted and analyzed cases of BRCA1/2 variants that were presumed to be germline, which were repeatedly detected using the CGP test for solid tumors in northeastern Japan. The frequencies of BRCA1/2 variants in regional areas were compared with those of healthy individuals or nationwide cancer cohorts to investigate regional distribution. RESULTS: Our findings revealed regional disparities in BRCA1/2 pathogenic germline variants, while variants of unknown significance (VUS) showed no such differences. The regional distribution of BRCA1 and BRCA2 variants showed distinct patterns: pathogenic variants of BRCA1 exhibited regional differences and were less prevalent compared to VUS, whereas BRCA2 variants, including both pathogenic variants and VUS, did not exhibit such clear regional localization. This discrepancy in regional distribution between BRCA1 and BRCA2 variants could be attributed to factors such as the diversity of the genome, gender differences, and cancer types. CONCLUSIONS: These results highlight the importance of considering regional differences in comparative cohort studies, particularly in assessing the differential extension of mutations in pathogenic changes and VUS. Moreover, a presumption of pathogenicity variants would need to be discussed at the regional level.
J-TAIL-2: A Prospective, Observational Study of Atezolizumab Combined With Carboplatin and Etoposide in Patients With Extensive-Stage SCLC in Japan. International-journal

Eisaku Miyauchi, Makoto Nishio, Kadoaki Ohashi, Atsushi Osoegawa, Eiki Kikuchi, Hideharu Kimura, Yasushi Goto, Junichi Shimizu, Hiroshige Yoshioka, Ichiro Yoshino, Toshihiro Misumi, Nobuyuki Katakami, Masahide Oki, Takashi Kijima, Kenichi Chikamori, Kazumi Nishino, Yuki Kobayashi, Asako Miwa, Misa Tanaka, Akihiko Gemma

JTO clinical and research reports　6　(3)　100783-100783　2025/03

DOI： 10.1016/j.jtocrr.2024.100783 　

More details Close

INTRODUCTION: On the basis of the IMpower133 trial, atezolizumab plus carboplatin and etoposide (CE) is approved as first-line treatment for extensive-stage (ES)-SCLC. The J-TAIL-2 study evaluated atezolizumab plus CE in routine clinical practice settings. METHODS: J-TAIL-2 was a prospective, multicenter observational study in Japan. Patients with ES-SCLC received atezolizumab plus CE in clinical practice. The primary end point was 12-month OS rate. Secondary end points included overall survival (OS), progression-free survival (PFS), and safety in select subgroups, including the IMpower133-unlike (i.e., Eastern Cooperative Oncology Group performance status 2 or more, interstitial lung disease, autoimmune disease) versus IMpower133-like groups. RESULTS: Overall, 403 patients were included; the median age was 71 years, 16.6% (n = 67) had an Eastern Cooperative Oncology Group performance status 2 or more, 26.8% (n = 108) had brain metastasis, 6.9% (n = 28) had interstitial lung disease, 4.0% (n = 16) had autoimmune disease, and 72.7% (n = 293) were IMpower133-unlike. In the efficacy population (n = 399), the 12-month OS rate was 63.7%, median OS was 16.5 months, and median PFS was 5.1 months. In IMpower133-unlike versus IMpower133-like subgroups, the 12-month OS rate was 58.5% versus 77.5%, median OS was 15.5 versus 19.1 months (hazard ratio, 1.32; 95% confidence interval: 0.98-1.77), and median PFS was 4.8 versus 5.4 months (hazard ratio, 1.14; 95% confidence interval: 0.90-1.45). No new safety signals were observed (safety population, n = 400); safety outcomes in the IMpower133-unlike and IMpower133-like subgroups were similar. CONCLUSIONS: In J-TAIL-2, atezolizumab plus CE had efficacy in patients with ES-SCLC in clinical practice that was consistent with that in IMpower133. Taken together with the acceptable safety profile, these data support the use of atezolizumab plus CE in patients with ES-SCLC in Japan, including those who would have been ineligible for IMpower133.
Skin disorder within 30 days is a favorable prognostic factor in patients with lung squamous cell carcinoma treated with necitumumab plus gemcitabine and cisplatin: a sub-analysis of the NINJA study. International-journal

Fumihiko Kinoshita, Shigeru Tanzawa, Toshihiro Misumi, Hiroshige Yoshioka, Eisaku Miyauchi, Kiichiro Ninomiya, Yasunori Murata, Masafumi Takeshita, Masafumi Yamaguchi, Shunichi Sugawara, Yosuke Kawashima, Kazuki Hashimoto, Masahide Mori, Akihiko Miyanaga, Anna Hayashi, Hisashi Tanaka, Ryoichi Honda, Masafumi Nojiri, Yuki Sato, Ken Yamamoto, Ken Masuda, Toshiyuki Kozuki, Takahisa Kawamura, Takuji Suzuki, Teppei Yamaguchi, Kazuhiro Asada, Satoshi Tetsumoto, Hiroshi Tanaka, Satoshi Watanabe, Yukihiro Umeda, Kakuhiro Yamaguchi, Shoichi Kuyama, Kosuke Tsuruno, Yuki Misumi, Hiroshi Kuraishi, Ken Yoshihara, Akira Nakao, Akihito Kubo, Toshihiko Yokoyama, Kana Watanabe, Nobuhiko Seki

Therapeutic advances in medical oncology　17　17588359241312503-17588359241312503　2025

DOI： 10.1177/17588359241312503 　

More details Close

BACKGROUND: Skin disorders are major adverse events associated with necitumumab plus gemcitabine and cisplatin (Neci + GC) administration. However, the prognostic effect of skin disorders in patients with lung squamous cell carcinoma (LSCC) administered Neci + GC is unclear. OBJECTIVES: We examined this prognostic effect in patients with LSCC, and the usefulness of minocycline administration. DESIGN: This was a sub-analysis of the retrospective multicenter NINJA study. METHODS: We performed a landmark survival analysis according to the presence of skin disorders at Day 30 of treatment and examined the usefulness of minocycline for treating skin disorders. RESULTS: Among the 93 patients, 62 (66.7%) had a skin disorder at Day 30. Nineteen, 30, and 13 patients experienced Grade 1, 2, and 3 skin disorders, respectively. The overall survival (OS) and progression-free survival (PFS) of patients with skin disorders at Day 30 were longer than those of patients without skin disorders (median OS: 434 vs 278 days, p = 0.0201; median PFS: 148 vs 82 days, p = 0.0835). Multivariable analysis showed that a skin disorder at Day 30 was an independent prognostic factor for both OS (p = 0.0044) and PFS (p = 0.0514). Of the 62 patients with skin disorders at Day 30, 38 (61.3%) were taking minocycline, and their time to treatment failure (TTF) was better than that in patients not taking minocycline (median TTF: 148 vs 101 days, p = 0.0495). CONCLUSION: A skin disorder within 30 days was a favorable prognostic factor for patients with LSCC administered Neci + GC. Additionally, minocycline administration may be beneficial in patients who develop skin disorders within 30 days.
Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA study. International-journal

Shigeru Tanzawa, Hiroshige Yoshioka, Toshihiro Misumi, Eisaku Miyauchi, Kiichiro Ninomiya, Yasunori Murata, Masafumi Takeshita, Fumihiko Kinoshita, Takatoshi Fujishita, Shunichi Sugawara, Yosuke Kawashima, Kazuki Hashimoto, Masahide Mori, Akihiko Miyanaga, Anna Hayashi, Hisashi Tanaka, Ryoichi Honda, Masafumi Nojiri, Yuki Sato, Akito Hata, Nobuhisa Ishikawa, Toshiyuki Kozuki, Takahisa Kawamura, Go Saito, Teppei Yamaguchi, Kazuhiro Asada, Satoshi Tetsumoto, Hiroshi Tanaka, Satoshi Watanabe, Yukihiro Umeda, Kakuhiro Yamaguchi, Kazuya Nishii, Kosuke Tsuruno, Yuki Misumi, Hiroshi Kuraishi, Ken Yoshihara, Akira Nakao, Akihito Kubo, Toshihiko Yokoyama, Kana Watanabe, Nobuhiko Seki

Therapeutic advances in medical oncology　17　17588359251318850-17588359251318850　2025

DOI： 10.1177/17588359251318850 　

More details Close

BACKGROUND: The clinical impact of hypomagnesemia induced by necitumumab plus gemcitabine and cisplatin (GCN) as a second-line or later therapy is unclear. OBJECTIVE: We aimed to evaluate the clinical characteristics and survival impact of hypomagnesemia induced by this therapy. DESIGN: This was a sub-analysis of the retrospective multicenter NINJA study. METHODS: Among the 93 patients enrolled in the NINJA study, this subanalysis included 75 patients with baseline serum magnesium concentrations. RESULTS: The incidence of grade ⩾2 hypomagnesemia was 18.0% in the patients with normal baseline serum magnesium concentrations and 42.8% in those with low concentrations (p = 0.073). The discontinuation rates of GCN treatment owing to hypomagnesemia in each group were 0% and 7.1%, respectively (p = 0.187). The number of necitumumab doses and severity of hypomagnesemia were positively correlated (r = 0.389, p < 0.001). Patients who developed hypomagnesemia in fewer than 21 days after the first dose of GCN (n = 12) had significantly poorer progression-free survival (PFS) than those without the condition (n = 63; median: 4.1 vs 4.4 months, p = 0.048). A similar trend was observed for OS (median: 9.7 vs 15.7 months, p = 0.062). These results were maintained after multivariate analyses (PFS: hazard ratio (HR) 2.46, p = 0.014; OS: HR 2.78, p = 0.021). CONCLUSION: GCN as a second-line or later therapy may be tolerable regardless of the patient's baseline serum magnesium concentration. On the other hand, early serum magnesium reduction with this therapy is associated with a poor prognosis. However, caution should be needed because our results lacked sufficient information for confounding variables other than those analyzed here that may influence the correlation between hypomagnesemia and survival.
Identification of key gene signatures for predicting chemo-immunotherapy efficacy in extensive-stage small-cell lung cancer using machine learning. International-journal

Daichi Fujimoto, Ryota Shibaki, Keiichi Kimura, Koji Haratani, Motohiro Tamiya, Takashi Kijima, Yuki Sato, Akito Hata, Toshihide Yokoyama, Yoshihiko Taniguchi, Junji Uchida, Hisashi Tanaka, Naoki Furuya, Satoru Miura, Mihoko Imaji Onishi, Shinya Sakata, Eisaku Miyauchi, Nobuyuki Yamamoto, Yasuhiro Koh, Hiroaki Akamatsu

Lung cancer (Amsterdam, Netherlands)　199　108079-108079　2025/01

DOI： 10.1016/j.lungcan.2024.108079 　

More details Close

OBJECTIVES: The lack of definitive biomarkers presents a significant challenge for chemo-immunotherapy in extensive-stage small-cell lung cancer (ES-SCLC). We aimed to identify key genes associated with chemo-immunotherapy efficacy in ES-SCLC through comprehensive gene expression analysis using machine learning (ML). METHODS: A prospective multicenter cohort of patients with ES-SCLC who received first-line chemo-immunotherapy was analyzed. RNA sequencing was performed on tumor samples to assess gene expression levels. ML techniques were applied to identify key gene features associated with treatment efficacy. A panel of genes was then developed and validated using the nCounter system, and the model's performance in predicting 180-day progression-free survival (PFS) was evaluated. RESULTS: A total of 93 patients were included in the analysis. ML-based gene selection identified a gene set comprising 83 genes from the comprehensive gene expression data. An nCounter panel was developed using these genes, and an ML model was developed based on their expression levels. In the validation set, the model achieved an accuracy of 0.93, precision of 1.00, a true positive rate of 0.83, and a true negative rate of 1.00. PFS was significantly longer in the high-efficacy group than in the low-efficacy group in the validation set (P < 0.001). CONCLUSIONS: These findings provide a foundation for biomarker development in ES-SCLC and highlight the potential of this method as a cost-effective, simple, and rapid tool for assessing treatment efficacy in clinical practice.
Histological and genetic features and therapeutic responses of lung cancers explored via the global analysis of their metabolome profile International-journal

Daisuke Narita, Eiji Hishinuma, Risa Ebina-Shibuya, Eisaku Miyauchi, Naomi Matsukawa, Ikuko N. Motoike, Kengo Kinoshita, Seizo Koshiba, Yoko Tsukita, Hirotsugu Notsuda, Nozomu Kimura, Ryota Saito, Hisatoshi Sugiura

Lung Cancer　200　108082-108082　2025/01
Publisher: Elsevier BV
DOI： 10.1016/j.lungcan.2025.108082 　

ISSN： 0169-5002

More details Close

BACKGROUND: Lung cancer is the deadliest disease globally, with more than 120,000 diagnosed cases and more than 75,000 deaths annually in Japan. Several treatment options for advanced lung cancer are available, and the discovery of biomarkers will be useful for personalized medicine. Using metabolome analysis, we aimed to identify biomarkers for diagnosis and treatment response by examining the changes in metabolites associated with lung cancer progression. METHODS: Plasma samples from patients with recurrent or metastatic non-small cell lung carcinomas diagnosed at Tohoku University Hospital between 2019 and 2024 were used in this study. Metabolomic analysis was performed using the Biocrates Life Sciences MxP Quant 500 kit. Multivariate, principal component, and orthogonal partial least squares discriminant analyses were performed. RESULTS: The triglyceride and phosphatidylcholine concentrations were higher in the patients with early than in those with advanced lung adenocarcinomas. However, the cholesterol ester concentrations were higher for the patients with advanced lung cancer. The concentrations of hexosylceramide were higher in patients with early lung adenocarcinoma than in those with squamous cell carcinoma. Relative to epidermal growth factor receptor (EGFR)-mutation negative cases, the EGFR-mutation positive cases showed marked differences between the ceramide and triglyceride concentrations. For the best therapeutic effect of EGFR-TKI treatment, the hexosylceramide (HexCer) (d18:1/24:0), ceramide (Cer) (d18:2/22:0), and ceramide (Cer) (d18:2/24:0) concentrations were higher for the stable and progressive disease groups. The concentrations of phosphatidylcholine (PC) ae C42:2, sphingomyelin (SM) C24:1, and lysophosphatidylcholine (lysoPC) a C18:2 were higher in the partial response group treated with immune checkpoint inhibitors and chemotherapy. CONCLUSION: Metabolomic analysis may be useful for the diagnosis and treatment of lung cancer and may provide clues for new therapeutic strategies. PC ae C42:2, SM C24:1, and lysoPC a C18:2 can serve as predictive biomarkers for monitoring the therapeutic effects of the combination of immune checkpoint inhibitors and chemotherapy.
Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study. International-journal

Jun Sugisaka, Daichi Fujimoto, Motohiro Tamiya, Akito Hata, Hirotaka Matsumoto, Toshihide Yokoyama, Yoshihiko Taniguchi, Junji Uchida, Yuki Sato, Takashi Kijima, Hisashi Tanaka, Naoki Furuya, Takeshi Masuda, Yoshihiko Sakata, Eisaku Miyauchi, Go Saito, Satoru Miura, Teppei Yamaguchi, Haruko Daga, Shinya Sakata, Nobuyuki Yamamoto, Hiroaki Akamatsu

Lung cancer (Amsterdam, Netherlands)　199　108056-108056　2024/12/09

DOI： 10.1016/j.lungcan.2024.108056 　

More details Close

BACKGROUND: Chemoimmunotherapy is the standard first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC); however, its real-world long-term outcomes associated with patient backgrounds are still unclear. We explored this association using an updated large real-world prospective cohort with a minimum follow-up of 3 years. METHODS: This prospective cohort study, conducted across 32 hospitals, enrolled patients with ES-SCLC receiving carboplatin, etoposide, and atezolizumab between September 1, 2019 and September 30, 2020. Updated data with a minimum 3-year follow-up period were analyzed. Patients who met eligibility criteria for pivotal phase 3 clinical trials were considered "trial-eligible." RESULTS: The median (range) time from the treatment initiation to data cutoff (September 30, 2023) was 42.2 (35.8-48.2) months for the enrolled 207 patients. Most patients (89 %) had an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients fulfilling the inclusion criteria (132 [64 %]) were categorized as trial-eligible. The 3-year progression-free survival (PFS) probability and overall survival (OS) were 6.1 % and 20.9 %, respectively. The 3-year OS probabilities for trial-eligible and trial-ineligible patients were 26.7 and 9.5 %, respectively. The trial-eligible cohort had a larger percentage of patients achieving a 3-year OS (30/132, 22.7 %) than the trial-ineligible cohort (5/75, 6.7 %) (P = 0.003) CONCLUSIONS: Our study provides the first documentation of the long-term outcomes following chemoimmunotherapy in a large prospective real-world cohort of patients with ES-SCLC. Key eligibility criteria significantly influenced the long-term effectiveness. These findings provide valuable insights into the practical effectiveness of chemoimmunotherapy and clinical decision-making for patients with ES-SCLC.
Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer. International-journal

Takaaki Fujimura, Koh Furugaki, Hayato Mizuta, Satoshi Muraoka, Makoto Nishio, Jun Adachi, Ken Uchibori, Eisaku Miyauchi, Hidetoshi Hayashi, Ryohei Katayama, Shigeki Yoshiura

NPJ precision oncology　8　(1)　264-264　2024/11/17

DOI： 10.1038/s41698-024-00757-w 　

More details Close

Targeting the drug tolerant persister (DTP) state in cancer cells should prevent further development of resistance mechanisms. This study explored combination therapies to inhibit alectinib-induced DTP cell formation from anaplastic lymphoma kinase-positive non-small cell lung cancer (ALK + NSCLC) patient-derived cells. After drug-screening 3114 compounds, pan-HER inhibitors (ErbB pathway) and tankyrase1/2 inhibitors (Wnt/β-catenin signaling) emerged as top candidates to inhibit alectinib-induced DTP cells growth. We confirmed knockdown of both TNKS1/2 in DTP cells recovered the sensitivity to alectinib. Further, our study suggested knockdown of TNKS1/2 increased stability of Axin1/2, which induced β-catenin degradation and decreased its nuclear translocation, thereby suppressing transcription of antiapoptotic and proliferation-related genes (survivin, c-MYC). Targeting both pathways with alectinib+pan-HER inhibitor and alectinib+TNKS1/2 inhibitor suppressed alectinib-induced DTP cells, and the triple combination almost completely prevented the appearance of DTP cells. In conclusion, combination with ALK-TKI, pan-HER and TNKS1/2 inhibitors has the potential to prevent the emergence of DTP in ALK + NSCLC.
Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01. International-journal

Hisashi Tanaka, Tomonori Makiguchi, Takehiro Tozuka, Yosuke Kawashima, Tomohiro Oba, Ryosuke Tsugitomi, Junji Koyama, Yuichi Tambo, Shinsuke Ogusu, Masafumi Saiki, Hiroshi Gyotoku, Tsukasa Hasegawa, Eisaku Miyauchi, Tomoaki Sonoda, Ryota Saito, Katsumi Nakatomi, Toshio Sakatani, Keita Kudo, Yuko Tsuchiya-Kawano, Makoto Nishio

European journal of cancer (Oxford, England : 1990)　213　115117-115117　2024/11/05

DOI： 10.1016/j.ejca.2024.115117 　

More details Close

INTRODUCTION: Immune checkpoint inhibitors (ICIs) plus chemotherapy is now a standard treatment for non-small cell lung cancer (NSCLC). Whether ICI plus chemotherapy (ICI-chemo) or ipilimumab plus nivolumab (I-N)-based therapy is superior for patients with NSCLC with a programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) of 1-49 % has not been evaluated. METHODS: This multicenter retrospective study included NSCLC patients with a TPS score of 1-49 %, who began first-line chemotherapy. Propensity score matching analysis was used to adjust for various confounders and evaluate treatment efficacy. RESULTS: A total of 401 patients were enrolled, of whom 308 received ICI-chemo and 93 received I-N-based therapy. The median OS was 21.0 months in the ICI-chemo group and 20.0 months in the I-N-based therapy group. After propensity score matching, there was no difference in OS or PFS between the ICI-chemo group and the I-N-based therapy group (OS: hazard ratios (HR), 0.83; 95 % confidence interval [CI], 0.54-1.26, PFS: HR, 0.72; 95 % CI, 0.52-1.00). Among PD-L1 TPS 25-49 %, there was a tendency for OS to be favorable for the ICI-chemo group (OS: HR, 0.30; 95 % CI, 0.09-0.85). Treatment discontinuation occurred for 26.2 % of the patients in the ICI-chemo group and 41.9 % in the I-N-based therapy group. CONCLUSIONS: Among PD-L1 TPS 1-49 %, there was no significant difference in survival outcomes between the ICI-chemo group and the I-N-based therapy group. Based on the results of a subgroup analysis, ICI-chemo may be superior for treating NSCLC with a TPS of 25-49 %.
Combined blockade of GPX4 and activated EGFR/HER3 bypass pathways inhibits the development of ALK-inhibitor-induced tolerant persister cells in ALK-fusion-positive lung cancer. International-journal

Koh Furugaki, Takaaki Fujimura, Narumi Sakaguchi, Yasutaka Watanabe, Ken Uchibori, Eisaku Miyauchi, Hidetoshi Hayashi, Ryohei Katayama, Shigeki Yoshiura

Molecular oncology　2024/10/06

DOI： 10.1002/1878-0261.13746 　

More details Close

Cancers can develop resistance to treatment with ALK tyrosine kinase inhibitors (ALK-TKIs) via emergence of a subpopulation of drug-tolerant persister (DTP) cells that can survive initial drug treatment long enough to acquire genetic aberrations. DTP cells are thus a potential therapeutic target. We generated alectinib-induced DTP cells from a patient-derived ALK+ non-small-cell lung cancer (NSCLC) cell line and screened 3114 agents in the anticancer compounds library (TargetMol). We identified phospholipid hydroperoxide glutathione peroxidase GPX4 as being involved in promoting the survival of DTP cells. GPX4 was found to be upregulated in DTP cells and to promote cell survival by suppressing reactive oxygen species (ROS) accumulation; GPX4 inhibitors blocked this upregulation and facilitated ROS-mediated cell death. Activated bypass signals involving epidermal growth factor receptor (EGFR)/receptor tyrosine-protein kinase erbB-3 (HER3) were also identified in DTP cells, and co-treatment with EGFR-TKI plus ALK-TKI enhanced ROS levels. Triple combination with an ALK-TKI plus a bypass pathway inhibitor plus a GPX4 inhibitor suppressed cell growth and induced intracellular ROS accumulation more greatly than did treatment with each agent alone. The combined inhibition of ALK plus inhibition of activated bypass signals plus inhibition of GPX4 may be a potent therapeutic strategy for patients with ALK+ NSCLC to prevent the development of resistance to ALK-TKIs and lead to tumor eradication.
進展型小細胞肺癌患者に対するカルボプラチン/エトポシド/アテゾリズマブの多施設前向き研究 3年update

松本啓孝, 藤本大智, 横山俊秀, 谷口善彦, 内田純二, 佐藤悠城, 田中寿志, 古屋直樹, 益田武, 坂田能彦, 宮内栄作, 山口哲平, 駄賀晴子, 池田英樹, 坂田晋也, 山本信之, 赤松弘朗

肺癌　64　(5)　504-504　2024/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
PD-L1 TPS1-49%における化学療法+ICI,ipilimumab+nivolumab±化学療法の比較検討 TOPGAN2023-01

大場智広, 田中寿志, 牧口友紀, 戸塚猛大, 川嶋庸介, 次富亮輔, 神山潤二, 丹保裕一, 小楠真典, 齊木雅史, 行徳宏, 長谷川司, 宮内栄作, 園田智明, 齋藤良太, 中富克己, 酒谷俊雄, 工藤慶太, 土屋裕子, 西尾誠人

肺癌　64　(5)　495-495　2024/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
進行非小細胞肺癌患者に対するイピリムマブ+ニボルマブ療法と放射線照射の第2相試験(NEJ053B)

宮内栄作, 田中寿志, 中川拓, 坂田能彦, 守田亮, 柳澤悟, 松本啓孝, 齋藤良太, 田中智, 角俊行, 突田容子, 前門戸任

肺癌　64　(5)　612-612　2024/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
Impact of Cachexia and First-Line Systemic Therapy for Previously Untreated Advanced Non-Small Cell Lung Cancer: NEJ050A. International-journal

Keita Miura, Takehito Shukuya, Naoki Furuya, Ryo Morita, Akira Kisohara, Atsuto Mouri, Satoshi Watanabe, Hisashi Tanaka, Aya Hirata, Taiki Hakozaki, Kosuke Hamai, Naoko Matsumoto, Kana Watanabe, Hironori Ashinuma, Eisaku Miyauchi, Koji Sugano, Shinobu Hosokawa, Koji Amano, Satoshi Morita, Kunihiko Kobayashi, Makoto Maemonodo, Kazuhisa Takahashi

Journal of cachexia, sarcopenia and muscle　2024/10/01

DOI： 10.1002/jcsm.13606 　

More details Close

BACKGROUND: Cancer cachexia complicates advanced non-small cell lung cancer (NSCLC); however, it remains unclear how often cachexia occurs and how it affects the course of chemotherapy in patients receiving first-line systemic therapy. METHODS: We conducted a multicentre, prospective observational study and enrolled previously untreated NSCLC patients with Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-2 and cachexia between September 2020 and September 2021. The primary outcome measure was the trends in the Functional Assessment of Anorexia/Cachexia Treatment and Anorexia/Cachexia Subscale [FAACT (A/CS)] scores by cohort. Secondary outcome measures included the incidence of cachexia before the initiation of first-line systemic therapy, quality of life (QOL) measures, body weight (BW) changes, and efficacy and safety of first-line systemic therapy. RESULTS: A total of 887 consecutive patients with previously untreated advanced NSCLC and ECOG PS of 0-2 who were initiated on first-line systemic therapy were evaluated. A total of 281 patients (31.7%) experienced BW loss consistent with the criteria of cachexia, and 186 were evaluated for QOL, BW and outcome measurements. Overall, 180/186 patients received first-line systemic therapy. Cohort 1 (targeted therapy), cohort 2 [cytotoxic chemotherapy (CTx) ± immune checkpoint inhibitors (ICIs)] and cohort 3 (ICIs) included 42, 98 and 40 patients, respectively. There were significant variations in QOL trends by cohort, with chemotherapy-associated emesis affecting early appetite-related QOL. The change in the FAACT (A/CS) score at 1 week from baseline was worse in cohort 2 (the least square mean change ± standard error: -3.0 ± 0.9) than in cohorts 1 (1.6 ± 1.2, p = 0.003) and 3 (1.8 ± 1.0, p = 0.002); meanwhile, the change at 6 weeks was worse in cohort 1 (-1.5 ± 1.2) than in cohorts 2 (3.6 ± 0.9, p = 0.001) and 3 (3.5 ± 1.1, p = 0.004). BW reduction was observed in all cohorts within 6 weeks of therapy initiation. The targeted therapy cohort demonstrated superior progression-free survival (PFS) and overall survival (OS) to CTx ± ICIs cohort or ICIs cohort (median PFS was 9.7 months, 6.3 months, 3.1 months, in cohort 1, 2, 3, respectively (cohort 1 vs. cohort 2: HR, 0.58, p = 0.018; cohort 1 vs. cohort 3: HR, 0.41, p = 0.001); median OS was not reached, 15.8 months, 9.9 months, respectively (cohort 1 vs. cohort 2: HR, 0.52, p = 0.033; cohort 1 vs. cohort 3: HR, 0.37, p = 0.003). CONCLUSIONS: Approximately 1/3 patients with previously untreated advanced NSCLC have cachexia. Appetite-related QOL trends vary based on the type of first-line systemic therapy in cachectic NSCLC patients, and the PFS and OS of these patients seemed to be shorter.
Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trial. International-journal

Ryota Shibaki, Daichi Fujimoto, Eisaku Miyauchi, Yoko Tsukita, Ichiro Nakachi, Daisuke Arai, Yoshihiko Sakata, Naoki Shingu, Toshio Shimokawa, Takashi Kijima, Motohiro Tamiya, Sachiko Kawana, Satoshi Hara, Go Saito, Yuki Sato, Toshihide Yokoyama, Shinya Sakata, Yoshihiko Taniguchi, Akito Hata, Hirotaka Matsumoto, Teppei Yamaguchi, Nobuyuki Yamamoto

Lung cancer (Amsterdam, Netherlands)　196　107958-107958　2024/09/19

DOI： 10.1016/j.lungcan.2024.107958 　

More details Close

OBJECTIVES: Certain guidelines recommend caution when administering immunotherapy in patients with pre-existing interstitial lung disease (ILD) owing to the high incidence of pneumonitis induced by anti-cancer therapy. A prospective clinical trial assessing the safety of chemoimmunotherapy in patients with small-cell lung cancer (SCLC) and pre-existing ILD is warranted. Therefore, this study evaluated the safety and efficacy of chemoimmunotherapy in patients with extensive-stage (ES)-SCLC and mild idiopathic interstitial pneumonia (IIP). METHODS: In this multicenter prospective trial, patients with ES-SCLC and pre-existing mild chronic fibrosing IIP were recruited. Mild IIP was defined as the exclusion of poor pulmonary function, a definite usual interstitial pneumonia (UIP) pattern, and positivity for autoantibodies in blood tests. The patients received durvalumab, etoposide, and carboplatin every three weeks (induction phase), followed by 1,500 mg durvalumab every four weeks (maintenance phase). The primary endpoint was severe pneumonitis-free rate. RESULTS: Twenty-one patients were included in the analysis. Among them, 13 patients displayed a probable UIP pattern, whereas eight patients exhibited an indeterminate for UIP pattern. Two patients (9.5 %) had pneumonitis of any grade during the induction phase; one had Grade 1 and the other had Grade 5 pneumonitis. No other patient developed pneumonitis during the maintenance phase. The severe pneumonitis-free rate was 95.2 % (95 % confidence interval (CI): 77.3-99.2 %). The median progression-free survival was 5.5 months (95 % CI: 3.6-6.4 months). Median overall survival was 10.7 months (95 % CI: 6.0 months to not reached). CONCLUSIONS: Chemoimmunotherapy is a feasible treatment approach for patients with ES-SCLC and mild IIP.
Prognostic significance and response to immune checkpoint inhibitors of RIPK3, MLKL and necroptosis in non-small cell lung cancer. International-journal

Nattaya Duangthim, Thanpisit Lomphithak, Ryoko Saito-Koyama, Yasuhiro Miki, Chihiro Inoue, Ikuro Sato, Eisaku Miyauchi, Jiro Abe, Hironobu Sasano, Siriporn Jitkaew

Scientific reports　14　(1)　21625-21625　2024/09/16

DOI： 10.1038/s41598-024-72545-2 　

More details Close

Lung cancer remains the leading cause of cancer death. Treatment with immune checkpoint inhibitor (ICI) alone or combination with chemotherapy served as first-line therapy in non-small cell lung cancer (NSCLC). However, only 20-50% of NSCLC patients respond to ICI. Necroptosis, an inflammatory form of cell death plays an important role in the regulation of tumor immune microenvironment which may affect prognosis and ICI response but its clinical significance in NSCLC patients has remained largely unknown. Therefore, we aimed to analyze the correlation between key necroptotic proteins and necroptosis and clinical outcomes, the status of tumor-infiltrating immune cells, and response to ICI in NSCLC patients. The expression of receptor-interacting protein kinase 3 (RIPK3), mixed lineage kinase domain-like protein (MLKL) and phosphorylated MLKL (pMLKL) were immunolocalized in 125 surgically resected NSCLC patients and 23 NSCLC patients administered with ICI therapy. CD8 + and FOXp3 + T cells and CD163 + M2 macrophages were also immunolocalized. High RIPK3 status was positively correlated with survival of the patients and RIPK3 turned out an independent favorable prognostic factor of the patients. RIPK3 was negatively correlated with CD8 + T cells, while MLKL positively correlated with CD163 + M2 macrophages, suggesting the possible involvement of RIPK3 and MLKL in formulating immunosuppressive microenvironment. In addition, high RIPK3 status tended to be associated with clinical resistance to ICI therapy (P-value = 0.057). Furthermore, NSCLC cells-expressing RIPK3 suppressed T cells response to ICI therapy in vitro. Therefore, RIPK3 and MLKL could induce an immunosuppressive microenvironment, resulting in low response to ICI therapy in NSCLC.
気管支鏡による再生検で小細胞癌への組織転化が確認されたEGFR遺伝子変異陽性肺腺癌の1例

岩崎史, 宮内栄作, 杉山初美, 松本周一郎, 渡邊裕文, 東出直樹, 玉田勉, 杉浦久敏

気管支学　46　(5)　303-303　2024/09
Publisher: (一社)日本呼吸器内視鏡学会
ISSN： 0287-2137

eISSN： 2186-0149
当院における進行期非小細胞肺癌患者に対する院内AMOY遺伝子変異検査の検査成功率とTurn Around Timeの検討

岩崎史, 宮内栄作, 井上千裕, 青山弥生, 小泉照樹, 渋谷里紗, 突田容子, 木村望, 伊藤辰徳, 小野祥直, 松本周一郎, 成田大輔, 遠藤卓人, 鈴木眞奈美, 野津田泰嗣, 小野寺賢, 岡田克典

気管支学　46　(Suppl.)　S292-S292　2024/05
Publisher: (一社)日本呼吸器内視鏡学会
ISSN： 0287-2137

eISSN： 2186-0149
Peripheral blood biomarkers associated with combination of immune checkpoint blockade plus chemotherapy in NSCLC. International-journal

Nozomu Kimura, Yoko Tsukita, Risa Ebina-Shibuya, Eisaku Miyauchi, Mitsuhiro Yamada, Daisuke Narita, Ryota Saito, Chihiro Inoue, Naoya Fujino, Tomohiro Ichikawa, Tsutomu Tamada, Hisatoshi Sugiura

Cancer biomarkers : section A of Disease markers　2024/03/20

DOI： 10.3233/CBM-230301 　

More details Close

BACKGROUND: Biomarkers predicting clinical outcomes of treating non-small cell lung cancer (NSCLC) with combination of immune checkpoint inhibitors (ICIs) and chemotherapy would be valuable. OBJECTIVE: This study aims to seek predictors of combination of ICI/chemotherapy response in NSCLC patients using peripheral blood samples. METHODS: Patients diagnosed with advanced NSCLC between July 2019 and May 2021 receiving combination of ICI/chemotherapy were included and assessed for partial responses (PR), stable disease (SD) or progressive disease (PD). We measured circulating immune cells, plasma cytokines and chemokines. RESULTS: Nineteen patients were enrolled. The proportions of circulating natural killer (NK) cells within CD45 + cells, programmed death 1 (PD-1) + Tim-3 + T cells within CD4 + cells, and the amount of chemokine C-X-C ligand (CXCL10) in the plasma were significantly elevated in PR relative to SD/PD patients (median 8.1%-vs-2.1%, P= 0.0032; median 1.2%-vs-0.3%, P= 0.0050; and median 122.6 pg/ml-vs-76.0 pg/ml, P= 0.0125, respectively). Patients with 2 or 3 elevated factors had longer progression-free survival than patients with 0 or only one (not reached-vs-5.6 months, P= 0.0002). CONCLUSIONS: We conclude that NK cells, CD4 + PD-1 + Tim-3 + T cells, and CXCL10 levels in pre-treatment peripheral blood may predict the efficacy of combination of ICI/chemotherapy in NSCLC.
Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non-Small Cell Lung Cancer. International-journal

Yoko Tsukita, Takehiro Tozuka, Kohei Kushiro, Shinobu Hosokawa, Toshiyuki Sumi, Mao Uematsu, Osamu Honjo, Ou Yamaguchi, Tetsuhiko Asao, Jun Sugisaka, Go Saito, Jun Shiihara, Ryo Morita, Seigo Katakura, Takehiro Yasuda, Kakeru Hisakane, Eisaku Miyauchi, Satoshi Morita, Kunihiko Kobayashi, Hajime Asahina

JAMA oncology　2024/03/07

DOI： 10.1001/jamaoncol.2023.6277 　

More details Close

IMPORTANCE: Immune checkpoint inhibitor (ICI) plus chemotherapy combination treatment (ICI-chemotherapy) is now a standard treatment for non-small cell lung cancer (NSCLC) without targetable oncogene alterations, but there are few data on ICI-chemotherapy for patients 75 years and older. OBJECTIVE: To inform the choice of first-line drugs in clinical practice and assess the safety and efficacy of ICI-chemotherapy combination treatment in older adult patients with previously untreated advanced NSCLC. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included 58 centers in Japan. The cohort consisted of patients 75 years and older with clinical stage IIIB, IIIC, IV, postoperative or radiotherapy recurrent NSCLC. Patients started first-line systemic therapy between December 2018 and March 2021. Those receiving first-line molecular targeted drugs were excluded. The data were analyzed from February 2022 to October 2022. EXPOSURES: Systemic therapy. MAIN OUTCOMES AND MEASURES: The main outcomes were overall survival (OS), progression-free survival (PFS), and safety. RESULTS: A total of 1245 patients (median [range] age, 78 [75-95] years; 967 [78%] male) with NSCLC were included in the cohort. Programmed death ligand-1 (PD-L1) expression of less than 1% occurred in 268 tumors (22%); 1% to 49% in 387 tumors (31%); 50% and higher in 410 tumors (33%), and unknown expression in 180 tumors (14%). Median OS was 20.0 (95% CI, 17.1-23.6) months for the 354 patients receiving ICI-chemotherapy (28%); 19.8 (95% CI, 16.5-23.8) months for the 425 patients receiving ICI alone (34%); 12.8 (95% CI, 10.7-15.6) months for the 311 patients receiving platinum-doublet chemotherapy (25%); and 9.5 (95% CI, 7.4-13.4) months for the 155 patients receiving single-agent chemotherapy (12%). After propensity score matching, no differences in OS and PFS were found between the patients receiving ICI-chemotherapy vs ICI alone. Each group consisted of 118 patients. For PD-L1 expression of 1% and higher the OS hazard ratio (HR) was 0.98 (95% CI, 0.67-1.42; P = .90), and the PFS HR was 0.92 (95% CI, 0.67-1.25; P = .59). Significance was also not reached when separately analyzed for lower or higher PD-L1 expression (1%-49% or ≥50%). However, grade 3 or higher immune-related adverse events occurred in 86 patients (24.3%) treated with ICI-chemotherapy and 76 (17.9%) with ICI alone (P = .03). CONCLUSIONS AND RELEVANCE: In this study, ICI-chemotherapy combination treatment did not improve survival and increased the incidence of grade 3 and higher immune-related adverse events compared with ICI alone in patients 75 years and older. Based on these results, ICI alone may be recommended for older adult patients with PD-L1-positive NSCLC.
Comparing the Effectiveness of Afatinib and Osimertinib for Patients With PD-L1-positive EGFR-mutant Non-small Cell Carcinoma. International-journal

Minehiko Inomata, Yosuke Kawashima, Ryota Saito, Daisuke Morinaga, Hitomi Nogawa, Masamichi Sato, Yohei Suzuki, Satoru Yanagisawa, Takashi Kikuchi, Daisuke Jingu, Naruo Yoshimura, Toshiyuki Harada, Eisaku Miyauchi

Cancer diagnosis & prognosis　4　(4)　515-520　2024

DOI： 10.21873/cdp.10357 　

More details Close

BACKGROUND/AIM: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are effective for treating non-small cell lung cancer (NSCLC) harboring EGFR mutations. However, higher tumor programmed death ligand-1 (PD-L1) expression is associated with a poor response to EGFR-TKIs, and information on the comparison between afatinib and osimertinib in PD-L1-positive EGFR-mutant NSCLC is scarce. PATIENTS AND METHODS: We retrospectively analyzed data of patients with PD-L1-positive EGFR-mutant NSCLC to compare the effectiveness of afatinib and osimertinib. RESULTS: A total of 177 patients were included in the study. The Cox proportion hazard model was adjusted for age, sex, performance status, EGFR mutation status, PD-L1 expression level, and brain metastasis, revealing that there was no significant difference in risk for progression [hazard ratio (HR)=0.99, 95% confidence interval (CI)=0.64-1.53] or death (HR=0.96, 95% CI=0.54-1.73) between afatinib and osimertinib. CONCLUSION: In conclusion, the EGFR-TKI treatment duration and overall survival after the treatment with afatinib or osimertinib were similar in patients with PD-L1-positive EGFR-mutant NSCLC in the present study.
植込み型除細動器の近傍に生じた限局型肺小細胞癌に根治的化学放射線療法を施行した1例

両國啓, 宮内栄作, 山本友梨, 佐野寛仁, 相澤洋之, 沼倉忠久, 玉田勉, 杉浦久敏

肺癌　63　(7)　1015-1015　2023/12
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
化学免疫療法後にサルベージ手術を行い完全奏効が確認された肺腺癌の1例

岩崎史, 宮内栄作, 井上千裕, 杉浦久敏, 野津田泰嗣, 岡田克典

日本呼吸器学会誌　12　(6)　319-323　2023/11
Publisher: (一社)日本呼吸器学会
ISSN： 2186-5876

eISSN： 2186-5884
PD-L1陽性EGFR陽性NSCLCに対するEGFR-TKI併用療法の有効性 NJLCG2202

齋藤良太, 猪又峰彦, 川嶋庸介, 森永大亮, 野川ひとみ, 佐藤正道, 鈴木洋平, 柳澤悟, 菊池崇史, 神宮大輔, 吉村成央, 原田敏之, 宮内栄作

肺癌　63　(5)　522-522　2023/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
ステロイド治療中に自己免疫性肺胞蛋白症が続発した線維性過敏性肺炎の一例

杉山初美, 村上康司, 東出直樹, 玉田勉, 山本友梨, 鈴木眞奈美, 岩崎史, 相澤洋之, 沼倉忠久, 宮内栄作, 杉浦久敏

日本サルコイドーシス/肉芽腫性疾患学会雑誌　43　(サプリメント号)　66-66　2023/10
Publisher: 日本サルコイドーシス
ISSN： 1883-1273

eISSN： 1884-6114
Necitumumabの皮膚障害と有効性の関連性多施設共同後方視的観察(NINJA Study)からの新たな知見

川嶋庸介, 丹澤盛, 村田泰規, 藤下卓才, 宮永晃彦, 田中寿志, 野尻正文, 佐藤悠城, 秦明登, 益田健, 上月稔幸, 川村卓久, 山口哲平, 朝田和博, 吉岡弘鎮, 宮内栄作, 二宮貴一朗, 三角俊裕, 関順彦

肺癌　63　(5)　487-487　2023/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation. International-journal

Kana Watanabe, Ryota Saito, Eisaku Miyauchi, Hiromi Nagashima, Atsushi Nakamura, Shunichi Sugawara, Nobuyuki Tanaka, Hiroshi Terasaki, Tatsuro Fukuhara, Makoto Maemondo

Cancers　15　(17)　2023/08/24

DOI： 10.3390/cancers15174231 　

More details Close

BACKGROUND: Osimertinib was first approved for the treatment of non-small cell lung cancer (NSCLC) in patients who have developed the epidermal growth factor receptor (EGFR) T790M mutation after treatment with EGFR tyrosine kinase inhibitors (TKIs). We routinely evaluated the plasma of NSCLC patients with the T790M mutation to more rapidly detect an increase in disease activity and resistance to treatment. METHODS: Eligible patients received osimertinib after resistance to the first- or second-generation of EGFR-TKIs in NSCLC harboring T790M mutation detectable in tumor tissue or plasma. Plasma samples were collected every 8 weeks during osimertinib treatment. The plasma analysis was performed using an improved PNA-LNA PCR clamp method. We tested samples for a resistance mechanism, including EGFR-activating, T790M, and C797S mutations, and assessed the association between the mutations and osimertinib treatment. RESULTS: Of the 60 patients enrolled in the study, 58 were eligible for this analysis. In plasma collected before osimertinib treatment, activating mutations were detected in 47 of 58 patients (81.0%) and T790M was detected in 44 patients (75.9%). Activating mutations were cleared in 60.9% (28/46) and T790M was cleared in 93.0% (40/43). Of these, 71.4% (20/28) of activating mutations and 87.5% (35/40) of T790M mutation were cleared within 8 weeks of treatment. The total response rate (RR) was 53.4% (31/58). The median duration of treatment was 259 days, with a trend toward longer treatment duration in patients who experienced the clearance of activating mutations with osimertinib. At the time of disease progression during osimertinib treatment, C797S was detected in 3 of 37 patients (8.1%). CONCLUSION: Plasma EGFR mutation analysis was effective in predicting the effect of osimertinib treatment.
Phase II trial of daily S-1 combined with weekly irinotecan in previously treated patients with advanced or recurrent squamous cell lung cancer: North Japan lung cancer group 1101. International-journal

Yosuke Kawashima, Osamu Ishimoto, Eisaku Miyauchi, Tomohiro Sakakibara, Toshiyuki Harada, Kazuhiro Usui, Akira Inoue, Shunichi Sugawara

Thoracic cancer　2023/08/17

DOI： 10.1111/1759-7714.15076 　

More details Close

BACKGROUND: This phase II trial was designed to evaluate the efficacy and safety of S-1 combined with weekly irinotecan as a second- or third-line treatment for patients with advanced or recurrent squamous cell lung cancer. METHODS: Patients with a body surface area <1.25, 1.25-1.50, and >1.50 m2 received oral S-1 on days 1-14 at 80, 100, and 120 mg/day, respectively, and irinotecan on days 1 and 8 at 70 mg/m2 every 3 weeks. The primary endpoint was the overall response rate, and the secondary endpoints were progression-free survival, overall survival, and the incidence and severity of adverse effects. RESULTS: Between September 2011 and December 2014, 30 patients were enrolled in this study. The overall response rate was 6.7% (95% confidence interval [CI]: 0.8%-22.1%), and the disease control rate was 73.3%. The median progression-free survival was 3.0 months (95% CI: 2.5-3.4 months), and the median overall survival was 10.5 months (95% CI: 5.6-13.7 months). Grade 3/4 treatment-related adverse events were reported in ≥10% of the patients, including leukopenia (21%), neutropenia (21%), anemia (17%), anorexia (10%), and hypokalemia (10%). CONCLUSIONS: Although the treatment-related adverse events were manageable, the combination of weekly irinotecan and S-1 did not have the expected effect.
A retrospective study of the efficacy of combined EGFR‑TKI plus VEGF inhibitor/cytotoxic therapy vs. EGFR‑TKI monotherapy for PD‑L1‑positive EGFR‑mutant non‑small cell lung cancer: North Japan Lung Cancer Study Group 2202. International-journal

Minehiko Inomata, Yosuke Kawashima, Ryota Saito, Daisuke Morinaga, Hitomi Nogawa, Masamichi Sato, Yohei Suzuki, Satoru Yanagisawa, Takashi Kikuchi, Daisuke Jingu, Naruo Yoshimura, Toshiyuki Harada, Eisaku Miyauchi

Oncology letters　26　(2)　334-334　2023/08

DOI： 10.3892/ol.2023.13920 　

More details Close

The present multicenter study was performed to compare the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) monotherapy with that of combined EGFR-TKI plus vascular endothelial growth factor receptor (VEGF) inhibitor/cytotoxic therapy in patients with programmed death-ligand 1 (PD-L1)-positive EGFR-mutant non-small cell lung cancer (NSCLC). Data from patients with PD-L1-positive EGFR-mutant NSCLC were collected from 12 institutes. Survival in patients treated with first- and second-generation EGFR-TKIs, osimertinib (third-generation EGFR-TKI), and combined EGFR-TKI plus VEGF inhibitor/cytotoxic therapy was analyzed by multiple regression analysis with adjustments for sex, performance status, EGFR mutation status, PD-L1 expression level, and the presence or absence of brain metastasis using a Cox proportional hazards model. Data from a total of 263 patients were analyzed, including 111 (42.2%) patients who had received monotherapy with a first- or second-generation EGFR-TKI, 132 (50.2%) patients who had received osimertinib monotherapy, and 20 (7.6%) patients who had received combined EGFR-TKI plus VEGF inhibitor/cytotoxic therapy (hereafter referred to as combined therapy). Multiple regression analysis using the Cox proportional hazards model showed that the hazard ratio (95% confidence interval) for progression-free survival was 0.73 (0.54-1.00) in the patients who had received osimertinib monotherapy and 0.47 (0.25-0.90) in patients who had received combined therapy. The hazard ratio for overall survival was 0.98 (0.65-1.48) in the patients who had received osimertinib monotherapy and 0.52 (0.21-1.31) in patients who had received combined therapy. In conclusion, combined therapy was associated with a significant reduction in the risk of progression compared with first- and second-generation EGFR-TKI monotherapy, and therefore, may be promising for the treatment of patients of NSCLC.
Pathological images machine learning and prediction of long-term efficacy for immunotherapy in small cell lung cancer.

Yuki Sato, Ryota Shibaki, Daichi Fujimoto, Tsukasa Nozawa, Satoshi Hara, Junji Uchida, Eisaku Miyauchi, Ryota Hiraoka, Haruko Daga, Takeshi Masuda, Satoshi Tanaka, Satoshi Ikeda, Go Saito, Hidekazu Suzuki, Shinya Sakata, Yoshihiko Sakata, Takashi Kijima, Nobuyuki Yamamoto, Yasuhiro Koh, Hiroaki Akamatsu

Journal of Clinical Oncology　41　(16{\_}suppl)　8578-8578　2023/06/01
Publisher: American Society of Clinical Oncology ({ASCO})
DOI： 10.1200/jco.2023.41.16_suppl.8578 　

ISSN： 0732-183X 1527-7755

More details Close

<jats:p> 8578 </jats:p><jats:p> Background: In development of effective treatment such as immune checkpoint inhibitors (ICIs) among patients with small-cell lung cancer (SCLC), the absence of biomarkers is critical. Tumor-infiltrating lymphocytes are the main activator of antitumor immunity and could be a promising biomarker if TIL can be objectively assessed throughout the whole tumor immune microenvironment (TIME). To evaluate TIME, pathological assessment is one of the easiest ways. Recently, several studies showed that machine learning analysis can assess type of lymphocytes and their localization in pathological images. Here, we aimed to develop a novel biomarker to predict efficacy of ICI in SCLC using machine learning of pathological images. Methods: This study was a biomarker analysis of the APOLLO study which was 32-centered, prospective cohort study of patients with extensive-stage SCLC who received chemo-immunotherapy as the first-line treatment between September 2019 and September 2020. The patient who can provide sufficient tumor tissue sample from the primary tumor were enrolled. We trained a classifier which predicts 365-day progression-free survival (PFS) by all three types of pathological images (hematoxylin and eosin, programmed death-ligand 1, and CD8_FoxP3) and patient information, and developed the patient information model, pathological image model, and combination model. We used the area under the curves (AUC) to evaluate the machine learning models. Results: Of 78 patients, the median age was 78 (interquartile range, 48-87), 65 patients (83%) were male, 67 patients (86%) had a performance status of 0 or 1, and three patients (3.8%) treated with steroid therapy. Among all patients, the median PFS and the 365-day PFS rates were 145 days and 10.3%. The mean AUC of these models was 0.789 (range, 0.571-0.982) in the patient information model, 0.782 (range, 0.750-0.911) in the pathological image model, and 0.868 (range, 0.786-0.929) in the combination model, respectively. According to the median precision model, the median PFS was longer for the high efficacy group than the low efficacy group (the patient information model; hazard ratio (HR) 0.468, 95% confidence intervals (CI) 0.287-0.762. the pathological image model; HR 0.334, 95%CI 0.117-0.628. the combination model; HR 0.353, 95%CI 0.195-0.637). Conclusions: Using machine learning by pathological images, we could predict the efficacy of immunotherapy in SCLC. This study demonstrated the potential of machine learning to help the biomarker development in SCLC by assessing TIME. Clinical trial information: UMIN000038064 . </jats:p>
心房中隔欠損症によるplatypnea-orthodeoxia症候群の1例

佐藤章広, 東出直樹, 鈴木眞奈美, 杉山初美, 相澤洋之, 宮内栄作, 玉田勉, 杉浦久敏

日本呼吸器学会誌　12　(増刊)　387-387　2023/03
Publisher: (一社)日本呼吸器学会
ISSN： 2186-5876

eISSN： 2186-5884
Management of patients with presumed germline pathogenic variant from tumor-only genomic sequencing: A retrospective analysis at a single facility. International-journal

Maako Kawamura, Hidekazu Shirota, Tetsuya Niihori, Keigo Komine, Masanobu Takahashi, Shin Takahashi, Eisaku Miyauchi, Hidetaka Niizuma, Atsuo Kikuchi, Hiroshi Tada, Muneaki Shimada, Naoki Kawamorita, Masayuki Kanamori, Ikuko Sugiyama, Mari Tsubata, Hitotshi Ichikawa, Jun Yasuda, Toru Furukawa, Yoko Aoki, Chikashi Ishioka

Journal of human genetics　68　(6)　399-408　2023/02/20

DOI： 10.1038/s10038-023-01133-5 　

More details Close

Cancer treatment is increasingly evolving toward personalized medicine, which sequences numerous cancer-related genes and identifies therapeutic targets. On the other hand, patients with germline pathogenic variants (GPV) have been identified as secondary findings (SF) and oncologists have been urged to handle them. All SF disclosure considerations for patients are addressed and decided at the molecular tumor boards (MTB) in the facility. In this study, we retrospectively summarized the results of all cases in which comprehensive genomic profiling (CGP) test was conducted at our hospital, and discussed the possibility of presumed germline pathogenic variants (PGPV) at MTB. MTB recommended confirmatory testing for 64 patients. Informed consent was obtained from attending physicians for 53 of them, 30 patients requested testing, and 17 patients tested positive for a confirmatory test. Together with already known variants, 4.5 % of the total confirmed in this cohort. Variants verified in this study were BRCA1 (n = 12), BRCA2 (n = 6), MSH2 (n = 2), MSH6 (n = 2), WT1 (n = 2), TP53, MEN1, CHEK2, MLH1, TSC2, PTEN, RB1, and SMARCB1. There was no difference in the tumor's VAF between confirmed positive and negative cases for variants determined as PGPV by MTB. Current results demonstrate the actual number of cases until confirmatory germline test for patients with PGPV from tumor-only CGP test through the discussion at the MTB. The practical results at this single facility will serve as a guide for the management of the selection and distribution of SF in the genome analysis.
Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility. International-journal

Daichi Fujimoto, Takeshi Morimoto, Motohiro Tamiya, Akito Hata, Hirotaka Matsumoto, Atsushi Nakamura, Toshihide Yokoyama, Yoshihiko Taniguchi, Junji Uchida, Yuki Sato, Takashi Yokoi, Hisashi Tanaka, Naoki Furuya, Takeshi Masuda, Yoshihiko Sakata, Eisaku Miyauchi, Satoshi Hara, Go Saito, Satoru Miura, Masaki Kanazu, Nobuyuki Yamamoto, Hiroaki Akamatsu

JAMA network open　6　(2)　e230698　2023/02/01

DOI： 10.1001/jamanetworkopen.2023.0698 　

More details Close

IMPORTANCE: Chemoimmunotherapy is the standard first-line therapy for patients with extensive-stage small cell lung cancer (ES-SCLC). However, whether findings from pivotal trials can be extrapolated to the clinical practice setting remains unclear. OBJECTIVE: To compare treatment outcome gaps following first-line chemoimmunotherapy for patients with ES-SCLC between those who met and did not meet the eligibility criteria used in previous clinical trials. DESIGN, SETTING, AND PARTICIPANTS: A prospective cohort study was conducted from September 1, 2019, to September 30, 2020, at 32 hospitals in Japan, with at least 12 months of follow-up. Participants included consecutive patients with ES-SCLC who received carboplatin and etoposide with atezolizumab as first-line therapy. EXPOSURES: Patients who met eligibility criteria for pivotal phase 3 clinical trials were considered trial-eligible. MAIN OUTCOMES AND MEASURES: The primary outcome was 6-month progression-free survival. The secondary outcomes were differences in progression-free survival, overall survival, and safety according to whether key clinical trial eligibility criteria were met. RESULTS: A total of 207 patients were analyzed (median age, 72 years; range, 46-87 years; 170 [82%] were male). Sixty-four patients (31%) were older adults (age ≥75 years), and most (184 [89%]) had an Eastern Cooperative Oncology Group performance status of 0 or 1. There were 132 (64%) trial-eligible patients. The 6-month progression-free survival rate for all patients was 38.8% (95% CI, 32.4%-45.7%). The median progression-free survival was 5.1 months in trial-eligible patients and 4.7 months in trial-ineligible patients (hazard ratio, 0.72; 95% CI, 0.53-0.97; P = .03). The proportion of patients who achieved disease control was 93% (118 of 127) in trial-eligible patients and 77% (55 of 71) in trial-ineligible patients (P = .002). The median overall survival was 15.8 months in trial-eligible patients and 13.1 months in trial-ineligible patients (hazard ratio, 0.73; 95% CI, 0.51-1.07; P = .10). The rate of severe adverse events was numerically higher among trial-ineligible patients than among trial-eligible patients (39% vs 27%; P = .07). CONCLUSIONS AND RELEVANCE: In this cohort study, the overall treatment outcome was comparable to that reported in pivotal clinical trials. However, treatment outcomes after chemoimmunotherapy might differ between trial-eligible and trial-ineligible patients. These findings suggest that trial-eligibility criteria may be useful in clinical practice, and further studies using data from clinical practice settings are required to inform regulatory approval and clinical decision-making.
Antibody responses to second doses of COVID-19 vaccination in lung cancer patients undergoing treatment. International-journal

Daisuke Narita, Risa Ebina-Shibuya, Eisaku Miyauchi, Yoko Tsukita, Ryota Saito, Koji Murakami, Nozomu Kimura, Hisatoshi Sugiura

Respiratory investigation　61　(2)　247-253　2022/12/15

DOI： 10.1016/j.resinv.2022.11.005 　

More details Close

BACKGROUND: Several reports have revealed that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection tends to have more severe outcomes in cancer patients. Although vaccination reduces the risk of severe disease, data on antibody titers achieved by vaccination is scarce in cancer patients. METHODS: We collected 79 blood samples (69 lung cancer patients and 10 control individuals) and conducted an anti-SARS-CoV-2 antibody assay to compare the antibody titer achieved with current treatment. Sixty-eight patients (86%) received the BNT162 mRNA vaccine and 11 (14%) received the mRNA-1273 vaccine. They were categorized according to the current treatment: control individuals without cancer (cohort A), lung cancer patients who were treated with cytotoxic chemotherapy (cohort B), immunotherapy (cohort C), combination of cytotoxic chemotherapy and immunotherapy (cohort D), tyrosine kinase inhibitors (cohort E), and radiation therapy (cohort F). RESULTS: Among 69 lung cancer patients (cohort B-F), 57 (83%) had adenocarcinoma, and 66 (96%) had advanced-stage cancer. In the anti-SARS-CoV-2 antibody assay, the antibody titer was significantly lower in lung cancer patients than in control individuals (p = 0.01). The median antibody titers were 161 AU/ml in control individuals and 59.9 AU/ml in lung cancer patients. CONCLUSIONS: Antibody titers after the second vaccination were lower in cancer patients than those in healthy individuals. Our findings provide essential information for understanding the benefits and necessity of additional vaccination to prevent SARS-CoV-2 infection in lung cancer patients.
亜急性小脳変性症を契機に診断された小細胞肺癌の1例

鈴木眞奈美, 宮内栄作, 杉山初美, 相澤洋之, 東出直樹, 玉田勉, 杉浦久敏, 藤野春海, 四條友望, 高井良樹

肺癌　62　(7)　1063-1063　2022/12
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
亜急性小脳変性症を契機に診断された小細胞肺癌の1例

鈴木眞奈美, 宮内栄作, 杉山初美, 相澤洋之, 東出直樹, 玉田勉, 杉浦久敏, 藤野春海, 四條友望, 高井良樹

肺癌　62　(7)　1063-1063　2022/12
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
COVID-19ワクチン接種を契機に副腎クリーゼを発症した続発性副腎不全合併肺癌の1例

宮内栄作, 今野周一, 渋谷里紗, 相澤洋之, 東出直樹, 玉田勉, 杉浦久敏

肺癌　62　(7)　1063-1063　2022/12
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
髄膜癌腫症と診断された非小細胞肺癌患者に対する全脳照射の有効性の検討(NEJ049)

芦沼宏典, 宮内栄作, 鈴木綾, 古川恵, 荒井大輔, 下西淳, 細川忍, 堀田尚誠, 猪又峰彦, 森田智視, 高遼, 大熊裕介, 佐々木高明, 解良恭一, 小林国彦, 杉浦久敏

肺癌　62　(6)　638-638　2022/11
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
髄膜癌腫症と診断された非小細胞肺癌患者に対する全脳照射の有効性の検討(NEJ049)

芦沼宏典, 宮内栄作, 鈴木綾, 古川恵, 荒井大輔, 下西淳, 細川忍, 堀田尚誠, 猪又峰彦, 森田智視, 高遼, 大熊裕介, 佐々木高明, 解良恭一, 小林国彦, 杉浦久敏

肺癌　62　(6)　638-638　2022/11
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
The efficacy profiles of concurrent chemoradiotherapy with intensity-modulated radiotherapy followed by durvalumab in patients with unresectable stage III non-small cell lung cancer: A multicenter retrospective cohort study. International-journal

Yuichiro Takeda, Yusaku Kusaba, Yoko Tsukita, Yukari Uemura, Eisaku Miyauchi, Takaya Yamamoto, Hiroshi Mayahara, Akito Hata, Hidetsugu Nakayama, Satoshi Tanaka, Junji Uchida, Kazuhiro Usui, Tatsuya Toyoda, Motohiro Tamiya, Masahiro Morimoto, Yuko Oya, Takeshi Kodaira, Keiichi Jingu, Hisatoshi Sugiura

Clinical and translational radiation oncology　37　57-63　2022/11

DOI： 10.1016/j.ctro.2022.08.010 　

More details Close

Purpose: Intensity-modulated radiotherapy (IMRT) is currently used more commonly than 3-dimensional conformal radiation for definitive thoracic radiation. We examined the efficacy profiles of concurrent chemoradiotherapy (CCRT) with IMRT after durvalumab became clinically available. Methods: We reviewed the clinical records of patients with stage III non-small cell lung cancer (NSCLC) treated with CCRT and IMRT at seven centers in Japan and investigated relapse and survival from May 2018 to December 2019. The primary endpoint of this report was progression-free survival (PFS). Results: Among 107 patients enrolled in the study, 87 were sequentially administered durvalumab. From CCRT commencement, patients were followed up for a median period of 29.7 months. The median PFS at the end of the CCRT was 20.7 months. Among the 87 patients, 58 experienced disease relapses, of whom 36 (62.1 %) had distant metastases. Multivariate Cox regression analysis revealed that a favorable response to CCRT, a radiation dose ≥ 62 Gy, and stage IIIA NSCLC were associated with prolonged PFS (all P = 0.04). Multivariate logistic regression by landmark analysis revealed that mortality risk factors were durvalumab treatment duration ≤ 11.7 months, a lower maximum grade of immune-related adverse events, FEV1 < 2805 mL, and radiation dose < 62 Gy (P = 0.01, 0.01, 0.03, and 0.04, respectively). Conclusions: In patients with NSCLC receiving CCRT using IMRT, long PFS was associated with a better response to CCRT, stage IIIA NSCLC, and an increased radiation dose. The duration of durvalumab consolidation also played an essential role in the survival of patients receiving CCRT with IMRT. (250 words).
Clinical decisions by the molecular tumor board on comprehensive genomic profiling tests in Japan: A retrospective observational study. International-journal

Hidekazu Shirota, Keigo Komine, Masanobu Takahashi, Shin Takahashi, Eisaku Miyauchi, Hidetaka Niizuma, Hiroshi Tada, Muneaki Shimada, Tetsuya Niihori, Yoko Aoki, Ikuko Sugiyama, Maako Kawamura, Jun Yasuda, Shuhei Suzuki, Takeshi Iwaya, Motonobu Saito, Tsuyoshi Saito, Hiroyuki Shibata, Toru Furukawa, Chikashi Ishioka

Cancer medicine　12　(5)　6170-6181　2022/10/17

DOI： 10.1002/cam4.5349 　

More details Close

BACKGROUND: A paradigm shift has occurred in cancer chemotherapy from tumor-specific treatment with cytotoxic agents to personalized medicine with molecular-targeted drugs. Thus, it is essential to identify genomic alterations and molecular features to recommend effective targeted molecular medicines regardless of the tumor site. Nevertheless, it takes considerable expertise to identify treatment targets from primary-sequencing data in order to provide drug recommendations. The Molecular Tumor Board (MTB) denotes a platform that integrates clinical and molecular features for clinical decisions. METHODS: This study retrospectively analyses all the cases of discussion and decision at the MTB in Tohoku University Hospital and summarizes genetic alterations and treatment recommendations. RESULTS: The MTB discussed 1003 comprehensive genomic profiling (CGP) tests conducted in patients with solid cancer, and the resulting rate of assessing treatment recommendations was approximately 19%. Among hundreds of genes in the CGP test, only 30 genetic alterations or biomarkers were used to make treatment recommendations. The leading biomarkers that led to treatment recommendations were tumor mutational burden-high (TMB-H) (n = 32), ERBB2 amplification (n = 24), BRAF V600E (n = 16), and BRCA1/2 alterations (n = 32). Thyroid cancer accounted for most cancer cases for which treatment recommendation was provided (81.3%), followed by non-small cell lung cancer (42.4%) and urologic cancer (31.3%). The number of tests performed for gastrointestinal cancers was high (n = 359); however, the treatment recommendations for the same were below average (13%). CONCLUSION: The results of this study may be used to simplify treatment recommendations from the CGP reports and help select patients for testing, thereby increasing the accuracy of personalized medicine.
リゾリン脂質産生酵素によるサルコイドーシス疾患活動性の評価

村上康司, 玉田勉, 三枝大輔, 奈良正之, 宮内栄作, 蔵野信, 矢冨裕, 杉浦久敏

日本サルコイドーシス/肉芽腫性疾患学会雑誌　42　(サプリメント号)　74-74　2022/10
Publisher: 日本サルコイドーシス
ISSN： 1883-1273

eISSN： 1884-6114
Stereotactic Radiosurgery for Lung Cancer with a Risk-Adapted Strategy Using the Volumetric Modulated Arc Therapy Technique: A Single Arm Phase II Study

Takaya Yamamoto, Yu Katagiri, Yoko Tsukita, Haruo Matsushita, Rei Umezawa, Yoshiyuki Katsuta, Noriyuki Kadoya, Noriyoshi Takahashi, Yu Suzuki, Kazuya Takeda, Keita Kishida, So Omata, Eisaku Miyauchi, Ryota Saito, Keiichi Jingu

Cancers　14　(16)　3993-3993　2022/08/18
Publisher: MDPI AG
DOI： 10.3390/cancers14163993 　

eISSN： 2072-6694

More details Close

Purpose: A phase II study carried out to assess the efficacy of a risk-adapted strategy of stereotactic radiosurgery (SRS) for lung cancer. The primary endpoint was 3-year local recurrence, and the secondary endpoints were overall survival (OS), disease-free survival (DFS), rate of start of systemic therapy or best supportive care (SST-BSC), and toxicity. Materials and Methods: Eligible patients fulfilled the following criteria: performance status of 2 or less, forced expiratory volume in 1 s of 700 mL or more, and tumor not located in central or attached to the chest wall. Twenty-eight Gy was prescribed for primary lung cancers with diameters of 3 cm or less and 30 Gy was prescribed for primary lung cancers with diameters of 3.1–5.0 cm or solitary metastatic lung cancer diameters of 5 cm or less. Results: Twenty-one patients were analyzed. The patients included 7 patients with adenocarcinoma, 2 patients with squamous cell carcinoma, 1 patient with metastasis, and 11 patients with clinical diagnosis. The median tumor diameter was 1.9 cm. SRS was prescribed at 28 Gy for 18 tumors and 30 Gy for 3 tumors. During the median follow-up period of 38.9 months for survivors, 1 patient had local recurrence, 7 patients had regional or distant metastasis, and 5 patients died. The 3-year local recurrence, SST-BSC, DFS, and OS rates were 5.3% (95% confidence interval [CI]: 0.3–22.2%), 20.1% (95% CI: 6.0–40.2%), 59.2% (95% CI: 34.4–77.3%), and 78.2% (95% CI: 51.4–91.3%), respectively. The 95% CI upper value of local recurrence was lower than the null local recurrence probability. There was no severe toxicity, and grade 2 radiation pneumonitis occurred in 1 patient. Conclusions: Patients who received SRS for lung cancer had a low rate of 3-year local recurrence and tolerable toxicity.
Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFR. International-journal

Eisaku Miyauchi, Satoshi Morita, Atsushi Nakamura, Yukio Hosomi, Kana Watanabe, Satoshi Ikeda, Masahiro Seike, Yuka Fujita, Koichi Minato, Ryo Ko, Toshiyuki Harada, Koichi Hagiwara, Kunihiko Kobayashi, Toshihiro Nukiwa, Akira Inoue

Journal of clinical oncology : official journal of the American Society of Clinical Oncology　40　(31)　JCO2102911-3592　2022/08/12

DOI： 10.1200/JCO.21.02911 　

More details Close

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.In a randomized, open-label, phase III NEJ009 study, gefitinib plus chemotherapy significantly improved progression-free survival (PFS) and overall survival (OS) compared with gefitinib-alone in patients with untreated non-small-cell lung cancer harboring mutations in epidermal growth factor receptor. Herein, we report the updated survival outcome and long-term tolerability. Patients were randomly assigned to gefitinib (gefitinib 250 mg orally, once daily) and gefitinib combined with carboplatin plus pemetrexed (GCP in a 3-week cycle for six cycles followed by concurrent gefitinib and pemetrexed maintenance) groups. At the data cutoff (May 22, 2020), GCP demonstrated significantly better PFS2 (hazard ratio, 0.77; 95% CI, 0.62 to 0.97; P = .027) than gefitinib. However, the updated median OS was 38.5 months (95% CI, 31.1 to 47.1) and 49.0 months (95% CI, 41.8 to 56.7) in the gefitinib and GCP groups, respectively (hazard ratio, 0.82; 95% CI, 0.64 to 1.06; P = .127). The OS in both groups was similar for the overall patient population. No severe adverse events occurred since the first report. This updated analysis revealed that the GCP regimen improved PFS and PFS2 with an acceptable safety profile compared with gefitinib-alone. GCP is more efficient than gefitinib monotherapy as a first-line treatment for non-small-cell lung cancer with epidermal growth factor receptor mutations.
Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study. International-journal

Hayato Kawachi, Motohiro Tamiya, Yoshihiko Taniguchi, Toshihide Yokoyama, Shinya Yokoe, Yuko Oya, Mihoko Imaji, Fukuko Okabe, Masaki Kanazu, Yoshihiko Sakata, Shinya Uematsu, Satoshi Tanaka, Daisuke Arai, Go Saito, Hiroshi Kobe, Eisaku Miyauchi, Asuka Okada, Satoshi Hara, Toru Kumagai

JTO clinical and research reports　3　(7)　100355-100355　2022/07

DOI： 10.1016/j.jtocrr.2022.100355 　

More details Close

Introduction: Malignant pleural effusion (MPE) is associated with poor treatment outcome in patients with NSCLC receiving immune checkpoint inhibitors (ICIs). ICIs and chemotherapy (ICI/Chemo) combination therapy is currently the standard therapy for NSCLC, and some ICI/Chemo regimens for nonsquamous (non-Sq) NSCLC contain bevacizumab (BEV), which is effective for controlling MPE and may enhance immune response. This study aimed to determine the optimal first-line treatment for this clinical population. Methods: We retrospectively enrolled consecutive patients with non-Sq NSCLC with MPE who received ICI/Chemo or pembrolizumab monotherapy. Treatment outcomes were analyzed in patients with programmed death-ligand 1 (PD-L1) tumor proportion score more than or equal to 50% who were administered ICI/Chemo or pembrolizumab monotherapy (PD-L1 high cohort) and in patients with any PD-L1 status, treated with ICI/Chemo with or without BEV (ICI/Chemo cohort). We used propensity score matching (PSM) to reduce bias. Results: PD-L1 high and ICI/Chemo cohorts included 143 and 139 patients, respectively. In PD-L1 high cohort, 37 patients received ICI/Chemo. With PSM, the median progression-free survival was significantly longer in the ICI/Chemo group than in the pembrolizumab group (11.1 versus 3.9 mo, respectively, p = 0.0409). In the ICI/Chemo cohort, 23 patients received BEV. With PSM, no significant difference occurred in median progression-free survival between BEV and non-BEV groups (6.1 versus 7.4 mo, p = 0.9610). Conclusion: ICI/Chemo seemed more effective than pembrolizumab monotherapy for patients with non-Sq NSCLC with MPE. Nevertheless, the synergistic effect of BEV with ICI/Chemo may be limited. Further studies are needed to clarify the key factor in the tumor-induced immunosuppression environment in these patients.
軟性気管支鏡下に食物残渣による窒息を解除し得た肺腺癌の一例

松本周一郎, 宮内栄作, 杉山初美, 佐野寛仁, 光根歩, 鈴木眞奈美, 成田大輔, 小野祥直, 小荒井晃, 玉田勉, 杉浦久敏

気管支学　44　(Suppl.)　S311-S311　2022/05
Publisher: (一社)日本呼吸器内視鏡学会
ISSN： 0287-2137

eISSN： 2186-0149
Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non-small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020-02). International-journal

Hisashi Tanaka, Hiroaki Sakamoto, Takahiro Akita, Fumiyoshi Ohyanagi, Yosuke Kawashima, Yuichi Tambo, Azusa Tanimoto, Atsushi Horiike, Eisaku Miyauchi, Yuko Tsuchiya-Kawano, Noriko Yanagitani, Makoto Nishio

Thoracic cancer　13　(10)　1471-1478　2022/05

DOI： 10.1111/1759-7714.14415 　

More details Close

BACKGROUND: Dacomitinib is the second-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) for mutant non-small cell lung cancer (NSCLC). EGFR-TKIs are often re-administered in Japan after the disease progression prior EGFR-TKI. There is little evidence of dacomitinib in rechallenge setting. This study evaluated clinical outcomes of dacomitinib in rechallenge setting. METHODS: Patients who received dacomitinib for advanced EGFR-mutant NSCLC who had progressed after EGFR-TKI in nine institutions in Japan were included in the analyses. RESULTS: In total, 43 patients were analyzed. The median progression-free survival (PFS) was 4.3 months (95% confidence interval [CI], 2.5-5.6). The overall survival (OS) was 10.5 months (95% CI, 7.4-not reached). The overall response rate was 25.5% (95% CI, 13.1-33.7). Subset analysis indicated that patients with EGFR exon 21 L858R showed longer PFS than those with EGFR exon 19 deletion (5.8 vs. 4.1 months) (p = 0.018). The most common adverse events leading to dose modification were diarrhea, paronychia, rash, and oral mucositis. CONCLUSION: In the real practice in Japan, dacomitinib showed a worthwhile treatment option for NSCLC patients with EGFR mutation after failure of previous EGFR-TKI. The benefit was especially pronounced in patients with the exon 21 mutation.
軟性気管支鏡下に食物残渣による窒息を解除し得た肺腺癌の一例

松本周一郎, 宮内栄作, 杉山初美, 佐野寛仁, 光根歩, 鈴木眞奈美, 成田大輔, 小野祥直, 小荒井晃, 玉田勉, 杉浦久敏

気管支学　44　(Suppl.)　S311-S311　2022/05
Publisher: (NPO)日本呼吸器内視鏡学会
ISSN： 0287-2137

eISSN： 2186-0149
Durvalumab after chemoradiotherapy for locally advanced non-small cell lung cancer prolonged distant metastasis-free survival, progression-free survival and overall survival in clinical practice. International-journal

Takaya Yamamoto, Yoko Tsukita, Yu Katagiri, Haruo Matsushita, Rei Umezawa, Yojiro Ishikawa, Noriyoshi Takahashi, Yu Suzuki, Kazuya Takeda, Eisaku Miyauchi, Ryota Saito, Yoshiyuki Katsuta, Noriyuki Kadoya, Keiichi Jingu

BMC cancer　22　(1)　364-364　2022/04/04

DOI： 10.1186/s12885-022-09354-1 　

More details Close

BACKGROUND: In clinical practice, the effect of durvalumab and radiation pneumonitis (RP) on survival after intensity-modulated radiotherapy (IMRT) is not fully understood. The purpose of this retrospective study was to investigate factors related to distant metastasis-free survival (DMFS), progression-free survival (PFS) and overall survival (OS) after IMRT for locally advanced non-small cell lung cancer (LA-NSCLC). METHODS: All patients who were treated with conventional fractionated IMRT for LA-NSCLC between April 2016 and March 2021 were eligible. Time-to-event data were assessed by using the Kaplan-Meier estimator, and the Cox proportional hazards model was used for prognostic factor analyses. Factors that emerged after the start of IMRT, such as durvalumab administration or the development of RP, were analysed as time-dependent covariates. RESULTS: A total of 68 consecutive patients treated with conventional fractionated IMRT for LA-NSCLC were analysed. Sixty-six patients completed radiotherapy, 50 patients received concurrent chemotherapy, and 36 patients received adjuvant durvalumab. During the median follow-up period of 14.3 months, 23 patients died, and tumour progression occurred in 37 patients, including 28 patients with distant metastases. The 1-year DMFS rate, PFS rate and OS rate were 59.9%, 48.7% and 84.2%, respectively. Grade 2 RP occurred in 16 patients, grade 3 in 6 patients and grade 5 in 1 patient. The 1-year cumulative incidences of grade 2 or higher RP and grade 3 or higher RP were 33.8% and 10.3%, respectively. The results of multivariate analyses showed that durvalumab had a significantly lower hazard ratio (HR) for DMFS, PFS and OS (HR 0.31, p < 0.01; HR 0.33, p < 0.01 and HR 0.32, p = 0.02), respectively. Grade 2 or higher RP showed significance for DMFS and a nonsignificant trend for OS (HR 2.28, p = 0.04 and HR 2.12, p = 0.13), respectively, whereas a higher percentage of lung volume receiving 20 Gy or higher was significant for PFS (HR 2.25, p = 0.01). CONCLUSIONS: In clinical practice, durvalumab administration following IMRT with concomitant chemotherapy showed a significant survival benefit. Reducing the risk of grade 2 or higher RP would also be beneficial.
Urine autotaxin levels reflect the disease activity of sarcoidosis. International-journal

Koji Murakami, Tsutomu Tamada, Daisuke Saigusa, Eisaku Miyauchi, Masayuki Nara, Masakazu Ichinose, Makoto Kurano, Yutaka Yatomi, Hisatoshi Sugiura

Scientific reports　12　(1)　4372-4372　2022/03/14

DOI： 10.1038/s41598-022-08388-6 　

More details Close

Since the clinical outcome of patients with sarcoidosis is still unpredictable, a good prognostic biomarker is necessary. Autotaxin (ATX) and phosphatidylserine-specific phospholipase A1 (PS-PLA1) function as main enzymes to produce lysophospholipids (LPLs), and these enzymes are attracting attention as useful biomarkers for several chronic inflammatory diseases. Here, we investigated the relationships between LPLs-producing enzymes and the disease activity of sarcoidosis. In total, 157 patients with sarcoidosis (active state, 51%) were consecutively enrolled. Using plasma or urine specimens, we measured the values of LPLs-producing enzymes. Urine ATX (U-ATX) levels were significantly lower in the active state compared to those in the inactive state, while the plasma ATX (P-ATX) and PS-PLA1 levels showed no significant difference between these two states. Concerning the comparison with existing clinical biomarkers for sarcoidosis, U-ATX showed a weak negative correlation to ACE, P-ATX a weak positive correlation to both ACE and sIL-2R, and PS-PLA1 a weak positive one to sIL-2R. Notably, only the U-ATX levels inversely fluctuated depending on the status of disease activity whether OCS had been used or not. These findings suggest that U-ATX is likely to be a novel and useful molecule for assessing the disease activity of sarcoidosis.
Histologic transformation of epidermal growth factor receptor-mutated lung cancer. International-journal

Daichi Fujimoto, Hiroaki Akamatsu, Takeshi Morimoto, Kazushige Wakuda, Yuki Sato, Yoshitaka Kawa, Toshihide Yokoyama, Motohiro Tamiya, Ryota Hiraoka, Naoki Shingu, Hideki Ikeda, Akihiro Tamiya, Masaki Kanazu, Eisaku Miyauchi, Satoru Miura, Masaaki Yanai, Makiko Yomota, Ryotaro Morinaga, Takashi Yokoi, Akito Hata, Hidekazu Suzuki, Hirotaka Matsumoto, Shinya Sakata, Naoki Furuya, Yuhei Harutani, Ichiro Nakachi, Ayumu Otsuki, Shinya Uematsu, Satoshi Hara, Keiki Yokoo, Takeya Sugimoto, Nobuyuki Yamamoto

European journal of cancer (Oxford, England : 1990)　166　41-50　2022/03/09

DOI： 10.1016/j.ejca.2022.02.006 　

More details Close

PURPOSE: This study aimed to determine the incidence and clinical course of epidermal growth factor receptor (EGFR)-mutated lung cancer with histologic transformation (HT). PATIENTS AND METHODS: We conducted a multicentre, retrospective, cohort study of patients with advanced EGFR-mutated lung cancer who received EGFR-tyrosine kinase inhibitors (TKIs) between 2012 and 2019. The primary outcome was the incidence of HT. The secondary outcome was treatment efficacy in patients with HT. RESULTS: In total, 6356 patients were enrolled. In 2624 patients, the histological type was proven by rebiopsy after acquiring resistance to EGFR-TKIs. Among them, 74 patients had HT (incidence rate: 2.8% [95% confidence interval: 2.3%-3.5%]). The median progression-free survival after EGFR-TKIs and first-line therapy after confirming HT was 10.4 and 4.4 months, respectively, which was not significantly different between patients with transformation to high-grade neuroendocrine carcinoma and those with transformation to another subtype of non-small cell lung cancer. Overall survival after confirming HT was 12.2 months. Twenty-seven patients received immune checkpoint inhibitors: 6 and 21 received immune checkpoint inhibitors before and after confirming HT, respectively. No patients achieved 1-year progression-free survival. The median progression-free survival after immune checkpoint inhibitor therapy after confirming HT was 1.6 months. CONCLUSION: HT occurred in approximately 3% of EGFR-mutated patients who developed resistance to EGFR-TKIs. Cytotoxic agents are likely to be effective in patients with HT. However, the therapeutic effectiveness of immune checkpoint inhibitors was limited in these patients. Given the rarity of HT and absence of prospective trials, our findings are important to inform the treatment of these patients.
修飾核酸一斉定量系を用いたCOPD・肺がん鑑別手法の検討

渡辺匠, 平本航大, 沼倉忠久, 宮内栄作, 突田容子, 杉浦久敏, 松本洋太郎, 富岡佳久

日本薬学会年会要旨集　142年会　26M-pm08S　2022/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
修飾核酸一斉定量系を用いたCOPD・肺がん鑑別手法の検討

渡辺匠, 平本航大, 沼倉忠久, 宮内栄作, 突田容子, 杉浦久敏, 松本洋太郎, 富岡佳久

日本薬学会年会要旨集　142年会　26M-pm08S　2022/03
Publisher: (公社)日本薬学会
ISSN： 0918-9823
Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study. International-journal

Tomoyasu Mimori, Takehito Shukuya, Ryo Ko, Yusuke Okuma, Tomonobu Koizumi, Hisao Imai, Yuichi Takiguchi, Eisaku Miyauchi, Hiroshi Kagamu, Tomohide Sugiyama, Keisuke Azuma, Yukiko Namba, Masahiro Yamasaki, Hisashi Tanaka, Yuta Takashima, Sayo Soda, Osamu Ishimoto, Nobuyuki Koyama, Kunihiko Kobayashi, Kazuhisa Takahashi

Cancers　14　(2)　2022/01/11

DOI： 10.3390/cancers14020331 　

More details Close

The optimal tumor marker for predicting the prognosis of advanced thymic carcinoma (ATC) remains unclear. We conducted a multi-institutional retrospective study of patients with ATC. A total of 286 patients were treated with chemotherapy. Clinicopathological information, including serum tumor markers, was evaluated to determine the overall survival (OS) and progression-free survival (PFS). The carcinoembryonic antigen, cytokeratin-19 fragment, squamous cell carcinoma (SCC) antigen, progastrin-releasing peptide, neuron-specific enolase (NSE), and alpha-fetoprotein levels were evaluated. In the Kaplan-Meier analysis, the OS was significantly shorter in the patients with elevated NSE levels than in those with normal NSE levels (median, 20.3 vs. 36.8 months; log-rank test p = 0.029; hazard ratio (HR), 1.55; 95% confidence interval (CI), 1.05-2.31 (Cox proportional hazard model)); a similar tendency regarding the PFS was observed (median, 6.4 vs. 11.0 months; log-rank test p = 0.001; HR, 2.04; 95% CI, 1.31-3.18). No significant differences in the OS and PFS were observed among the other tumor markers. In both univariate and multivariate analyses of the patients with SCC only, the NSE level was associated with the OS and PFS. Thus, the NSE level may be a prognostic tumor marker for thymic carcinoma, regardless of histology.
Longitudinal analyses and predictive factors of radiation-induced lung toxicity-related parameters after stereotactic radiotherapy for lung cancer. International-journal

Takaya Yamamoto, Yoshiyuki Katsuta, Kiyokazu Sato, Yoko Tsukita, Rei Umezawa, Noriyoshi Takahashi, Yu Suzuki, Kazuya Takeda, Keita Kishida, So Omata, Eisaku Miyauchi, Ryota Saito, Noriyuki Kadoya, Keiichi Jingu

PloS one　17　(12)　e0278707　2022

DOI： 10.1371/journal.pone.0278707 　

More details Close

BACKGROUND AND PURPOSE: The purpose of this prospective study was to investigate changes in longitudinal parameters after stereotactic radiotherapy for lung cancer and to identify possible pretreatment factors related to radiation-induced lung toxicity and the decline in pulmonary function after radiotherapy. MATERIALS AND METHODS: Protocol-specified examinations, including 4-D CT, laboratory tests, pulmonary function tests (PFTs) and body composition measurements, were performed before SRT and at 1 month, 4 months and 12 months after stereotactic radiotherapy. Longitudinal differences were tested by using repeated-measures analysis of variance. Correlations were examined by using the Pearson product-moment correlation coefficient (r). RESULTS: Sixteen patients were analyzed in this study. During a median follow-up period of 26.6 months, grade 1 and 2 lung toxicity occurred in 11 patients and 1 patient, respectively. The mean Hounsfield units (HU) and standard deviation (SD) of the whole lung, as well as sialylated carbohydrate antigen KL-6 (KL-6) and surfactant protein-D (SP-D), peaked at 4 months after radiotherapy (p = 0.11, p<0.01, p = 0.04 and p<0.01, respectively). At 4 months, lung V20 Gy (%) and V40 Gy (%) were correlated with changes in SP-D, whereas changes in the mean HU of the lung were related to body mass index and lean body mass index (r = 0.54, p = 0.02; r = 0.57, p = 0.01; r = 0.69, p<0.01; and r = 0.69, p<0.01, respectively). The parameters of PFTs gradually declined over time. When regarding the change in PFTs from pretreatment to 12 months, lung V5 Gy (cc) showed significant correlations with diffusion capacity for carbon monoxide (DLCO), DLCO/alveolar volume and the relative change in DLCO (r = -0.72, p<0.01; r = -0.73, p<0.01; and r = -0.63, p = 0.01, respectively). CONCLUSIONS: The results indicated that some parameters peaked at 4 months, but PFTs were the lowest at 12 months. Significant correlations between lung V5 Gy (cc) and changes in DLCO and DLCO/alveolar volume were observed.
リンパ行性転移が示唆された小細胞肺癌術後気管内再発の1例

木村望, 突田容子, 宮内栄作, 小室英恵, 齊藤涼子, 佐藤輝幸, 宍倉裕, 野津田泰嗣, 桜田晃, 杉浦久敏

気管支学　44　(1)　69-72　2022/01
Publisher: (NPO)日本呼吸器内視鏡学会
ISSN： 0287-2137

eISSN： 2186-0149
アレクチニブ、ロルラチニブ耐性後にブリガチニブが奏効したALK陽性肺癌の1例

宮内栄作, 今野周一, 角藤翔, 東出直樹, 佐藤慶, 玉田勉, 杉浦久敏

肺癌　61　(7)　1003-1003　2021/12
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
Phase I/II study of biweekly nab-paclitaxel in patients with platinum-pretreated non-small cell lung cancer: NJLCG1402. International-journal

Eisaku Miyauchi, Hisashi Tanaka, Atsushi Nakamura, Toshiyuki Harada, Taku Nakagawa, Mami Morita, Daisuke Jingu, Tomoya Kuda, Shunichi Gamou, Ryota Saito, Akira Inoue

Thoracic cancer　2021/09/14

DOI： 10.1111/1759-7714.14149 　

More details Close

BACKGROUND: NJLCG1402 was a phase I/II trial investigating biweekly nanoparticle albumin-bound paclitaxel (nab-PTX) in patients with advanced non-small cell lung cancer (NSCLC). METHODS: The study included patients aged ≥20 years with previously treated NSCLC. Nab-PTX (100-150 mg/m2 ) was administered biweekly in a 28-day cycle. The phase I portion was performed to determine the recommended phase II dose of nab-PTX. In the phase II portion, the primary endpoint was the objective response rate. Secondary endpoints were disease control rate, progression-free survival, overall survival, and safety. RESULTS: A total of 15 patients received biweekly nab-PTX (100-150 mg/m2 ) and 12 patients in phase II were treated with 150 mg/m2 . In the phase I portion, 150 mg/m2 was determined as the recommended dose. Among those treated with 150 mg/m2 , the objective response rate was 22%, and the median progression-free and overall survival was 3.6 and 11.2 months, respectively. Adverse events grade ≥3 were observed in 39% of patients. CONCLUSIONS: Biweekly nab-PTX monotherapy was well tolerated and exhibited favorable antitumor activity in patients with previously treated NSCLC.
Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON). International-journal

Go Saito, Yuko Oya, Yoshihiko Taniguchi, Hayato Kawachi, Fujimoto Daichi, Hirotaka Matsumoto, Shunichiro Iwasawa, Hidekazu Suzuki, Takayuki Niitsu, Eisaku Miyauchi, Takashi Yokoi, Toshihide Yokoyama, Takeshi Uenami, Yoshihiko Sakata, Daisuke Arai, Asuka Okada, Kenji Nagata, Shunsuke Teraoka, Masaki Kokubo

Lung cancer (Amsterdam, Netherlands)　161　86-93　2021/09/05

DOI： 10.1016/j.lungcan.2021.08.019 　

More details Close

OBJECTIVES: The incidence of real-world pneumonitis and durvalumab rechallenge during chemoradiotherapy and durvalumab consolidation for non-small cell lung cancer is unknown. MATERIALS AND METHODS: We retrospectively evaluated the medical records of 302 consecutive patients diagnosed with non-small cell lung cancer who started chemoradiotherapy between May 2018 and May 2019. RESULTS: Median age was 70 (range: 40-87) years. Volume of lung parenchyma that received 20 Gy (V20) exceeded 35% in 2% and mean lung dose exceeded 20 Gy in 1% of patients. Durvalumab consolidation was delivered to 225 patients (75%). Overall, 83% (n = 251), 34% (n = 103), 7% (n = 21), and 1% (n = 4) of the patients developed any grade of pneumonitis, symptomatic pneumonitis, ≥grade 3 pneumonitis, and fatal (grade 5) pneumonitis, respectively. Corticosteroids were administered to 25% of the patients to treat pneumonitis. Multivariate analysis identified the predictive factors for the development of symptomatic pneumonitis: V20 Gy or more ≥ 25% (odds ratio [OR]: 2.37, P = 0.008) and mean lung dose (MLD) ≥ 10 Gy (OR: 1.93, P < 0.0047). Of the 52 patients who received corticosteroids for pneumonitis after durvalumab initiation, 21 were rechallenged with durvalumab. Overall, 81% of patients met the PACIFIC study's rechallenge criteria and did not experience a severe pneumonitis relapse. CONCLUSION: High V20 and MLD were independent risk factors of symptomatic pneumonitis. More than 80% of the patients who were rechallenged with durvalumab after pneumonitis met the PACIFIC study's rechallenge criteria. Consequently, severe relapse did not occur. Cooperation between radiation and medical oncologists is important for safe chemoradiotherapy and the safe completion of durvalumab consolidation therapy.
気管支鏡検査により軟口蓋血腫を認めた原発性アミロイドーシスの1例

成田大輔, 宮内栄作, 宍倉裕, 佐藤慶, 光根歩, 佐野寛仁, 杉山初美, 玉田勉, 杉浦久敏

気管支学　43　(5)　565-565　2021/09
Publisher: (NPO)日本呼吸器内視鏡学会
ISSN： 0287-2137

eISSN： 2186-0149
Intensity-modulated radiation therapy with concurrent chemotherapy followed by durvalumab for stage III non-small cell lung cancer: a multi-center retrospective study. International-journal

Yoko Tsukita, Takaya Yamamoto, Hiroshi Mayahara, Akito Hata, Yuichiro Takeda, Hidetsugu Nakayama, Satoshi Tanaka, Junji Uchida, Kazuhiro Usui, Tatsuya Toyoda, Motohiro Tamiya, Masahiro Morimoto, Yuko Oya, Takeshi Kodaira, Eisaku Miyauchi, Keiichi Jingu, Hisatoshi Sugiura

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology　160　266-272　2021/05/20

DOI： 10.1016/j.radonc.2021.05.016 　

More details Close

BACKGROUND AND PURPOSE: Intensity-modulated radiation therapy (IMRT) is increasingly applied in concurrent chemoradiotherapy (CCRT) for locally-advanced non-small cell lung cancer (NSCLC), with improvement of target coverage and better sparing of normal tissue. IMRT tends to have a larger low-dose irradiation volume than 3D conformal radiotherapy, but the incidence of and risk factors for pneumonitis remain unclear, especially following the approval of durvalumab. MATERIALS AND METHODS: We retrospectively reviewed the records of NSCLC patients treated by CCRT using IMRT at seven Japanese institutions. Primary outcomes were incidence of symptomatic pneumonitis and progression-free survival (PFS). Multivariate logistic regression analysis was used to identify risk factors for ≥grade 2 pneumonitis. RESULTS: Median follow-up from the start of CCRT was 14.3 months (n=107 patients; median age 70 years, 29% female). Median lung V5 and V20 was 49.2% and 19.5%, respectively. Durvalumab was administered to 87 patients (81%). Pneumonitis developed in 95 (89%) patients of which 53% had grade 1, 28% grade 2, 6.5% grade 3, and 0.9% grade 4. Durvalumab had been discontinued in 16 patients (18.4%) due to pneumonitis. By multivariate analysis, age ≥70 years, male sex, and V5 ≥58.9% were identified as significantly associated with ≥grade 2 pneumonitis (p = 0.0065, 0.036 and 0.0013 respectively). The median PFS from the start of CCRT was not reached (95% CI, 14.2 months to not reached) in patients receiving durvalumab. CONCLUSION: CCRT using IMRT followed by durvalumab was generally effective and tolerable; V5 <60% would be recommended to avoid symptomatic pneumonitis.
PD-L1高発現未治療進行非小細胞肺がんに対するネシツムマブ+ペムブロリズマブ療法の第II相試験(K-TAIL-202)

堀池篤, 楠本壮二郎, 白石英晶, 酒谷俊雄, 和久井大, 宮内栄作, 下川恒夫, 細見幸生, 塩豊, 竹ノ下祥子, 龍家圭, 三邉武彦, 今村知世, 田坂定智, 井上永介, 和田聡, 吉村清, 相良博典, 小林真一, 角田卓也

日本がん免疫学会総会プログラム・抄録集　25回　192-192　2021/05
Publisher: 日本がん免疫学会
Targeting stanniocalcin-1-expressing tumor cells elicits efficient antitumor effects in a mouse model of human lung cancer. International-journal

Kotaro Abe, Masahiko Kanehira, Shinya Ohkouchi, Sakiko Kumata, Yamato Suzuki, Hisashi Oishi, Masafumi Noda, Akira Sakurada, Eisaku Miyauchi, Tohru Fujiwara, Hideo Harigae, Yoshinori Okada

Cancer medicine　10　(9)　3085-3100　2021/05

DOI： 10.1002/cam4.3852 　

More details Close

Lung cancer is the most common cause of cancer-related death in developed countries; therefore, the generation of effective targeted therapeutic regimens is essential. Recently, gene therapy approaches toward malignant cells have emerged as attractive molecular therapeutics. Previous studies have indicated that stanniocalcin-1 (STC-1), a hormone involved in calcium and phosphate homeostasis, positively regulates proliferation, apoptosis resistance, and glucose metabolism in lung cancer cell lines. In this study, we investigated if targeting STC-1 in tumor cells could be a promising strategy for lung cancer gene therapy. We confirmed that STC-1 levels in peripheral blood were higher in lung cancer patients than in healthy donors and that STC-1 expression was observed in five out of eight lung cancer cell lines. A vector expressing a suicide gene, uracil phosphoribosyltransferase (UPRT), under the control of the STC-1 promoter, was constructed (pPSTC-1 -UPRT) and transfected into three STC-1-positive cell lines, PC-9, A549, and H1299. When stably transfected, we observed significant cell growth inhibition using 5-fluorouracil (5-FU) treatment. Furthermore, growth of the STC-1-negative lung cancer cell line, LK-2 was significantly arrested when combined with STC-1-positive cells transfected with pPSTC-1 -UPRT. We believe that conferring cytotoxicity in STC-1-positive lung cancer cells using a suicide gene may be a useful therapeutic strategy for lung cancer.
Results of the non-small cell lung cancer part of a phase III, open-label, randomized trial evaluating topical corticosteroid therapy for facial acneiform dermatitis induced by EGFR inhibitors: stepwise rank down from potent corticosteroid (FAEISS study, NCCH-1512). International-journal Peer-reviewed

Kazumi Nishino, Yutaka Fujiwara, Yuichiro Ohe, Ryota Saito, Eisaku Miyauchi, Tetsu Kobayashi, Yasuo Nakai, Toshiaki Takahashi, Taro Shibata, Tetsuya Hamaguchi, Katsuko Kikuchi, Naoya Yamazaki, Haruhiko Fukuda, Keiko Nozawa, Yoshio Kiyohara

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer　29　(5)　2327-2334　2021/05

DOI： 10.1007/s00520-020-05765-7 　

More details Close

PURPOSE: This FAEISS study was designed to confirm the superior efficacy of reactive topical corticosteroid strategies employing serially ranking-DOWN from very strong steroid levels for the treatment of facial acneiform rash induced by epidermal growth factor receptor (EGFR) inhibitors (EGFRIs), in comparison with strategies employing serially ranking-UP from weak steroid levels. This article reports the primary results of the non-small cell lung cancer (NSCLC) part of the trial. METHODS: Patients with EGFR-mutated advanced NSCLC treated with erlotinib or afatinib were enrolled in the first registration. All patients received preemptive therapy with oral minocycline and heparinoid moisturizer from the initiation of an EGFR inhibitor. Enrolled patients who developed facial acneiform rash within 2 weeks were randomized at second registration to either a ranking-UP (WEAK) group or a ranking-DOWN group. The primary endpoint was incidence of grade ≥ 2 facial acneiform rash over 8 weeks. RESULTS: Fifty-one patients were enrolled at the first registration and received EGFRIs (n = 30 for afatinib, n = 21 for erlotinib). However, 35 patients did not develop facial acneiform rash within 2 weeks; one patient discontinued preemptive treatment. Fifteen patients (29.4%) were enrolled in the second registration; nine were assigned to the WEAK group and six to the DOWN group. There was no significant difference in the incidence of grade ≥ 2 facial acneiform rash between the WEAK group (one patient, twice) and the DOWN group (one patient, twice; p = 0.8417). No patients developed severe facial acneiform rash within 10 weeks. CONCLUSION: In NSCLC patients who received EGFRIs, preemptive therapy of oral minocycline and heparinoid moisturizer reduced facial acneiform rash incidence. TRIAL REGISTRATION: UMIN000024113.
Randomized phase II trial of uracil/tegafur and cisplatin versus pemetrexed and cisplatin with concurrent thoracic radiotherapy for locally advanced unresectable stage III non-squamous non-small cell lung cancer: NJLCG1001. International-journal Peer-reviewed

Kana Watanabe, Yukihiro Toi, Atsushi Nakamura, Ryosuke Chiba, Masachika Akiyama, Jun Sakakibara-Konishi, Hisashi Tanaka, Naruo Yoshimura, Eisaku Miyauchi, Taku Nakagawa, Ryotaro Igusa, Hiroyuki Minemura, Yoshiaki Mori, Keisuke Fujimoto, Haruo Matsushita, Fumiaki Takahashi, Tatsuro Fukuhara, Akira Inoue, Shunichi Sugawara, Makoto Maemondo

Translational lung cancer research　10　(2)　712-722　2021/02

DOI： 10.21037/tlcr-20-721 　

ISSN： 0732-183X
Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations. International-journal

Kiichiro Ninomiya, Shunsuke Teraoka, Yoshitaka Zenke, Hirotsugu Kenmotsu, Yukiko Nakamura, Yusuke Okuma, Akihiro Tamiya, Kaname Nosaki, Masahiro Morise, Keiju Aokage, Yuko Oya, Toshiyuki Kozuki, Tomohiro Sakamoto, Kentaro Tanaka, Hisashi Tanaka, Junko Tanizaki, Satoru Miura, Hideaki Mizutani, Eisaku Miyauchi, Ou Yamaguchi, Noriyuki Ebi, Yasushi Goto, Takaaki Sasaki, Haruko Daga, Satoshi Morita, Takeharu Yamanaka, Shinsuke Amano, Kazuo Hasegawa, Chiyo K Imamura, Kenichi Suzuki, Kazuko Nakajima, Hitomi Nishimoto, Satoshi Oizumi, Toyoaki Hida, Katsuyuki Hotta, Yuichi Takiguchi

JTO clinical and research reports　2　(1)　100107-100107　2021/01

DOI： 10.1016/j.jtocrr.2020.100107 　

More details Close

Patients with NSCLC in East Asia, including Japan, frequently contain EGFR mutations. In 2018, we published the latest full clinical practice guidelines on the basis of those provided by the Japanese Lung Cancer Society Guidelines Committee. The purpose of this study was to update those recommendations, especially for the treatment of metastatic or recurrent EGFR-mutated NSCLC. We conducted a literature search of systematic reviews of randomized controlled and nonrandomized trials published between 2018 and 2019 that multiple physicians had reviewed independently. On the basis of those studies and the advice from the Japanese Society of Lung Cancer Expert Panel, we developed updated guidelines according to the Grading of Recommendations, Assessment, Development, and Evaluation system. We also evaluated the benefits of overall and progression-free survival, end points, toxicities, and patients' reported outcomes. For patients with NSCLC harboring EGFR-activating mutations, the use of EGFR tyrosine kinase inhibitors (EGFR TKIs), especially osimertinib, had the best recommendation as to first-line treatment. We also recommended the combination of EGFR TKI with other agents (platinum-based chemotherapy or antiangiogenic agents); however, it can lead to toxicity. In the presence of EGFR uncommon mutations, except for an exon 20 insertion, we also recommended the EGFR TKI treatment. However, we could not provide recommendations for the treatment of EGFR mutations with immune checkpoint inhibitors, including monotherapy, and its combination with cytotoxic chemotherapy, because of the limited evidence present in the literature. The 2020 Japanese Lung Cancer Society Guidelines can help community-based physicians to determine the most appropriate treatments and adequately provide medical care to their patients.
化学放射線療法後デュルバルマブの投与回避要因(TOPGAN2020-01)

有安亮, 内堀健, 田中寿志, 宮内栄作, 川嶋庸介, 大柳文義, 堀池篤, 酒谷俊雄, 齊木雅史, 丹保裕一, 谷本梓, 園田智明, 神山潤二, 上浪健, 工藤慶太, 土屋裕子, 西尾誠人

肺癌　60　(7)　966-971　2020/12
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
Prognostic factors for patients with metastatic or recurrent thymic carcinoma receiving palliative-intent chemotherapy. International-journal Peer-reviewed

Yusuke Okuma, Ryo Ko, Takehito Shukuya, Kazunari Tateishi, Hisao Imai, Shunichiro Iwasawa, Eisaku Miyauchi, Tetsuya Kojima, Yuka Fujita, Toshihiko Hino, Shinsuke Yamanda, Toshiro Suzuki, Aya Fukuizumi, Tomohiro Sakakibara, Toshiyuki Harada, Satoshi Morita, Kunihiko Kobayashi, Toshihiro Nukiwa, Kazuhisa Takahashi

Lung cancer (Amsterdam, Netherlands)　148　122-128　2020/10

DOI： 10.1016/j.lungcan.2020.08.014 　

More details Close

BACKGROUND: Thymic malignancies are a model of rare cancer. However, little clinical data is available based on the large database. We aimed to clarify the prognostic factors, particularly the metastatic sites, for thymic malignancies using one of the largest, representative, multi-institutional databases, the NEJ023 database. PATIENTS AND METHODS: Patients with Stage IVA/IVB or recurrent thymic carcinoma were enrolled between 1995 and 2014. Clinicopathologic information was evaluated, and the patients were subdivided according to the metastatic organs of involvement (serosal dissemination, liver, lymph node, pulmonary, and bone metastasis). A Kaplan-Meier analysis and multivariate Cox regression were used to evaluate survival. RESULTS: Two hundred and seventy-nine patients with metastases and a predominantly squamous histology (66.7%) were included. Most patients (53.0%) had serosal dissemination, whereas 26.5%, 21.9%, 19.7%, and 15.8% had pulmonary, lymph node, bone and liver metastases, respectively. Over a median follow-up time of 21.5 months, the median overall survival (mOS) was 30.7 months. When the subjects were grouped according to involved metastatic sites, patients with more than 3 involved metastatic organs had the worst survival outcome. Among patients with isolated involvement, those with bone metastasis had the poorest survival, followed by patients with liver metastasis. Subjects with hypoalbuminemia also had poor survival outcomes. When patients treated with platinum and anthracycline-containing pharmacotherapy were compared with those treated with platinum and non-anthracycline-containing pharmacotherapy, no significant difference was observed. Bone metastasis (P = 0.0005), liver metastasis (P =  0.047), and hypoalbuminemia (P =  0.0021) were identified as prognostic factors in a multivariate analysis. CONCLUSION: The site of metastatic involvement affects the survival outcomes of patients with thymic carcinoma, and this result may reflect the sensitivity of metastatic sites to pharmacotherapy. As a next step, controlling liver metastasis with pharmacotherapy could help to improve the prognosis of patients with thymic carcinoma.
Immunotherapy-related hepatitis and thrombocytopaenia induced by the very low dose of only 90 mg of atezolizumab. International-journal Peer-reviewed

Yoko Tsukita, Eisaku Miyauchi, Masahide Fukudo, Takaaki Sasaki, Masakazu Ichinose

European journal of cancer (Oxford, England : 1990)　133　22-24　2020/07

DOI： 10.1016/j.ejca.2020.04.008 　
Plasma or Serum: Which Is Preferable for Mutation Detection in Liquid Biopsy? International-journal Peer-reviewed

Fabio Pittella-Silva, Yoon Ming Chin, Hiu Ting Chan, Satoshi Nagayama, Eisaku Miyauchi, Siew-Kee Low, Yusuke Nakamura

Clinical chemistry　66　(7)　946-957　2020/07/01

DOI： 10.1093/clinchem/hvaa103 　

More details Close

BACKGROUND: Blood-based analysis of circulating tumor DNA (ctDNA) is a promising tool for cancer screening, monitoring relapse/recurrence and evaluating response to treatment. Although plasma is widely used to obtain ctDNA, biorepositories worldwide possess a huge number of serum samples and comparative studies on the use of serum vs plasma as ctDNA sources are essential. METHODS: We analyzed cell-free DNA (cfDNA) from matched EDTA-plasma and serum samples from healthy donors and patients with colorectal or lung cancer, and used targeted next-generation sequencing to evaluate mutation detection efficiency and reproducibility. Matched samples from healthy individuals were spiked with reference oligonucleotides and sequenced using the Ion-S5 Oncomine-Pan-Cancer panel. Detection efficiency in matched samples from patients with cancer was evaluated using 2 distinct gene panels and compared to mutations found in tissue-biopsy samples at diagnosis. RESULTS: Mean total cfDNA was 55% higher in serum samples and the presence of longer DNA fragments was significantly increased in serum compared with plasma samples (P = 0.0001 to 0.015). Spiked mutated nucleotides were detected in both samples, but allele frequencies (AF) were approximately half in serum compared with plasma, suggesting ctDNA from serum was more diluted by DNA of noncancerous origins. Matched samples from patients with cancer revealed that up to 44.8% of mutations with low AF were missed in serum samples and concordance rates with somatic mutations found in tissue biopsy at diagnosis was better in plasma samples. CONCLUSION: The use of serum in retrospective studies should consider the limitations for detecting low AF mutations. Plasma is clearly preferable for prospective clinical applications of liquid biopsy.
11β hydroxysteroid dehydrogenase 1: a new marker for predicting response to immune-checkpoint blockade therapy in non-small-cell lung carcinoma. International-journal Peer-reviewed

Ryoko Saito, Yasuhiro Miki, Takuto Abe, Eisaku Miyauchi, Jiro Abe, Ren Nanamiya, Chihiro Inoue, Ikuro Sato, Hironobu Sasano

British journal of cancer　123　(1)　61-71　2020/07

DOI： 10.1038/s41416-020-0837-3 　

More details Close

BACKGROUND: Understanding the status of intratumoural immune microenvironment is necessary to ensure the efficacy of immune-checkpoint (IC) blockade therapy. Cortisol plays pivotal roles in glucocorticoid interactions in the immune system. We examined the correlation between intratumourally synthesised cortisol through 11β hydroxysteroid dehydrogenase (HSD) 1 and the immune microenvironment in non-small-cell lung carcinoma (NSCLC). METHODS: We correlated 11βHSD1 immunoreactivity in 125 cases of NSCLC with the amount of intratumoural immune cells present, and 11βHSD1 immunoreactivity with the efficacy of IC blockade therapy in 18 specimens of NSCLC patients. In vitro studies were performed to validate the immunohistochemical examination. RESULTS: 11βHSD1 immunoreactivity showed a significant inverse correlation with the number of tumour-infiltrating lymphocytes and CD3- or CD8-positive T cells. 11βHSD1 immunoreactivity tended to be inversely correlated with the clinical efficacy of the IC blockade therapy. In vitro studies revealed that 11βHSD1 promoted the intratumoural synthesis of cortisol. This resulted in a decrease in cytokines and in the inhibition of monocyte migration. CONCLUSIONS: Our study is the first report clarifying the inhibitory effects of intratumourally synthesised cortisol through 11βHSD1 on immune cell migration. We propose that the response to IC blockade therapy in NSCLC may be predicted by 11βHSD1.
Factors influencing decision-making in relation to the administration of durvalumab after chemoradiotherapy (TOPGAN2020-01)

Ariyasu, R., Uchibori, K., Tanaka, H., Miyauchi, E., Kawashima, Y., Ohyanagi, F., Horiike, A., Sakatani, T., Saiki, M., Tambo, Y., Tanimoto, A., Sonoda, T., Koyama, J., Uenami, T., Kudo, K., Tsuchiya, Y., Nishio, M.

Japanese Journal of Lung Cancer　60　(7)　2020

DOI： 10.2482/HAIGAN.60.966 　

ISSN： 0386-9628
CD45+CD326+ Cells are Predictive of Poor Prognosis in Non-Small Cell Lung Cancer Patients. International-journal Peer-reviewed

Kota Ishizawa, Mie Yamanaka, Yuriko Saiki, Eisaku Miyauchi, Shinichi Fukushige, Tetsuya Akaishi, Atsuko Asao, Takahiro Mimori, Ryota Saito, Yutaka Tojo, Riu Yamashita, Michiaki Abe, Akira Sakurada, Nhu-An Pham, Ming Li, Yoshinori Okada, Tadashi Ishii, Naoto Ishii, Seiichi Kobayashi, Masao Nagasaki, Masakazu Ichinose, Ming-Sound Tsao, Akira Horii

Clinical cancer research : an official journal of the American Association for Cancer Research　25　(22)　6756-6763　2019/11/15

DOI： 10.1158/1078-0432.CCR-19-0545 　

ISSN： 1078-0432

More details Close

PURPOSE: The epithelial-to-mesenchymal transition, the major process by which some cancer cells convert from an epithelial phenotype to a mesenchymal one, has been suggested to drive chemo-resistance and/or metastasis in patients with cancer. However, only a few studies have demonstrated the presence of CD45/CD326 doubly-positive cells (CD45/CD326 DPC) in cancer. We deployed a combination of cell surface markers to elucidate the phenotypic heterogeneity in non-small cell lung cancer (NSCLC) cells and identified a new subpopulation that is doubly-positive for epithelial and non-epithelial cell-surface markers in both NSCLC cells and patients' malignant pleural effusions. EXPERIMENTAL DESIGN: We procured a total of 39 patients' samples, solid fresh lung cancer tissues from 21 patients and malignant pleural effusion samples from 18 others, and used FACS and fluorescence microscopy to check their surface markers. We also examined the EGFR mutations in patients with known acquired EGFR mutations. RESULTS: Our data revealed that 0.4% to 17.9% of the solid tumor tissue cells and a higher percentage of malignant pleural effusion cells harbored CD45/CD326 DPC expressing both epithelial and nonepithelial surface markers. We selected 3 EGFR mutation patients and genetically confirmed that the newly identified cell population really originated from cancer cells. We also found that higher proportions of CD45/CD326 DPC are significantly associated with poor prognosis. CONCLUSIONS: In conclusion, varying percentages of CD45/CD326 DPC exist in both solid cancer tissue and malignant pleural effusion in patients with NSCLC. This CD45/CD326 doubly-positive subpopulation can be an important key to clinical management of patients with NSCLC.
Comparison of TCR repertoires between cancer tissues and lymph nodes in colorectal cancer patients Peer-reviewed

Kiyotani Kazuma, Matsuda Tatsuo, Miyauchi Eisaku, Hsu Yu-Wen, Nagayama Satoshi, Zewde Makda, Park Jae-Hyun, Kato Taigo, Harada Makiko, Suzuki Nobuaki, Nagano Hiroaki, Hazama Shoichi, Nakamura Yusuke

CANCER RESEARCH　79　(13)　2019/07

DOI： 10.1158/1538-7445.SABCS18-1091 　

ISSN： 0008-5472

eISSN： 1538-7445
TCR sequencing analysis of cancer tissues and tumor draining lymph nodes in colorectal cancer patients. International-journal Peer-reviewed

Matsuda T, Miyauchi E, Hsu YW, Nagayama S, Kiyotani K, Zewde M, Park JH, Kato T, Harada M, Matsui S, Ueno M, Fukuda K, Suzuki N, Hazama S, Nagano H, Takeuchi H, Vigneswaran WT, Kitagawa Y, Nakamura Y

Oncoimmunology　8　(6)　e1588085　2019/03

DOI： 10.1080/2162402X.2019.1588085 　

ISSN： 2162-4011

More details Close

Tumor draining lymph nodes (TDLNs) are located in the routes of lymphatic drainage from a primary tumor and have the highest risk of metastasis in various types of solid tumors. TDLNs are also considered as a tissue to activate the antitumor immunity, where antigen-specific effector T cells are generated. However, T cell receptor (TCR) repertoires in TDLNs have not been well characterized. We collected 23 colorectal cancer tumors with 203 lymph nodes with/without metastatic cancer cells (67 were metastasis-positive and the remaining 136 were metastasis-negative) and performed TCR sequencing. Metastasis-positive TDLNs showed a significantly lower TCR diversity and shared TCR clonotypes more frequently with primary tumor tissues compared to metastasis-negative TDLNs. Principal component analysis indicated that TDLNs with metastasis showed similar TCR repertoires. These findings suggest that cancer-reactive T cell clones could be enriched in the metastasis-positive TDLNs.
Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas Peer-reviewed

Yoko Tsukita, Naoya Fujino, Eisaku Miyauchi, Ryoko Saito, Fumiyoshi Fujishima, Koji Itakura, Yorihiko Kyogoku, Koji Okutomo, Mitsuhiro Yamada, Tatsuma Okazaki, Hisatoshi Sugiura, Akira Inoue, Yoshinori Okada, Masakazu Ichinose

Molecular Cancer　18　(1)　24　2019/02/11

DOI： 10.1186/s12943-019-0953-y 　

eISSN： 1476-4598
Significant differences in T cell receptor repertoires in lung adenocarcinomas with and without EGFR mutations. International-journal Peer-reviewed

Miyauchi E, Matsuda T, Kiyotani K, Low SK, Hsu YW, Tsukita Y, Ichinose M, Sakurada A, Okada Y, Saito R, Nakamura Y

Cancer science　110　(3)　867-874　2018/12

DOI： 10.1111/cas.13919 　

ISSN： 1347-9032

More details Close

Recent clinical trials of non-small cell lung cancer with immune checkpoint inhibitors revealed that patients with epidermal growth factor receptor (EGFR) mutations had more unfavorable outcomes compared with those with wild-type EGFR. However, the underlying mechanism for the link between EGFR mutations and immune resistance remains unclear. We performed T cell receptor (TCR) repertoire analysis of resected lung adenocarcinoma tissues with and without EGFR mutations to investigate the characteristics of TCR repertoires. We collected a total of 39 paired (normal and tumor) lung tissue samples (20 had EGFR mutations) and conducted TCR repertoire analysis as well as whole-exome sequencing (WES) and transcriptome analysis. The TCR diversity index in EGFR-mutant tumors was significantly higher than that in EGFR-wild-type tumors (median [range] 552 [162-1,135] vs 230 [30-764]; P < .01), suggesting higher T cell clonal expansion in EGFR-wild-type tumors than in EGFR-mutant tumors. In WES, EGFR-mutant tumors showed lower numbers of non-synonymous mutations and predicted neoantigens than EGFR-wild-type tumors (P < .01, P = .03, respectively). The number of non-synonymous mutations revealed a positive correlation with the sum of frequencies of the TCRβ clonotypes of 1% or higher in tumors (r = .52, P = .04). The present study demonstrates significant differences in TCR repertoires and the number of predicted neoantigens between EGFR-mutant and wild-type lung tumors. Our findings provide important information for understanding the molecular mechanism behind EGFR-mutant patients showing unfavorable responses to immune checkpoint inhibitors.
Relapsed Myasthenia Gravis after Nivolumab Treatment. Peer-reviewed

Mitsune A, Yanagisawa S, Fukuhara T, Miyauchi E, Morita M, Ono M, Tojo Y, Ichinose M

Internal medicine (Tokyo, Japan)　57　(13)　1893-1897　2018/07

DOI： 10.2169/internalmedicine.9153-17 　

ISSN： 0918-2918

More details Close

Nivolumab is a newly introduced promising therapy for treating lung cancer that restores the anti-tumor immunity by disrupting programmed cell death-1-mediated immuno-suppressive signaling. Although "new-onset" autoimmune diseases are well-known immune-related adverse events, whether or not nivolumab exacerbates "pre-existing" autoimmune disease remains unclear. We herein report a patient with "pre-existing" myasthenia gravis in whom nivolumab was administered that flared up after the treatment with nivolumab. Regardless of the disease stability, nivolumab has the potential to exacerbate an autoimmune disease, and we must pay close attention to each patient's medical history before administering this agent.
Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study. International-journal Peer-reviewed

Ko R, Shukuya T, Okuma Y, Tateishi K, Imai H, Iwasawa S, Miyauchi E, Fujiwara A, Sugiyama T, Azuma K, Muraki K, Yamasaki M, Tanaka H, Takashima Y, Soda S, Ishimoto O, Koyama N, Morita S, Kobayashi K, Nukiwa T, Takahashi K, North East Japan, Study Group

The oncologist　23　(10)　1210-1217　2018/03

DOI： 10.1634/theoncologist.2017-0586 　

ISSN： 1083-7159

More details Close

BACKGROUND: The prognostic factors and the efficacy of first-line chemotherapy remain unclear in patients with advanced thymic carcinoma. MATERIALS AND METHODS: We conducted a multi-institutional retrospective study named NEJ023 for patients with advanced thymic carcinoma. All patients without any indication of curative treatment were treated with chemotherapy from 1995 to 2014 at 40 institutions of the North East Japan Study Group. RESULTS: A total of 286 patients with advanced thymic carcinoma were analyzed. First-line chemotherapy included platinum-based doublets in 62.2% of the patients, monotherapy in 3.5%, and other multidrug chemotherapy (e.g., cisplatin, doxorubicin, vincristine, and cyclophosphamide [ADOC]) in 34.3%. The median follow-up period was 55.5 months, and the median overall survival (OS) from the start of first-line chemotherapy was 30.7 months (95% confidence interval, 25.9-35.9 months). There was no significant difference in OS among different first-line chemotherapy regimens (e.g., between carboplatin/paclitaxel and ADOC, median OS: 27.8 vs. 29.9 months). Masaoka-Koga stage IVa and volume reduction surgery were favorable prognostic factors for OS in the multivariate analysis using the Cox proportional hazards model. CONCLUSION: The efficacy of each first-line chemotherapy regimen for advanced thymic carcinoma did not vary significantly. Our results might support the adequacy of the use of carboplatin/paclitaxel as first-line chemotherapy for these patients. IMPLICATIONS FOR PRACTICE: Because of its rarity, there is limited information about prognostic factors and efficacy of chemotherapy in patients with advanced thymic carcinoma. This is the largest data set for those patients treated with chemotherapy. This study suggests there is no significant difference in efficacy between carboplatin/paclitaxel and cisplatin/doxorubicin/vincristine/cyclophosphamide for advanced thymic carcinoma. This result can support the adequacy of the selection of platinum doublets as treatment for those patients, rather than anthracycline-based multidrug regimen.
Splenic tuberculosis Peer-reviewed

Yutaka Tojo, Satoru Yanagisawa, Eisaku Miyauchi, Masakazu Ichinose

International Journal of Infectious Diseases　67　41-42　2018/02/01
Publisher: Elsevier B.V.
DOI： 10.1016/j.ijid.2017.12.009 　

ISSN： 1878-3511 1201-9712

eISSN： 1878-3511
A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002) Peer-reviewed

Yasuyuki Ikezawa, Hajime Asahina, Satoshi Oizumi, Masahiro Watanabe, Kei Takamura, Yasutaka Kawai, Noriyuki Yamada, Toshiyuki Harada, Ichiro Kinoshita, Yuka Fujita, Eisaku Miyauchi, Takahiro Ogi, Toraji Amano, Megumi Furuta, Jun Sakakibara-Konishi, Hiroshi Nishihara, Hirotoshi Dosaka-Akita, Hiroshi Isobe, Masaharu Nishimura

CANCER CHEMOTHERAPY AND PHARMACOLOGY　80　(5)　955-963　2017/11

DOI： 10.1007/s00280-017-3432-4 　

ISSN： 0344-5704

eISSN： 1432-0843
Numb Chin Syndrome: An Ominous Sign of Lung Cancer Peer-reviewed

Satoru Yanagisawa, Eisaku Miyauchi, Masakazu Ichinose

Journal of Thoracic Oncology　12　(8)　e114-e116　2017/08/01
Publisher: Elsevier Inc
DOI： 10.1016/j.jtho.2017.03.014 　

ISSN： 1556-1380 1556-0864

eISSN： 1556-1380
Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301 Peer-reviewed

Eisaku Miyauchi, Akira Inoue, Kazuhiro Usui, Shunichi Sugawara, Makoto Maemondo, Heisuke Saito, Yuka Fujita, Terufumi Kato, Toshiro Suzuki, Toshiyuki Harada, Hiroshi Watanabe, Taku Nakagawa, Masakazu Ichinose

ONCOLOGIST　22　(6)　640-E59　2017/06

DOI： 10.1634/theoncologist.2017-0059 　

ISSN： 1083-7159

eISSN： 1549-490X
Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease Peer-reviewed

Eisaku Miyauchi, Masakazu Ichinose, Akira Inoue

Journal of Thoracic Oncology　12　(5)　e59-e61　2017/05/01
Publisher: Elsevier Inc
DOI： 10.1016/j.jtho.2017.01.027 　

ISSN： 1556-1380 1556-0864
Treatments and outcomes of advanced/recurrent non-small cell lung cancer harboring the EGFR T790M mutation: a retrospective observational study of 141 patients in Japan Peer-reviewed

Yuki Yamane, Ayako Shiono, Yoshiki Ishii, Kazutoshi Isobe, Eisaku Miyauchi, Kazuma Kishi, Makoto Nishino, Shunichi Sugawara, Ryo Ko, Nobuyuki Koyama, Yutaka Yabuki, Kunihiko Kobayashi

JAPANESE JOURNAL OF CLINICAL ONCOLOGY　46　(12)　1135-1142　2016/12

DOI： 10.1093/jjco/hyw124 　

ISSN： 0368-2811

eISSN： 1465-3621
Two cases of pseudo-achalasia with lung cancer: Case report and short literature review Peer-reviewed

Taizou Hirano, Eisaku Miyauchi, Akira Inoue, Ryotaro Igusa, Shigeki Chiba, Kazuhiro Sakamoto, Hisatoshi Sugiura, Toshiaki Kikuchi, Masakazu Ichinose

Respiratory Investigation　54　(6)　494-499　2016/11/01
Publisher: Elsevier B.V.
DOI： 10.1016/j.resinv.2016.04.006 　

ISSN： 2212-5353 2212-5345
Phase II study of carboplatin/ pemetrexed/bevacizumab for non-squamous NSCLC with carcinomatous pleuritis (NEJ013A) Peer-reviewed

Eisaku Miyauchi, Kazuhiro Usui, Shunichi Sugawara, Masaru Nishitsuji, Yuka Fujita, Atsuto Mouri, Hiroshi Watanabe, Hiroshi Sakai, Ichiro Kinoshita, Koichi Hagiwara

ANNALS OF ONCOLOGY　27　2016/07

ISSN： 0923-7534

eISSN： 1569-8041
Immune checkpoint therapy for non-small-cell lung cancer Peer-reviewed

Eisaku Miyauchi, Akira Inoue

Japanese Journal of Cancer and Chemotherapy　43　(6)　666-671　2016/06/01
Publisher: Japanese Journal of Cancer and Chemotherapy Publishers Inc.
ISSN： 0385-0684
Prognostic significance of CpG island methylator phenotype in surgically resected small cell lung carcinoma Peer-reviewed

Yuichi Saito, Genta Nagae, Noriko Motoi, Eisaku Miyauchi, Hironori Ninomiya, Hirofumi Uehara, Mingyon Mun, Sakae Okumura, Fumiyoshi Ohyanagi, Makoto Nishio, Yukitoshi Satoh, Hiroyuki Aburatani, Yuichi Ishikawa

CANCER SCIENCE　107　(3)　320-325　2016/03

DOI： 10.1111/cas.12876 　

ISSN： 1347-9032

eISSN： 1349-7006
Distinct Characteristics of Small Cell Lung Cancer Correlate With Central or Peripheral Origin Subtyping Based on Location and Expression of Transcription Factor TTF-1 Peer-reviewed

Eisaku Miyauchi, Noriko Motoi, Hiroshi Ono, Hironori Ninomiya, Fumiyoshi Ohyanagi, Makoto Nishio, Sakae Okumura, Masakazu Ichinose, Yuichi Ishikawa

MEDICINE　94　(51)　e2324　2015/12

DOI： 10.1097/MD.0000000000002324 　

ISSN： 0025-7974

eISSN： 1536-5964
Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer - data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002) Peer-reviewed

Eisaku Miyauchi, Akira Inoue, Kunihiko Kobayashi, Makoto Maemondo, Shunichi Sugawara, Satoshi Oizumi, Hiroshi Isobe, Akihiko Gemma, Yasuo Saijo, Hirohisa Yoshizawa, Koichi Hagiwara, Toshihiro Nukiwa

JAPANESE JOURNAL OF CLINICAL ONCOLOGY　45　(7)　670-676　2015/07

DOI： 10.1093/jjco/hyv054 　

ISSN： 0368-2811

eISSN： 1465-3621
Pulmonary Adenocarcinoma In Situ Analyses of a Large Series With Reference to Smoking, Driver Mutations, and Receptor Tyrosine Kinase Pathway Activation Peer-reviewed

Seijiro Sato, Noriko Motoi, Miyako Hiramatsu, Eisaku Miyauchi, Hiroshi Ono, Yuichi Saito, Hiroko Nagano, Hironori Ninomiya, Kentaro Inamura, Hirofumi Uehara, Mingyon Mun, Yukinori Sakao, Sakae Okumura, Masanori Tsuchida, Yuichi Ishikawa

AMERICAN JOURNAL OF SURGICAL PATHOLOGY　39　(7)　912-921　2015/07

DOI： 10.1097/PAS.0000000000000458 　

ISSN： 0147-5185

eISSN： 1532-0979
Treatment of advanced non-small-cell lung cancer in elderly patients Peer-reviewed

Eisaku Miyauchi, Akira Inoue

Japanese Journal of Cancer and Chemotherapy　42　(1)　6-11　2015/01/01
Publisher: Japanese Journal of Cancer and Chemotherapy Publishers Inc.
ISSN： 0385-0684
Long noncoding RNA HOTAIR is relevant to cellular proliferation, invasiveness, and clinical relapse in small-cell lung cancer Peer-reviewed

Hiroshi Ono, Noriko Motoi, Hiroko Nagano, Eisaku Miyauchi, Masaru Ushijima, Masaaki Matsuura, Sakae Okumura, Makoto Nishio, Tetsuro Hirose, Naohiko Inase, Yuichi Ishikawa

CANCER MEDICINE　3　(3)　632-642　2014/06

DOI： 10.1002/cam4.220 　

ISSN： 2045-7634
Significance of Morphological Heterogeneity of Lung Adenocarcinoma Evaluated by FFPE-Based miRNA Profile, in Comparison with Genotype Peer-reviewed

N. Motoi, H. Nagano, E. Miyauchi, Y. Saito, Y. Sugiura, H. Ninomiya, H. Kanda, S. Okumura, Y. Ishikawa

LABORATORY INVESTIGATION　94　489A-489A　2014/02

ISSN： 0023-6837

eISSN： 1530-0307
MORPHOLOGICAL AND MUCIN PROFILE OF LUNG ADENOCARCINOMA HARBORING DRIVER MUTATION Peer-reviewed

Noriko Motoi, Yuichi Saito, Eisaku Miyauchi, Seijiro Sato, Hironori Ninomiya, Yuichi Ishikawa

JOURNAL OF THORACIC ONCOLOGY　8　S203-S203　2013/11

ISSN： 1556-0864

eISSN： 1556-1380
DISTINCT CHARACTERISTICS OF SMALL CELL LUNG CANCER (SCLC) CORRELATE WITH CENTRAL OR PERIPHERAL ORIGIN - MICROARRAY ANALYSIS OF SNAP FROZEN TISSUE SAMPLES Peer-reviewed

Miyauchi Eisaku, Saito Yuichi, Ninomiya Hironori, Motoi Noriko, Nishio Makoto, Okumura Sakae, Ishikawa Yuichi

JOURNAL OF THORACIC ONCOLOGY　8　S740　2013/11

ISSN： 1556-0864
IDENTIFICATION OF CPG ISLAND METHYLATOR PHENOTYPE PREDICTS THE PROGNOSIS OF SMALL CELL LUNG CANCER Peer-reviewed

Saito Yuichi, Miyauchi Eisaku, Ninomiya Hironori, Motoi Noriko, Nakao Masayuki, Uehara Hirofumi, Mun Mingyon, Okumura Sakae, Nakagawa Ken, Nagae Genta, Aburatani Hiroyuki, Satoh Yukitoshi, Ishikawa Yuichi

JOURNAL OF THORACIC ONCOLOGY　8　S1044-S1045　2013/11

ISSN： 1556-0864
COPY NUMBER CHANGES IN CHROMOSOME 2P ARE UNIQUE EVENTS AMONG ALK FUSION POSITIVE LUNG ADENOCARCINOMAS Peer-reviewed

Hironori Ninomiya, Motohiro Kato, Masashi Sanada, Kengo Takeuchi, Yuichi Saito, Eisaku Miyauchi, Noriko Motoi, Hiroyuki Mano, Seishi Ogawa, Yuichi Ishikawa

JOURNAL OF THORACIC ONCOLOGY　8　S959-S959　2013/11

ISSN： 1556-0864

eISSN： 1556-1380
A phase II study of S-1 in relapsed small cell lung cancer. Peer-reviewed

Kudo K, Ohyanagi F, Horiike A, Miyauchi E, Tahanaka H, Yanagitani N, Saito R, Kaburaki K, Sakatani T, Horai T, Nishio M

Molecular and clinical oncology　1　(2)　263-266　2013/03

DOI： 10.3892/mco.2013.67 　

ISSN： 2049-9450
Clinicopathological findings of non-small-cell lung cancer with high serum progastrin-releasing peptide concentrations Peer-reviewed

Keita Kudo, Fumiyoshi Ohyanagi, Atushi Horiike, Eisaku Miyauchi, Noriko Yanagitani, Rira Hoshi, Yukitoshi Satoh, Noriko Motoi, Wakako Hamanaka, Yuichi Ishikawa, Mingyon Mun, Yukinori Sakao, Sakae Okumura, Ken Nakagawa, Takeshi Horai, Makoto Nishio

LUNG CANCER　74　(3)　401-404　2011/12

DOI： 10.1016/j.lungcan.2011.03.019 　

ISSN： 0169-5002
Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer Peer-reviewed

A. Horiike, K. Kudo, E. Miyauchi, F. Ohyanagi, K. Kasahara, T. Horai, M. Nishio

BRITISH JOURNAL OF CANCER　105　(8)　1131-1136　2011/10

DOI： 10.1038/bjc.2011.375 　

ISSN： 0007-0920
A case of cutaneous infection caused by Mycobacterium szulgai with progression to acute respiratory distress syndrome Peer-reviewed

Hiromitsu Ohta, Eisaku Miyauchi, Masahito Ebina, Toshihiro Nukiwa

Clinical Medicine Insights: Case Reports　4　29-33　2011
Publisher: Libertas Academica Ltd.
DOI： 10.4137/CCRep.S7180 　

ISSN： 1179-5476
A phase II study of S-1 for previously treated small cell lung cancer (SCLC) Peer-reviewed

K. Kudo, F. Ohyanagi, A. Horiike, E. Miyauchi, I. Motokawa, T. Horai, M. Mun, Y. Sakao, S. Okumura, K. Nakagawa, M. Nishio

JOURNAL OF CLINICAL ONCOLOGY　27　(15)　2009/05

ISSN： 0732-183X
A case of primary biliary cirrhosis accompanied with fibrinogen storage disease Peer-reviewed

H Mitsui, E Miyauchi, J Miyahara, K Wada, M Yamakawa, S Kawata

PATHOLOGY RESEARCH AND PRACTICE　201　(4)　341-345　2005

DOI： 10.1016/j.prp.2004.09.017 　

ISSN： 0344-0338

Show all ︎Show first 5

Misc. 179

簡易懸濁法を用いて在宅でオシメルチニブを経管投与した非小細胞肺癌の一例

水口敦史, 菊地正史, 成田佳奈, 宮内栄作, 眞野成康

医薬品相互作用研究　48　(1)　18-23　2024/06
Publisher: (一社)医薬品相互作用研究会
ISSN： 0385-5015
当院における進行期非小細胞肺癌患者に対する院内AMOY遺伝子変異検査の検査成功率とTurn Around Timeの検討

岩崎史, 宮内栄作, 井上千裕, 青山弥生, 小泉照樹, 渋谷里紗, 突田容子, 木村望, 伊藤辰徳, 小野祥直, 松本周一郎, 成田大輔, 遠藤卓人, 鈴木眞奈美, 野津田泰嗣, 小野寺賢, 岡田克典

気管支学　46　(Suppl.)　S292-S292　2024/05
Publisher: (一社)日本呼吸器内視鏡学会
ISSN： 0287-2137

eISSN： 2186-0149
小細胞肺癌治療間質性肺炎合併小細胞肺癌に対するデュルバルマブ/エトポシド/カルボプラチン療法の多施設前向き介入試験(DREAM試験)

藤本大智, 柴木亮太, 仲地一郎, 宮内栄作, 坂田能彦, 木島貴志, 田宮基裕, 川名祥子, 原聡志, 斎藤合, 佐藤悠城, 坂田晋也, 松本啓孝, 山口哲平, 山本信之

日本呼吸器学会誌　13　(増刊)　224-224　2024/03
Publisher: (一社)日本呼吸器学会
ISSN： 2186-5876

eISSN： 2186-5884
肺癌患者の血漿検体を用いたメタボローム解析による個別化医療への挑戦

成田大輔, 渋谷里紗, 宮内栄作, 突田容子, 木村望, 角藤翔, 杉浦久敏

日本呼吸器学会誌　13　(増刊)　268-268　2024/03
Publisher: (一社)日本呼吸器学会
ISSN： 2186-5876

eISSN： 2186-5884
簡易懸濁法を用いて在宅でのオシメルチニブ投与に繋げた非小細胞肺癌の一例

水口敦史, 成田佳奈, 宮内栄作, 菊地正史, 眞野成康

日本服薬支援研究会誌　11　(2)　26-26　2024/02
Publisher: 日本服薬支援研究会
化学免疫療法後にサルベージ手術を行い完全奏効が確認された肺腺癌の1例

岩崎史, 宮内栄作, 井上千裕, 杉浦久敏, 野津田泰嗣, 岡田克典

日本呼吸器学会誌　12　(6)　319-323　2023/11
Publisher: (一社)日本呼吸器学会
ISSN： 2186-5876

eISSN： 2186-5884
J-TAIL-2中間報告(NSCLCコホート) 切除不能な進行/再発のNSCLC又はED-SCLCに対するATZ併用療法の観察研究

木曽原朗, 西尾誠人, 菊地英毅, 清水淳市, 宮内栄作, 吉岡弘鎮, 吉野一郎, 三角俊裕, 高橋聡, 関順彦, 毛利篤人, 竹中賢, 岩澤俊一郎, 田中美早, 弦間昭彦

肺癌　63　(5)　353-353　2023/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
間質性肺炎合併小細胞肺癌に対するデュルバルマブ/エトポシド/カルボプラチン療法の多施設前向き介入試験

坂田能彦, 藤本大智, 柴木亮太, 仲地一郎, 荒井大輔, 宮内栄作, 突田容子, 神宮直樹, 木島貴志, 田宮基裕, 川名祥子, 原聡志, 齋藤合, 佐藤悠城, 横山俊秀, 坂田晋也, 谷口善彦, 秦明登, 松本啓孝, 山口哲平

肺癌　63　(5)　474-474　2023/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
進展型小細胞肺癌患者に対する免疫治療の長期効果を予測する病理画像を用いた機械学習バイオマーカー研究

木島貴志, 柴木亮太, 藤本大智, 野沢綸佐, 原聡志, 内田純二, 宮内栄作, 平岡亮太, 駄賀晴子, 益田武, 田中智, 池田慧, 齋藤合, 鈴木秀和, 坂田晋也, 坂田能彦, 山本信之, 洪泰浩, 赤松弘朗

肺癌　63　(5)　494-494　2023/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
進展型小細胞肺癌患者に対するカルボプラチン/エトポシド/アテゾリズマブの多施設前向き研究 2年update

谷口善彦, 藤本大智, 田宮基裕, 秦明登, 松本啓孝, 杉坂淳, 横山俊秀, 田中智, 佐藤悠城, 木島貴志, 田中寿志, 古屋直樹, 益田武, 坂田能彦, 宮内栄作, 原聡志, 鈴木秀和, 池田慧, 平岡亮太, 矢内正晶, 峯村浩之, 山本信之, 赤松弘朗

肺癌　63　(5)　505-505　2023/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
EGFR遺伝子変異陽性肺癌に対する薬物療法の新たな展開と課題

宮内栄作

肺癌　63　(5)　522-522　2023/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
非小細胞肺癌患者に対するAMOY遺伝子変異検査の院内導入における利点と今後の課題

宮内栄作, 井上千裕, 青山弥生, 小泉照樹, 渋谷里紗, 突田容子, 木村望, 成田大輔, 野津田泰嗣, 小野寺賢, 岡田克典, 杉浦久敏

肺癌　63　(5)　578-578　2023/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
RWDからNecitumumabによる低Mg血症を考察する多施設共同後方視的観察(NINJA Study)からの提言

森雅秀, 丹澤盛, 鉄本訓史, 田中洋史, 渡部聡, 山口覚博, 吉原健, 中尾明, 久保昭仁, 横山俊彦, 渡邉香奈, 鶴野広介, 吉岡弘鎮, 宮内栄作, 二宮貴一朗, 三角俊裕, 関順彦

肺癌　63　(5)　659-659　2023/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
ステロイド治療中に自己免疫性肺胞蛋白症が続発した線維性過敏性肺炎の一例

杉山初美, 村上康司, 東出直樹, 玉田勉, 山本友梨, 鈴木眞奈美, 岩崎史, 相澤洋之, 沼倉忠久, 宮内栄作, 杉浦久敏

日本サルコイドーシス/肉芽腫性疾患学会雑誌　43　(サプリメント号)　66-66　2023/10
Publisher: 日本サルコイドーシス
ISSN： 1883-1273

eISSN： 1884-6114
肺癌効果予測因子非小細胞肺癌に対する殺細胞性抗癌剤・免疫チェックポイント阻害薬併用療法の効果予測因子の探索

木村望, 突田容子, 渋谷里紗, 宮内栄作, 角藤翔, 成田大輔, 斎藤良太, 杉浦久敏

日本呼吸器学会誌　12　(増刊)　194-194　2023/03
Publisher: (一社)日本呼吸器学会
ISSN： 2186-5876

eISSN： 2186-5884
心房中隔欠損症によるplatypnea-orthodeoxia症候群の1例

佐藤章広, 東出直樹, 鈴木眞奈美, 杉山初美, 相澤洋之, 宮内栄作, 玉田勉, 杉浦久敏

日本呼吸器学会誌　12　(増刊)　387-387　2023/03
Publisher: (一社)日本呼吸器学会
ISSN： 2186-5876

eISSN： 2186-5884
COVID-19ワクチン接種を契機に副腎クリーゼを発症した続発性副腎不全合併肺癌の1例

宮内栄作, 今野周一, 渋谷里紗, 相澤洋之, 東出直樹, 玉田勉, 杉浦久敏

肺癌　62　(7)　1063-1063　2022/12
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
進展型小細胞肺癌患者に対するカルボプラチン/エトポシド/アテゾリズマブ療法の多施設前向き観察研究

松本啓孝, 藤本大智, 赤松弘朗, 森本剛, 横山俊秀, 谷口善彦, 内田純二, 田中寿志, 佐藤悠城, 古屋直樹, 益田武, 坂田能彦, 宮内栄作, 原聡志, 日野葵, 三浦理, 金津正樹, 山本信之

肺癌　62　(6)　583-583　2022/11
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
リアルワールドデータから本邦のNecitumumabの立ち位置を考える(NINJA study)

丹澤盛, 吉岡弘鎮, 宮内栄作, 二宮貴一朗, 三角俊裕, 関順彦

肺癌　62　(6)　649-649　2022/11
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
患者由来ALK融合遺伝子陽性肺がん細胞株を用いたdrug tolerant persisterに対する新規併用療法の探索

藤村多嘉朗, 横山俊秀, 内堀健, 宮内栄作, 林秀敏, 片山量平

肺癌　62　(6)　654-654　2022/11
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
癌性胸水合併Non-Sqに対する1st-line PembrolizumabおよびICI/Chemoの有効性多施設後ろ向き観察研究

河内勇人, 田宮基裕, 谷口善彦, 横山俊秀, 横江真弥, 大矢由子, 今地美帆子, 岡部福子, 金津正樹, 坂田能彦, 植松慎矢, 田中智, 荒井大輔, 齋藤合, 神戸寛史, 宮内栄作, 岡田あすか, 原聡志, 西野和美, Hanshin Oncology clinical Problem Evaluation group(HOPE group)

肺癌　62　(6)　709-709　2022/11
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
進行非小細胞肺癌(NSCLC)に対する化学療法の実施状況に関する多施設調査

井上彰, 川嶋庸介, 守田亮, 中川拓, 鶴見恭士, 田中寿志, 野川ひとみ, 長島広相, 柳澤悟, 菊池創, 木村望, 千葉茂樹, 菊池崇史, 宮内栄作

肺癌　62　(6)　778-778　2022/11
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
リゾリン脂質産生酵素によるサルコイドーシス疾患活動性の評価

村上康司, 玉田勉, 三枝大輔, 奈良正之, 宮内栄作, 蔵野信, 矢冨裕, 杉浦久敏

日本サルコイドーシス/肉芽腫性疾患学会雑誌　42　(サプリメント号)　74-74　2022/10
Publisher: 日本サルコイドーシス
ISSN： 1883-1273

eISSN： 1884-6114
維持期心疾患高齢患者の身体活動量は幸福度と運動耐容能に関連する多施設共同横断研究

山下亮, 佐藤真治, 阪井康友, 玉利光太郎, 荒井久仁子, 外山洋平, 高上英輝, 黒瀬聖司, 宮内拓史, 久保田眞由美, 板矢悠佑, 村上光世, 岡村大介, 原田栄作

日本臨床運動療法学会学術集会プログラム・抄録集　41回　68-68　2022/09
Publisher: (NPO)日本臨床運動療法学会
運動療法継続者の性格特性と動機付けおよび心理社会的要因との関連

荒井久仁子, 山下亮, 原田栄作, 黒瀬聖司, 宮内拓史, 木村穣, 今井優, 中島友里, 森山善文, 足立佳世

日本臨床運動療法学会学術集会プログラム・抄録集　41回　73-73　2022/09
Publisher: (NPO)日本臨床運動療法学会
リンパ行性転移が示唆された小細胞肺癌術後気管内再発の1例

木村望, 突田容子, 宮内栄作, 小室英恵, 齊藤涼子, 佐藤輝幸, 宍倉裕, 野津田泰嗣, 桜田晃, 杉浦久敏

気管支学　44　(1)　69-72　2022/01
Publisher: (NPO)日本呼吸器内視鏡学会
ISSN： 0287-2137

eISSN： 2186-0149
アレクチニブ、ロルラチニブ耐性後にブリガチニブが奏効したALK陽性肺癌の1例

宮内栄作, 今野周一, 角藤翔, 東出直樹, 佐藤慶, 玉田勉, 杉浦久敏

肺癌　61　(7)　1003-1003　2021/12
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
切除不能III期非小細胞肺癌に対する強度変調放射線治療を用いた化学放射線療法に関しての後方視的研究

草場勇作, 竹田雄一郎, 突田容子, 山本貴也, 宮内栄作, 馬屋原博, 秦明登, 田中智, 内田純二, 臼井一裕, 田宮基裕, 大矢由子

肺癌　61　(6)　592-592　2021/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
EGFR-TKI既治療症例に対するダコミチニブ療法の検討(TOPGAN2020-02)

椎原淳, 田中寿志, 坂本博昭, 川嶋庸介, 丹保裕一, 谷本梓, 堀池篤, 宮内栄作, 土屋裕子, 西尾誠人, 大柳文義

肺癌　61　(6)　601-601　2021/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
EGFR変異陽性肺癌患者における組織転化の多施設後ろ向き調査(HISTORIC study)

和久田一茂, 藤本大智, 森本剛, 佐藤悠城, 河良崇, 横山俊秀, 田宮基裕, 平岡亮太, 新宮直樹, 森永亮太郎, 谷口善彦, 金津正樹, 宮内栄作, 三浦理, 池田英樹, 矢内正晶, 四方田真紀子, 山本信之, HISTORIC試験グループ

肺癌　61　(6)　602-602　2021/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
気管支鏡検査により軟口蓋血腫を認めた原発性アミロイドーシスの1例

成田大輔, 宮内栄作, 宍倉裕, 佐藤慶, 光根歩, 佐野寛仁, 杉山初美, 玉田勉, 杉浦久敏

気管支学　43　(5)　565-565　2021/09
Publisher: (NPO)日本呼吸器内視鏡学会
ISSN： 0287-2137

eISSN： 2186-0149
PD-L1高発現未治療進行非小細胞肺がんに対するネシツムマブ+ペムブロリズマブ療法の第II相試験(K-TAIL-202)

堀池篤, 楠本壮二郎, 白石英晶, 酒谷俊雄, 和久井大, 宮内栄作, 下川恒夫, 細見幸生, 塩豊, 竹ノ下祥子, 龍家圭, 三邉武彦, 今村知世, 田坂定智, 井上永介, 和田聡, 吉村清, 相良博典, 小林真一, 角田卓也

日本がん免疫学会総会プログラム・抄録集　25回　192-192　2021/05
Publisher: 日本がん免疫学会
当院におけるIMRTによる根治的放射線化学療法後のデュルバルマブ投与症例の検討

木村望, 突田容子, 斎藤良太, 佐藤輝幸, 宮内栄作, 井上彰, 杉浦久敏

日本呼吸器学会誌　10　(増刊)　139-139　2021/04
Publisher: (一社)日本呼吸器学会
ISSN： 2186-5876

eISSN： 2186-5884
サルコイドーシスの疾患活動性評価におけるリゾリン脂質産生酵素の有用性

村上康司, 玉田勉, 三枝大輔, 奈良正之, 宮内栄作, 矢冨裕, 杉浦久敏

日本呼吸器学会誌　10　(増刊)　265-265　2021/04
Publisher: (一社)日本呼吸器学会
ISSN： 2186-5876

eISSN： 2186-5884
化学放射線療法後デュルバルマブの投与回避要因(TOPGAN2020-01)

有安亮, 内堀健, 田中寿志, 宮内栄作, 川嶋庸介, 大柳文義, 堀池篤, 酒谷俊雄, 齊木雅史, 丹保裕一, 谷本梓, 園田智明, 神山潤二, 上浪健, 工藤慶太, 土屋裕子, 西尾誠人

肺癌　60　(7)　966-971　2020/12
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
ALK-IHC陽性肺腺癌に対してアレクチニブを投与したが奏効せず、後にROS1陽性が判明しクリゾチニブが奏効した1例

杉山初美, 宮内栄作, 齋藤勉, 相澤洋之, 突田容子, 齋藤良太, 佐藤輝幸, 宍倉裕, 杉浦久敏, 齊藤涼子

肺癌　60　(7)　1032-1032　2020/12
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
第1世代EGFR-TKI耐性例に対するafatinibの効果と高感度PNA-LNA PCR clamp法による血漿EGFR変異との関連性

渡邉香奈, 渡部聡, 宮内栄作, 長島広相, 菅原俊一, 盛田麻美, 鈴木綾, 田中伸幸, 寺崎浩司, 福原達朗, 前門戸任

肺癌　60　(6)　670-670　2020/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
実臨床でのDurvalumab投与可否のDecision Making Factorに関する検討

上浪健, 田中寿志, 宮内栄作, 川嶋庸介, 大柳文義, 齊木雅史, 酒谷俊雄, 堀池篤, 有安亮, 谷本梓, 丹保裕一, 園田智明, 神山潤二, 工藤慶太, 土屋裕子, 西尾誠人

肺癌　60　(6)　661-661　2020/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
胸腔鏡下肺切除術で診断された印環細胞癌様の形態を呈した肺腺癌の1例

成田大輔, 宮内栄作, 齊藤涼子, 江場俊介, 岡田克典, 一ノ瀬正和

日本呼吸器学会誌　9　(5)　345-349　2020/09
Publisher: (一社)日本呼吸器学会
ISSN： 2186-5876

eISSN： 2186-5884
サルコイドーシスの血漿および尿中におけるリゾリン脂質産生酵素の解析

村上康司, 玉田勉, 三枝大輔, 奈良正之, 宮内栄作, 有竹秀美, 蒲生俊一, 矢冨裕, 一ノ瀬正和

日本呼吸器学会誌　9　(増刊)　205-205　2020/08
Publisher: (一社)日本呼吸器学会
ISSN： 2186-5876

eISSN： 2186-5884
【進行期肺癌治癒への道-がんゲノム医療と免疫プレシジョン医療の接点】分子標的治療薬最前線 EGFR-TKI世代ごとの特徴

宮内栄作, 井上彰

呼吸器ジャーナル　68　(3)　354-361　2020/08
Publisher: (株)医学書院
ISSN： 2432-3268
サルコイドーシスの血漿および尿中におけるリゾリン脂質産生酵素の解析

村上康司, 玉田勉, 三枝大輔, 奈良正之, 宮内栄作, 有竹秀美, 蒲生俊一, 矢冨裕, 一ノ瀬正和

日本呼吸器学会誌　9　(増刊)　205-205　2020/08
Publisher: (一社)日本呼吸器学会
ISSN： 2186-5876

eISSN： 2186-5884
抗菌薬不応性の難治性肺膿瘍病変をきっかけに発見された成人先天性嚢胞状腺腫様奇形の一例

山田充啓, 江場俊介, 鈴木歩, 佐藤輝幸, 宮内栄作, 齋藤良太, 光根歩, 板倉康司, 一ノ瀬正和

気管支学　42　(Suppl.)　S314-S314　2020/06
Publisher: (NPO)日本呼吸器内視鏡学会
ISSN： 0287-2137

eISSN： 2186-0149
結腸気管支瘻による肺炎,肺膿瘍に対して気管支充填術を施行し救命し得た一例

鈴木歩, 小荒井晃, 川副友, 宮内栄作, 東出直樹, 片平真人, 佐渡哲, 杉浦久敏, 一ノ瀬正和

気管支学　42　(Suppl.)　S409-S409　2020/06
Publisher: (NPO)日本呼吸器内視鏡学会
ISSN： 0287-2137

eISSN： 2186-0149
抗菌薬不応性の難治性肺膿瘍病変をきっかけに発見された成人先天性嚢胞状腺腫様奇形の一例

山田充啓, 江場俊介, 鈴木歩, 佐藤輝幸, 宮内栄作, 齋藤良太, 光根歩, 板倉康司, 一ノ瀬正和

気管支学　42　(Suppl.)　S314-S314　2020/06
Publisher: (NPO)日本呼吸器内視鏡学会
ISSN： 0287-2137

eISSN： 2186-0149
気管・気管支内に多発する転移結節を認めた小細胞肺癌の1例

鈴木歩, 宮内栄作, 成田大輔, 相澤洋之, 東條裕, 小林誠, 村上康司, 山田充啓, 杉浦久敏, 一ノ瀬正和

気管支学　42　(3)　269-273　2020/05
Publisher: (NPO)日本呼吸器内視鏡学会
ISSN： 0287-2137

eISSN： 2186-0149
ALK-IHC陽性肺腺癌に対してアレクチニブを投与したが奏効せず,後にROS1陽性が判明しクリゾチニブが奏効した1例

杉山初美, 宮内栄作, 齋藤勉, 相澤洋之, 突田容子, 齋藤良太, 佐藤輝幸, 宍倉裕, 杉浦久敏, 齊藤涼子

肺癌(Web)　60　(7)　2020

ISSN： 1348-9992
修飾核酸一斉定量系を用いたCOPD早期発見手法の開発検討

渡辺匠, 平本航大, 沼倉忠久, 滝田克也, 宮内栄作, 突田容子, 杉浦久敏, 松本洋太郎, 富岡佳久

日本薬学会東北支部大会講演要旨集　59th　2020
Analysis of plasma and urine lysophospholipids producing enzymes in sarcoidosis

村上康司, 玉田勉, 三枝大輔, 奈良正之, 宮内栄作, 有竹秀美, 蒲生俊一, 矢冨裕, 一ノ瀬正和

日本呼吸器学会誌(Web)　9　2020

ISSN： 2186-5884
Factors Influencing Decision-making in Relation to the Administration of Durvalumab After Chemoradiotherapy (TOPGAN2020-01)

有安亮, 内堀健, 田中寿志, 宮内栄作, 川嶋庸介, 大柳文義, 堀池篤, 酒谷俊雄, 齊木雅史, 丹保裕一, 谷本梓, 園田智明, 神山潤二, 上浪健, 工藤慶太, 土屋裕子, 西尾誠人

肺癌(Web)　60　(7)　2020

ISSN： 1348-9992
結腸気管支瘻による肺炎,肺膿瘍に対して気管支充填術を施行し救命し得た一例

鈴木歩, 小荒井晃, 川副友, 宮内栄作, 東出直樹, 片平真人, 佐渡哲, 杉浦久敏, 一ノ瀬正和

気管支学　42　(Suppl.)　S409-S409　2020
Publisher: (NPO)日本呼吸器内視鏡学会
ISSN： 0287-2137

eISSN： 2186-0149
切除不能III期NSCLCに対するUFT+CDDP+胸部放射線併用療法とPEM+CDDP+TRT併用療法のランダム化第II相試験

宮内栄作, 渡邉香奈, 戸井之裕, 中村敦, 福原達朗, 千葉亮祐, 秋山真親, 榊原純, 田中寿志, 吉村成央, 中川拓, 井草龍太郎, 峯村浩之, 守義明, 藤本圭介, 松下晴雄, 高橋史朗, 井上彰, 菅原俊一, 前門戸任

肺癌　59　(6)　672-672　2019/11
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
強度変調放射線治療による根治的化学放射線療法後のデュルバルマブ使用経験の報告

突田容子, 宮内栄作, 斎藤良太, 佐藤輝幸, 山本貴也, 片桐佑, 井上彰, 一ノ瀬正和

肺癌　59　(6)　674-674　2019/11
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
プラチナ製剤を含む2レジメン以上の治療歴を有する既治療NSCLCに対するnab-PTX単剤隔週投与の第I/II相試験

原田敏之, 宮内栄作, 田中寿志, 中村敦, 中川拓, 盛田麻美, 神宮大輔, 久田友哉, 蒲生俊一, 齊藤良太, 井上彰

肺癌　59　(6)　797-797　2019/11
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
気管内に多発する腫瘤を認めた小細胞肺癌の1例

鈴木歩, 宮内栄作, 成田大輔, 相澤洋之, 小林誠, 村上康司, 山田充啓, 杉浦久敏, 一ノ瀬正和, 東條裕

肺癌　59　(5)　513-513　2019/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
胸腔鏡下肺切除術で診断された印環細胞癌様の形態を呈した肺腺癌の1例

宮内栄作, 成田大輔, 相澤洋之, 村上康司, 小林誠, 突田容子, 東出直樹, 齋藤良太, 佐藤輝幸, 杉浦久敏, 一ノ瀬正和, 齊藤涼子, 松田安史, 岡田克典

肺癌　59　(5)　511-511　2019/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
免疫療法の効果と耐性 EGFR遺伝子変異陽性/陰性肺癌におけるT細胞受容体レパトア解析(Cancer immunotherapy sensitivity and resistance TCR repertoires in lung adenocarcinomas with and without EGFR mutation)

宮内栄作, 松田達雄, 清谷一馬, Low Siew-Kee, 突田容子, 一ノ瀬正和, 桜田晃, 岡田克典, 齊藤涼子, 中村祐輔

日本癌学会総会記事　78回　S19-1　2019/09
Publisher: (一社)日本癌学会
ISSN： 0546-0476
【非小細胞肺癌薬物療法の選択と実際】遺伝子診断の結果に基づくIV期非小細胞肺癌への薬物療法 EGFR遺伝子変異陽性非小細胞肺癌(非扁平上皮癌)に対する治療戦略

宮内栄作, 井上彰

臨床腫瘍プラクティス　15　(2)　99-105　2019/05
Publisher: (株)ヴァンメディカル
ISSN： 1880-3083
TCR repertoires in lung adenocarcinomas with and without EGFR mutation

宮内栄作, 松田達雄, 清谷一馬, LOW Siew-kee, 突田容子, 一ノ瀬正和, 桜田晃, 岡田克典, 齊藤涼子, 中村祐輔

日本癌学会学術総会抄録集(Web)　78th　2019
胸腔鏡下肺切除術で診断された印環細胞癌様の形態を呈した肺腺癌の1例

宮内栄作, 成田大輔, 相澤洋之, 村上康司, 小林誠, 突田容子, 東出直樹, 齋藤良太, 佐藤輝幸, 杉浦久敏, 一ノ瀬正和, 齊藤涼子, 松田安史, 岡田克典

肺癌(Web)　59　(5)　2019

ISSN： 1348-9992
TCR sequencing analysis of cancer tissues and lymph nodes in colorectal cancer patients

Kazuma Kiyotani, Tatsuo Matsuda, Satoshi Nagayama, Eisaku Miyauchi, Yuwen Hsu, Makda Zewde, Jae-Hyun Park, Taigo Kato, Makiko Harada, Nobuaki Suzuki, Hiroaki Nagano, Shoichi Hazama, Yusuke Nakamura

CANCER SCIENCE　109　1091-1091　2018/12

ISSN： 1349-7006
The establishment and optimization of customized circulating tumor DNA cancer screening panel

Siew-Kee Low, Tomoko Shibayama, Satoshi Nagayama, Eisaku Miyauchi, Kazuma Kiyotani, Takayuki Kobayashi, Shinji Ohno, Takayuki Ueno, Masakazu Ichinose, Masashi Ueno, Shunji Takahashi, Yusuke Nakamura

CANCER SCIENCE　109　652-652　2018/12

ISSN： 1349-7006
T cell receptor repertoire analysis of lung adenocarcinoma harboring EGFR mutations

Eisaku Miyauchi, Tatsuo Matsuda, Yu-wen Hsu, Yoko Tsukita, Masakazu Ichinose, Akira Sakurada, Yoshinori Okada, Ryoko Saito, Kazuma Kiyotani, Yusuke Nakamura

CANCER SCIENCE　109　1178-1178　2018/12

ISSN： 1349-7006
血中循環腫瘍DNAによる専用癌スクリーニングパネルの確立と最適化(The establishment and optimization of customized circulating tumor DNA cancer screening panel)

Low Siew-Kee, 柴山朋子, 長山聡, 宮内栄作, 清谷一馬, 小林隆之, 大野真司, 上野貴之, 一ノ瀬正和, Ueno Masashi, 高橋俊二, 中村祐輔

日本癌学会総会記事　77回　1199-1199　2018/09
Publisher: (一社)日本癌学会
ISSN： 0546-0476
大腸がん組織・リンパ節のTCRレパトア解析(TCR sequencing analysis of cancer tissues and lymph nodes in colorectal cancer patients)

清谷一馬, 松田達雄, 長山聡, 宮内栄作, Hsu Yuwen, Zewde Makda, Park Jae-Hyun, 加藤大悟, 原田真紀子, 鈴木伸明, 永野浩昭, 硲彰一, 中村祐輔

日本癌学会総会記事　77回　1781-1781　2018/09
Publisher: (一社)日本癌学会
ISSN： 0546-0476
EGFR遺伝子変異陽性肺腺癌においてAXLキナーゼは免疫抑制分子を促進する(Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas)

突田容子, 宮内栄作, 齊藤涼子, 岡崎達馬, 井上彰, 岡田克典, 一ノ瀬正和

日本癌学会総会記事　77回　1885-1885　2018/09
Publisher: (一社)日本癌学会
ISSN： 0546-0476
EGFR遺伝子変異陽性肺腺癌におけるT細胞受容体レパトア解析(T cell receptor repertoire analysis of lung adenocarcinoma harboring EGFR mutations)

宮内栄作, 松田達雄, Hsu Yu-Wen, 突田容子, 一ノ瀬正和, 桜田晃, 岡田克典, 齊藤涼子, 清谷一馬, 中村祐輔

日本癌学会総会記事　77回　2036-2036　2018/09
Publisher: (一社)日本癌学会
ISSN： 0546-0476
The establishment and optimization of customized circulating tumor DNA cancer screening panel(和訳中)

Low Siew-Kee, 柴山朋子, 長山聡, 宮内栄作, 清谷一馬, 小林隆之, 大野真司, 上野貴之, 一ノ瀬正和, Ueno Masashi, 高橋俊二, 中村祐輔

日本癌学会総会記事　77回　1199-1199　2018/09
Publisher: 日本癌学会
ISSN： 0546-0476
大腸がん組織・リンパ節のTCRレパトア解析(TCR sequencing analysis of cancer tissues and lymph nodes in colorectal cancer patients) International-journal

清谷一馬, 松田達雄, 長山聡, 宮内栄作, Hsu Yuwen, Zewde Makda, Park Jae-Hyun, 加藤大悟, 原田真紀子, 鈴木伸明, 永野浩昭, 硲彰一, 中村祐輔

日本癌学会総会記事　77回　(6)　1781-1781　2018/09
Publisher: 日本癌学会
DOI： 10.1080/2162402X.2019.1588085 　

ISSN： 0546-0476
EGFR遺伝子変異陽性肺腺癌においてAXLキナーゼは免疫抑制分子を促進する(Axl kinase drives immune checkpoint and chemokine signalling pathways in lung adenocarcinomas)

突田容子, 宮内栄作, 齊藤涼子, 岡崎達馬, 井上彰, 岡田克典, 一ノ瀬正和

日本癌学会総会記事　77回　1885-1885　2018/09
Publisher: 日本癌学会
ISSN： 0546-0476
EGFR遺伝子変異陽性肺腺癌におけるT細胞受容体レパトア解析(T cell receptor repertoire analysis of lung adenocarcinoma harboring EGFR mutations)

宮内栄作, 松田達雄, Hsu Yu-Wen, 突田容子, 一ノ瀬正和, 桜田晃, 岡田克典, 齊藤涼子, 清谷一馬, 中村祐輔

日本癌学会総会記事　77回　2036-2036　2018/09
Publisher: 日本癌学会
ISSN： 0546-0476
VV‐ECMO下でDumon stentの留置により化学療法が可能となった肺腺癌の1例

鈴木寛利, 桜田晃, 小林数真, 東郷威男, 江場俊介, 星史彦, 大石久, 鈴木大和, 阿部皓太郎, 小塩弘樹, 松田安史, 佐渡哲, 野田雅史, 齋藤良太, 宮内栄作, 岡田克典

気管支学　40　(Suppl.)　S288-S288　2018/05
Publisher: (NPO)日本呼吸器内視鏡学会
ISSN： 0287-2137

eISSN： 2186-0149
EGFR遺伝子変異陽性肺腺癌においてAXLキナーゼは免疫抑制分子を制御する

突田容子, 藤野直也, 宮内栄作, 井上彰, 板倉康司, 山田充啓, 岡崎達馬, 桜田晃, 杉浦久敏, 岡田克典, 一ノ瀬正和

日本呼吸器学会誌(Web)　7　(増刊)　267-267　2018/03/10
Publisher: (一社)日本呼吸器学会
ISSN： 2186-5884
EGFR遺伝子変異陽性肺腺癌においてAXLキナーゼは免疫抑制分子を制御する

突田容子, 藤野直也, 宮内栄作, 井上彰, 板倉康司, 山田充啓, 岡崎達馬, 桜田晃, 杉浦久敏, 岡田克典, 一ノ瀬正和

日本呼吸器学会誌　7　(増刊)　267-267　2018/03
Publisher: (一社)日本呼吸器学会
ISSN： 2186-5876

eISSN： 2186-5884
EGFR遺伝子変異陽性肺腺癌においてAXLキナーゼは免疫抑制分子を制御する

突田容子, 藤野直也, 宮内栄作, 井上彰, 板倉康司, 山田充啓, 岡崎達馬, 桜田晃, 杉浦久敏, 岡田克典, 一ノ瀬正和

日本呼吸器学会誌　7　(増刊)　267-267　2018/03
Publisher: (一社)日本呼吸器学会
ISSN： 2186-5876
Numb Chin Syndromeをきたした肺小細胞癌の1例

佐々木優作, 宮内栄作, 柳澤悟, 小野学, 東條裕, 一ノ瀬正和

肺癌　57　(6)　815-815　2017/11
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
Updated survival outcomes of NEJ005/TCOG0902, a randomized PII of gefitinib and chemotherapy in EGFR-mutant NSCLC

Eisaku Miyauchi, Satoshi Oizumi, Koichi Minato, Shunichi Sugawara, Toshiyuki Harada, Yuka Fujita, Makoto Maemondo, Satoshi Watanabe, Minoru Kurihara, Toshihiro Nukiwa

ANNALS OF ONCOLOGY　28　91-91　2017/10

ISSN： 0923-7534

eISSN： 1569-8041
EGFR陽性肺癌の初回EGFR‐TKI効果と高感度PNA‐LNA PCR clamp法による血漿EGFR遺伝子変異検出の関連性の検討

渡邉香奈, 盛田麻美, 鈴木綾, 福原達朗, 宮内栄作, 斎藤平佐, 長谷川幸裕, 菅原俊一, 田中伸幸, 寺崎浩司, 前門戸任

日本肺癌学会総会号　57　(5)　454-454　2017/09
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
自然崩壊型腫瘍崩壊症候群を合併した肺扁平上皮癌の1例

板倉康司, 平野泰三, 宮内栄作, 井上彰, 杉浦久敏, 一ノ瀬正和

日本呼吸器学会誌　6　(3)　200-204　2017/05
Publisher: (一社)日本呼吸器学会
ISSN： 2186-5876

eISSN： 2186-5884
A case of spontaneous tumor lysis syndrome complicated with squamous cell carcinoma of the lung

板倉康司, 平野泰三, 宮内栄作, 井上彰, 井上彰, 杉浦久敏, 一ノ瀬正和

日本呼吸器学会誌(Web)　6　(3)　200‐204 (WEB ONLY)-204　2017/05
Publisher: (一社)日本呼吸器学会
ISSN： 2186-5884
サルコイドーシス診断に有用な因子の検討

光根歩, 佐藤輝幸, 柳澤悟, 突田容子, 東條裕, 小野学, 宮内栄作, 一ノ瀬正和

気管支学　39　(Suppl.)　S274-S274　2017/05
Publisher: (NPO)日本呼吸器内視鏡学会
ISSN： 0287-2137

eISSN： 2186-0149
プラチナ既治療肺扁平上皮癌に対するTS‐1+CPT‐11併用療法のII相臨床試験(NJLCG1101)

原田敏之, 石本修, 宮内栄作, 榊原智博, 臼井一裕, 井上彰, 菅原俊一

日本呼吸器学会誌(Web)　6　140　2017/03/10

ISSN： 2186-5884
化学療法プラチナ既治療肺扁平上皮癌に対するTS-1+CPT-11併用療法のII相臨床試験(NJLCG1101)

原田敏之, 石本修, 宮内栄作, 榊原智博, 臼井一裕, 井上彰, 菅原俊一

日本呼吸器学会誌　6　(増刊)　140-140　2017/03
Publisher: (一社)日本呼吸器学会
ISSN： 2186-5876

eISSN： 2186-5884
プラチナ既治療肺扁平上皮癌に対するTS‐1+CPT‐11併用療法の第II相臨床試験(NJLCG1101)

宮内栄作, 石本修, 原田敏之, 榊原智博, 臼井一裕, 井上彰, 菅原俊一

日本肺癌学会総会号　56　(6)　511-511　2016/11
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
東京歯科大学市川総合病院における閉塞性睡眠時無呼吸に対する口腔内装置治療の現状

今井琴子, 大西雄英, 井坂栄作, 平賀智豊, 布施佑磨, 佐藤一道, 野村武史, 吉田知彦, 露無松里, 中島庸也, 宮内潤

歯科学報　116　(5)　396-396　2016/10
Publisher: 東京歯科大学学会
ISSN： 0037-3710
EBUS-TBNAで診断に至った肺原発血管肉腫の1例

京極自彦, 岡崎達馬, 三浦絵美里, 突田容子, 田中里江, 東條裕, 三橋善哉, 宮内栄作, 杉浦久敏, 一ノ瀬正和, 高橋信

肺癌　56　(5)　406-406　2016/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
尺骨動脈閉塞症を合併した肺腺癌の1例

山中駿, 宮内栄作, 平野泰三, 佐藤慶, 高橋秀徳, 村上康司, 玉井ときわ, 山田充啓, 岡崎達馬, 玉田勉, 杉浦久敏, 一ノ瀬正和, 井上彰

肺癌　56　(5)　404-404　2016/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
EBUS‐TBNAで診断に至った肺原発血管肉腫の1例

京極自彦, 岡崎達馬, 三浦絵美里, 突田容子, 田中里江, 東條裕, 三橋善哉, 宮内栄作, 杉浦久敏, 一ノ瀬正和, 高橋信

気管支学　38　(5)　445-446　2016/09
Publisher: (NPO)日本呼吸器内視鏡学会
ISSN： 0287-2137

eISSN： 2186-0149
Immune Checkpoint Therapy for Non-Small-Cell Lung Cancer

宮内栄作, 井上彰

癌と化学療法　43　(6)　666-671　2016/06
Publisher: (株)癌と化学療法社
ISSN： 0385-0684
Prognostic factors in patients with advanced thymic carcinoma treated with chemotherapy: A retrospective analysis of 289 patients from NEJ023 Study.

Yusuke Okuma, Ryo Ko, Takehito Shukuya, Kazunari Tateishi, Hisao Imai, Eisaku Miyauchi, Akiko Fujiwara, Tomohide Sugiyama, Keisuke Azuma, Keiko Muraki, Masahiro Yamasaki, Hisashi Tanaka, Yuta Takashima, Sayo Soda, Osamu Ishimoto, Nobuyuki Koyama, Shoichi Kuyama, Kyoko Murase, Satoshi Morita, Kazuhisa Takahashi

JOURNAL OF CLINICAL ONCOLOGY　34　(15)　2016/05

DOI： 10.1200/JCO.2016.34.15_suppl.8567 　

ISSN： 0732-183X

eISSN： 1527-7755
メタボロミクス解析を用いたサルコイドーシス新規バイオマーカーの検索

村松聡士, 三枝大輔, 玉田勉, 奈良正之, 宮内栄作, 蒲生俊一, 村上康司, 杉浦久敏, 一ノ瀬正和

日本呼吸器学会誌　5　(増刊)　197-197　2016/03
Publisher: (一社)日本呼吸器学会
ISSN： 2186-5876

eISSN： 2186-5884
PHASE II STUDY OF CARBOPLATIN (CBDCA) PLUS WEEKLY NAB-PACLITAXEL (NAB-PTX) IN ELDERLY PATIENTS (PTS) WITH NON-SMALL CELL LUNG CANCER (NSCLC): NORTH JAPAN LUNG CANCER STUDY GROUP TRIAL 1301

Naoto Morikawa, Shunichi Sugawara, Eisaku Miyauchi, Akira Inoue, Masakazu Ichinose

RESPIROLOGY　20　89-89　2015/12

ISSN： 1323-7799

eISSN： 1440-1843
Phase II study of carboplatin plus weekly nab-paclitaxel in elderly patients with NSCLC:NJLCG1301

Kazuhiro Usui, Eisaku Miyauchi, Shunichi Sugawara, Tatsuro Fukuhara, Heisuke Saito, Yuka Fujita, Terufumi Kato, Toshiro Suzuki, Akira Inoue, Masakazu Ishinose

ANNALS OF ONCOLOGY　26　92-92　2015/11

ISSN： 0923-7534

eISSN： 1569-8041
高齢者肺癌高齢者非小細胞肺癌に対するCarboplatin+少量分割nab-Paclitaxelの第II相臨床試験(NJLCG1301)

福原達朗, 齋藤平佐, 菅原俊一, 臼井一裕, 宮内栄作, 藤田結花, 加藤晃史, 鈴木俊郎, 中川拓, 原田敏之, 三浦弘之, 渡辺洋, 井上彰, 一ノ瀬正和

肺癌　55　(5)　394-394　2015/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
Phase II Study of Carboplatin plus Weekly Nab-Paclitaxel in Elderly Patients with NSCLC: North Japan Lung Cancer Study Group Trial 1301

Osamu Ishimoto, Kazuhiro Usui, Makoto Maemondo, Eisaku Miyauchi, Heisuke Saito, Yuka Fujita, Terufumi Kato, Toshiro Suzuki, Taku Nakagawa, Toshiyuki Harada, Hiroyuki Miura, Hiroshi Watanabe, Akira Inoue, Masakazu Ichinose

JOURNAL OF THORACIC ONCOLOGY　10　(9)　S657-S658　2015/09

ISSN： 1556-0864

eISSN： 1556-1380
病気のはなし慢性閉塞性肺疾患

宮内栄作, 一ノ瀬正和

検査と技術　43　(9)　744-750　2015/09
Publisher: (株)医学書院
ISSN： 0301-2611

eISSN： 1882-1375
【アレルギー性疾患における新規治療戦略】抗IgE抗体療法

宮内栄作, 一ノ瀬正和

臨床免疫・アレルギー科　64　(2)　145-149　2015/08
Publisher: (有)科学評論社
ISSN： 1881-1930
東北大学病院呼吸器バイオバンクの現状と課題

宮内栄作, 光石陽一郎, 東出直樹, 椎原淳, 三橋善哉, 村松聡士, 小林誠, 佐藤輝幸, 玉井ときわ, 山田充啓, 小荒井晃, 井上彰, 岡崎達馬, 大河内眞也, 玉田勉, 杉浦久敏, 菊地利明, 一ノ瀬正和

日本呼吸器学会誌　4　(増刊)　151-151　2015/03
Publisher: (一社)日本呼吸器学会
ISSN： 2186-5876

eISSN： 2186-5884
【高齢者のがん治療】高齢者の肺癌治療

宮内栄作, 井上彰

癌と化学療法　42　(1)　6-11　2015/01
Publisher: (株)癌と化学療法社
ISSN： 0385-0684
未治療進行EGFR遺伝子変異陽性肺がんに対するゲフィチニブ治療後のプラチナ併用化学療法の有効性の検討

宮内栄作, 井上彰, 小林国彦, 前門戸任, 菅原俊一, 大泉聡史, 磯部宏, 弦間昭彦, 西條康夫, 吉澤弘久, 森田智視, 萩原弘一, 貫和敏博

肺癌　54　(5)　397-397　2014/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
細径気管支鏡によって肉眼的に観察し得た食道原発悪性黒色腫の孤立肺転移の1例

西澤弘成, 柳谷典子, 谷本梓, 河野裕子, 中富克己, 堀池篤, 大柳文義, 宮内栄作, 上原浩文, 奥村栄, 宝来威, 西尾誠人

気管支学　36　(4)　417-421　2014/07
Publisher: (NPO)日本呼吸器内視鏡学会
ISSN： 0287-2137

eISSN： 2186-0149
肺癌の組織多様性とmiRNA発現様式

元井紀子, 長野裕子, 斎藤雄一, 宮内栄作, 二宮浩範, 杉浦善弥, 遠藤祐子, 木脇圭一, Yasen Mahmut, 石川雄一

日本病理学会会誌　103　(1)　202-202　2014/03
Publisher: (一社)日本病理学会
ISSN： 0300-9181
Significance of Morphological Heterogeneity of Lung Adenocarcinoma Evaluated by FFPE-Based miRNA Profile, in Comparison with Genotype

N. Motoi, H. Nagano, E. Miyauchi, Y. Saito, Y. Sugiura, H. Ninomiya, H. Kanda, S. Okumura, Y. Ishikawa

MODERN PATHOLOGY　27　489A-489A　2014/02

ISSN： 0893-3952

eISSN： 1530-0285
【新薬展望2014】 (第III部)治療における最近の新薬の位置付け<薬効別> 新薬の広場肺癌治療薬

宮内栄作, 井上彰

医薬ジャーナル　50　(増刊)　352-360　2014/01
Publisher: (株)医薬ジャーナル社
ISSN： 0287-4741
末梢型小細胞肺がんは中枢型に比べ予後不良で、遺伝子発現プロファイルが異なる

宮内栄作, 齋藤雄一, 二宮浩範, 元井紀子, 西尾誠人, 奥村栄, 石川雄一

肺癌　53　(5)　445-445　2013/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
ALK融合遺伝子陽性例における染色体2番短腕のコピー数変化の特徴(Copy number changes in chromosome 2p are unique events among ALK fusion positive lung adenocarcinomas)

二宮浩範, 加藤元博, 真田昌, 竹内賢吾, 宮内栄作, 斉藤雄一, 元井紀子, 小川誠司, 石川雄一

日本癌学会総会記事　72回　378-378　2013/10
Publisher: (一社)日本癌学会
ISSN： 0546-0476
当院における大腸癌肺転移巣に対するconversion chemotherapy

杉浦善弥, 文敏景, 宮内栄作, 元井紀子, 石川雄一

日本大腸肛門病学会雑誌　66　(4)　319-319　2013/04
Publisher: (一社)日本大腸肛門病学会
ISSN： 0047-1801

eISSN： 1882-9619
ALK肺癌の組織像と免疫染色によるスクリーニングの有用性について

元井紀子, 宮内栄作, 齋藤雄一, 二宮浩範, 長野裕子, 石川雄一

日本病理学会会誌　102　(1)　341-341　2013/04
Publisher: (一社)日本病理学会
ISSN： 0300-9181
【呼吸器内科:EVIDENCE UPDATE】肺癌

宮内栄作, 井上彰

呼吸器内科　22　(4)　285-294　2012/10
Publisher: (有)科学評論社
ISSN： 1884-2887
小型肺結節影の診断と治療画像診断、病理、予後小型肺腺癌の浸潤性判定における術中迅速組織診断の有用性と限界

元井紀子, 齋藤雄一, 宮内栄作, 小野宏, 佐藤征二郎, 二宮浩範, 上原浩文, 文敏景, 坂尾幸則, 奥村栄, 石川雄一

肺癌　52　(5)　522-522　2012/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
小細胞肺癌に対する治療戦略小細胞肺がんの層別化の試み発生起源の再検討と発がん機構に注目して

宮内栄作, 齋藤雄一, 二宮浩範, 元井紀子, 西尾誠人, 奥村栄, 石川雄一

肺癌　52　(5)　530-530　2012/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
喫煙習慣から観るAdenocarcinoma in-situ

佐藤征二郎, 平松美也子, 宮内栄作, 齋藤雄一, 二宮浩範, 稲村健太郎, 元井紀子, 奥村栄, 土田正則, 石川雄一

肺癌　52　(5)　662-662　2012/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
KIF5B-ALK陽性肺腺癌3例の臨床病理学的検討

二宮浩範, 宮内栄作, 齋藤雄一, 元井紀子, 竹内賢吾, 石川雄一

肺癌　52　(5)　670-670　2012/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
肺腺癌の組織亜型と遺伝子異常型の関連について(Evaluation of histologic phenotype and genotype of lung adenocarcinoma)

元井紀子, 佐藤征二郎, 齋藤雄一, 二宮浩範, 宮内栄作, 小野宏, 竹内賢吾, 長野裕子, 野村起美恵, 石川雄一

日本癌学会総会記事　71回　252-252　2012/08
Publisher: (一社)日本癌学会
ISSN： 0546-0476
小細胞肺がんでは長鎖非コードRNA、HOTAIRが細胞接着性に関係する遺伝子発現に影響を及ぼし再発と関連する(Long non-coding RNA HOTAIR affects cell adhesion- related gene expression in small cell lung cancer related to relapse)

小野宏, 長野裕子, 宮内栄作, 元井紀子, 奥村栄, 松浦正明, 廣瀬哲郎, 稲瀬直彦, 石川雄一

日本癌学会総会記事　71回　422-422　2012/08
Publisher: (一社)日本癌学会
ISSN： 0546-0476
当院における大腸癌肺転移巣に対するconversion chemotherapyの後向き研究(Retrospective study of conversion chemotherapy for pulmonary metastasis from colorectal cancer in our hospital)

杉浦善弥, 元井紀子, 文敏景, 宮内栄作, 石川雄一

日本癌学会総会記事　71回　535-535　2012/08
Publisher: (一社)日本癌学会
ISSN： 0546-0476
PRIMARY LOCATION OF SMALL CELL LUNG CANCER (SCLC) AND TTF-1 EXPRESSION: ARE MOST SCLCS REALLY OF HILAR ORIGIN?

E. Miyauchi, H. Ono, H. Ninomiya, K. Inamura, N. Motoi, M. Nishio, S. Okumura, Y. Ishikawa

JOURNAL OF THORACIC ONCOLOGY　7　(6)　S79-S79　2012/06

ISSN： 1556-0864
【肺癌実地医家に不可欠の最新の臨床知識とその活用】治療/特定の肺癌の治療戦略とその有効性進行期非小細胞肺癌の治療戦略 EGFR遺伝子変異陽性の腺癌

宮内栄作, 井上彰

Medical Practice　29　(6)　996-1000　2012/06
Publisher: (株)文光堂
ISSN： 0910-1551
肺小細胞がんにおけるHOTAIRの発現は術後再発と関連している

小野宏, 宮内栄作, 佐藤征二郎, 齋藤雄一, 元井紀子, 廣瀬哲郎, 石川雄一

日本病理学会会誌　101　(1)　258-258　2012/03
Publisher: (一社)日本病理学会
ISSN： 0300-9181
EML4-ALK肺癌のtyrosine kinase下流パスウェイの発現状況による層別化

佐藤征二郎, 宮内栄作, 小野宏, 齋藤雄一, 二宮浩範, 稲村健太郎, 元井紀子, 竹内賢吾, 石川雄一

日本病理学会会誌　101　(1)　389-389　2012/03
Publisher: (一社)日本病理学会
ISSN： 0300-9181
切除材料の病理学的検索にもとづく小細胞肺がんに対する外科治療の成績

齋藤雄一, 宮内栄作, 佐藤征二郎, 小野宏, 二宮浩範, 稲村健太郎, 元井紀子, 佐藤之俊, 石川雄一

日本病理学会会誌　101　(1)　390-390　2012/03
Publisher: (一社)日本病理学会
ISSN： 0300-9181
肺癌分子標的薬の感受性と耐性

宮内栄作, 井上彰

呼吸　30　(5)　444-450　2011/05
Publisher: (一社)呼吸研究
ISSN： 0286-9314
反復性胸水貯留に対し、局所麻酔下胸腔鏡検査が診断に有効であった一例

太田洋充, 宮内栄作, 大河内眞也, 海老名雅仁, 貫和敏博

気管支学　33　(Suppl.)　S302-S302　2011/05
Publisher: (NPO)日本呼吸器内視鏡学会
ISSN： 0287-2137

eISSN： 2186-0149
肺野に孤立性陰影を認めた悪性胸膜中皮腫の1例

宮内栄作, 工藤慶太, 星利良, 古田則行, 平井康夫, 元井紀子, 石川雄一, 宝来威

日本臨床細胞学会雑誌　50　(2)　115-119　2011/03
Publisher: (公社)日本臨床細胞学会
ISSN： 0387-1193

eISSN： 1882-7233
間質性肺炎と肺癌の合併に関する臨床的検討

宮内栄作, 太田洋充, 久田修, 大河内眞也, 井上彰, 海老名雅仁, 貫和敏博

肺癌　50　(5)　734-734　2010/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
Efficacy of erlotinib for CNS relapse in non-small cell lung cancer patients after gefitinib treatment

N. Yanagitani, H. Tanaka, E. Miyauchi, I. Motokawa, K. Kudo, F. Ohyanagi, A. Horiike, T. Horai, M. Nishio

JOURNAL OF CLINICAL ONCOLOGY　28　(15)　2010/05

ISSN： 0732-183X

eISSN： 1527-7755
肺アスペルギルス症の治療後同部位に発症した肺大細胞癌の1例

田中寿志, 工藤慶太, 宮内栄作, 本川郁代, 柳谷典子, 堀池篤, 大柳文義, 永嶋琢也, 前田純一, 上原浩文, 文敏景, 坂尾幸則, 奥村栄, 中川健, 元井紀子, 石川雄一, 宝来威, 西尾誠人

気管支学　32　(Suppl.)　S205-S205　2010/05
Publisher: (NPO)日本呼吸器内視鏡学会
ISSN： 0287-2137

eISSN： 2186-0149
ゲフィチニブ治療failure後の非小細胞肺癌の脳転移に対するエルロチニブの効果

柳谷典子, 西尾誠人, 田中寿志, 宮内栄作, 本川郁代, 工藤慶太, 大柳文義, 堀池篤, 宝来威

日本呼吸器学会雑誌　48　(増刊)　279-279　2010/03
Publisher: (一社)日本呼吸器学会
ISSN： 1343-3490
ラブドイド細胞が目立った肺大細胞神経内分泌癌の1例

鈴木奈緒子, 星利良, 佐藤之俊, 古田則行, 宮内栄作, 石川雄一, 平井康夫, 宝来威

日本臨床細胞学会雑誌　49　(1)　15-19　2010/01
Publisher: (公社)日本臨床細胞学会
ISSN： 0387-1193

eISSN： 1882-7233
EBUS-TBNAによる縦隔リンパ節の転移診断により治療方針が決定した2症例

前田純一, 中村崇, 永島琢也, 上原浩文, 文敏景, 坂尾幸則, 田中寿志, 柳谷典子, 本川郁代, 宮内栄作, 工藤慶太, 堀池篤, 大柳文義, 西尾誠人, 奥村栄, 宝来威, 中川健

気管支学　31　(6)　419-419　2009/11
Publisher: (NPO)日本呼吸器内視鏡学会
ISSN： 0287-2137

eISSN： 2186-0149
既治療小細胞肺癌に対するTS-1単剤療法の第2相臨床試験

工藤慶太, 宮内栄作, 田中寿志, 本川郁代, 堀池篤, 大柳文義, 永島琢也, 前田純一, 上原浩文, 文敏景, 坂尾幸則, 元井紀子, 石川雄一, 奥村栄, 中川健, 宝来威, 西尾誠人

肺癌　49　(5)　596-596　2009/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
孤立性脳転移を認めた原発性肺癌切除例の検討

前田純一, 坂尾幸則, 文敏景, 上原浩文, 永島琢也, 奥村栄, 中川健, 田中寿志, 宮内栄作, 本川郁代, 柳谷典子, 工藤慶太, 堀池篤, 大柳文義, 西尾誠人, 宝来威, 濱中和嘉子, 稲村健太郎, 元井紀子, 石川雄一

肺癌　49　(5)　648-648　2009/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
30mm以下の肺癌における臓側胸膜浸潤の予後因子としての意義

上原浩文, 奥村栄, 坂尾幸則, 文敏景, 永島琢也, 前田純一, 中川健, 田中寿志, 宮内栄作, 本川郁代, 柳谷典子, 工藤慶太, 堀池篤, 大柳文義, 西尾誠人, 宝来威, 濱中和嘉子, 稲村健太郎, 元井紀子, 石川雄一

肺癌　49　(5)　655-655　2009/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
気管支鏡検査で診断された非小細胞肺がんの組織型の検討

宮内栄作, 堀池篤, 田中寿志, 柳谷典子, 本川郁代, 工藤慶太, 大柳文義, 西尾誠人, 宝来威, 永島琢也, 前田純一, 中村崇, 上原浩文, 文敏景, 坂尾幸則, 奥村栄, 中川健, 元井紀子, 石川雄一

肺癌　49　(5)　668-668　2009/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
頸部腫瘤を契機に診断された肺癌甲状腺転移の2症例

本川郁代, 宮内栄作, 工藤慶太, 柳谷典子, 田中寿志, 大柳文義, 堀池篤, 西尾誠人, 宝来威, 文敏景, 坂尾幸則, 奥村栄, 中川健, 濱中和嘉子, 元井紀子, 石川雄一

肺癌　49　(5)　754-754　2009/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
2レジメン以上の治療歴を有する進行非小細胞肺癌に対するジェムシタビン+イリノテカン併用化学療法の検討

柳谷典子, 西尾誠人, 田中寿志, 宮内栄作, 本川郁代, 工藤慶太, 大柳文義, 堀池篤, 宝来威

肺癌　49　(5)　763-763　2009/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
若年者進行肺癌の臨床的検討

大柳文義, 田中寿志, 本川郁代, 宮内栄作, 柳谷典子, 堀池篤, 文敏景, 坂尾幸則, 奥村栄, 中川健, 濱中和嘉子, 元井紀子, 竹内賢吾, 石川雄一, 宝来威, 西尾誠人

肺癌　49　(5)　777-777　2009/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
肺原発Pleomorphic carcinoma 10例の検討

永島琢也, 坂尾幸則, 文敏景, 上原浩文, 前田純一, 奥村栄, 中川健, 田中寿志, 宮内栄作, 本川郁代, 柳谷典子, 工藤慶太, 堀池篤, 大柳文義, 西尾誠人, 宝来威, 濱中和嘉子, 稲村健太郎, 元井紀子, 石川雄一

肺癌　49　(5)　811-811　2009/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
Adjustment of creatinine (Cr) is needed to avoid severe thrombocytopenia of carboplatin (C) plus gemcitabine (G) in non-small cell lung cancer (NSCLC)

Eisaku Miyauchi, Atsushi Horiike, Ikuyo Motokawa, Keita Kudo, Fumiyoshi Ohyanagi, Mingyon Mun, Yukinori Sakao, Sakae Okumura, Ken Nakagawa, Takeshi Horai, Makoto Nishio

JOURNAL OF THORACIC ONCOLOGY　4　(9)　S920-S920　2009/09

ISSN： 1556-0864
長期生存した小細胞肺癌の10切除例臨床病理学的検討

濱中和嘉子, 大場岳彦, 中村裕, 稲村健太郎, 元井紀子, 石川雄一, 中村崇, 永島琢也, 前田純一, 上原浩文, 坂尾幸則, 文敏景, 奥村栄, 中川健, 田中寿志, 宮内栄作, 本川郁代, 柳谷典子, 工藤慶太, 堀池篤, 大柳文義, 西尾誠人, 宝来威

肺癌　49　(4)　515-515　2009/08
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
Talc散布後長期間の腫瘍縮小効果を認め、約6年半後に胸腔内再発と肝転移をきたした悪性胸膜中皮腫の1例

赤星拓, 中村崇, 上原浩文, 坂尾幸則, 文敏景, 奥村栄, 中川健, 本川郁代, 宮内栄作, 工藤慶太, 堀池篤, 大柳文義, 西尾誠人, 宝来威, 稲村健太郎, 濱中和歌子, 大場岳彦, 元井紀子, 石川雄一

肺癌　49　(3)　328-328　2009/06
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
EML4-ALK融合遺伝子を持つ癌とEGFR変異をもつ癌のdouble cancerを発症した非喫煙50歳男性症例

稲村健太郎, 竹内賢吾, 梅田茂明, 濱中和歌子, 大場岳彦, 元井紀子, 石川雄一, 上原浩文, 赤星拓, 坂尾幸則, 文敏景, 奥村栄, 中川健, 本川郁代, 宮内栄作, 工藤慶太, 堀池篤, 大柳文義, 西尾誠人, 宝来威

肺癌　49　(3)　332-332　2009/06
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
Adjustment of creatinine (Cr) to avoid severe thrombocytopenia of carboplatin (C) plus gemcitabine (G) in non-small cell lung cancer (NSCLC)

A. Horiike, E. Miyauchi, I. Motokawa, K. Kudo, F. Ohyanagi, M. Mun, Y. Sakao, S. Okumura, K. Nakagawa, T. Horai, M. Nishio

JOURNAL OF CLINICAL ONCOLOGY　27　(15)　2009/05

ISSN： 0732-183X
肺門・縦隔リンパ節に対する経気管支鏡下穿刺吸引細胞診の変遷(2方向透視下からEBUSへ)

奥村栄, 上原浩文, 赤星拓, 中村崇, 文敏景, 坂尾幸則, 中川健, 工藤慶太, 宮内栄作, 本川郁代, 堀池篤, 大柳文義, 西尾誠人, 宝来威

気管支学　31　(Suppl.)　S169-S169　2009/05
Publisher: (NPO)日本呼吸器内視鏡学会
ISSN： 0287-2137

eISSN： 2186-0149
肺癌との鑑別を要した肺原発悪性リンパ腫の一例

宮内栄作, 工藤慶太, 奥村栄, 星利良, 平井康夫, 元井紀子, 石川雄一, 宝来威

日本臨床細胞学会雑誌　48　(Suppl.1)　209-209　2009/03
Publisher: (公社)日本臨床細胞学会
ISSN： 0387-1193

eISSN： 1882-7233
肺癌の治療後経過観察中に血小板減少を来した1例

本川郁代, 宮内栄作, 工藤慶太, 大柳文義, 堀池篤, 西尾誠人, 宝来威

肺癌　49　(1)　134-134　2009/02
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
原発性肺癌の遠隔転移と適切なフォローアップ計画に関する検討

上原浩文, 奥村栄, 坂尾幸則, 文敏景, 今清水恒太, 矢部三男, 中川健, 宮内栄作, 工藤慶太, 赤星拓, 堀池篤, 大柳文義, 西尾誠人, 宝来威, 濱中和歌子, 二宮浩範, 稲村健太郎, 元井紀子, 石川雄一, 大場岳彦

肺癌　48　(5)　468-468　2008/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
ゲフィチニブ耐性非小細胞肺癌(NSCLC)に対するイリノテカン+ゲフィチニブ併用療法の第I-II相試験

堀池篤, 西尾誠人, 工藤慶太, 宮内栄作, 大柳文義, 笠原寿郎, 石川雄一, 宝来威

肺癌　48　(5)　476-476　2008/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
小細胞肺癌切除例における基底細胞分化の頻度と予後・治療感受性の検討

濱中和嘉子, 大場岳彦, 中村裕, 二宮浩範, 稲村健太郎, 元井紀子, 石川雄一, 今清水恒太, 矢部三男, 上原浩文, 坂尾幸則, 文敏景, 奥村栄, 中川健, 宮内栄作, 工藤慶太, 堀池篤, 大柳文義, 西尾誠人, 宝来威

肺癌　48　(5)　481-481　2008/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
胸腔鏡下肺葉切除術における剪刀を用いた右肺門リンパ節郭清の実際

文敏景, 奥村栄, 坂尾幸則, 上原浩文, 今清水恒太, 矢部三男, 中川健, 宮内栄作, 工藤慶太, 堀池篤, 大柳文義, 西尾誠人, 宝来威, 元井紀子, 二宮浩範, 稲村健太郎, 石川雄一

肺癌　48　(5)　484-484　2008/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
肺小細胞肺癌脳転移症例の臨床的検討

工藤慶太, 西尾誠人, 宮内栄作, 赤星拓, 本川郁代, 大柳文義, 堀池篤, 矢部三男, 今清水恒太, 文敏景, 坂尾幸則, 元井紀子, 奥村栄, 中川健, 宝来威

肺癌　48　(5)　631-631　2008/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
当院における前縦隔腫瘍の臨床的検討

宮内栄作, 本川郁代, 工藤慶太, 堀池篤, 大柳文義, 西尾誠人, 宝来威, 今清水恒太, 矢部三男, 上原浩文, 文敏景, 坂尾幸則, 奥村栄, 中川健, 石川雄一

肺癌　48　(5)　649-649　2008/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
胸膜発生の悪性孤立性線維腫瘍(SFT)の2例

矢部三男, 今清水恒太, 上原浩文, 文敏景, 坂尾幸則, 奥村栄, 中川健, 本川郁代, 赤星拓, 宮内栄作, 工藤慶太, 大柳文義, 堀池篤, 西尾誠人, 宝来威, 濱中和嘉子, 二宮浩範, 稲村健太郎, 元井紀子, 石川雄一

肺癌　48　(5)　669-669　2008/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
PHASE I-II STUDY OF IRINOTECAN (CPT-11) AND GEFITINIB IN PATIENTS (PTS) WITH GEFITINIB FAILURE FOR NON-SMALL CELL LUNG CANCER (NSCLC)

A. Horiike, F. Ohyanagi, K. Kudo, E. Miyauchi, K. Kasahara, T. Horai, M. Nishio

ANNALS OF ONCOLOGY　19　108-108　2008/09

ISSN： 0923-7534
胸腔鏡下に切除したSolitary Capillary Hemangioma of the Lungの1例

上原浩文, 奥村栄, 坂尾幸則, 文敏景, 今清水恒太, 矢部三男, 中川健, 宮内栄作, 工藤慶太, 堀池篤, 大柳文義, 西尾誠人, 宝来威, 元井紀子, 二宮浩範, 稲村健太郎, 石川雄一

気管支学　30　(5)　328-328　2008/09
Publisher: (NPO)日本呼吸器内視鏡学会
ISSN： 0287-2137

eISSN： 2186-0149
気管分岐部合併切除を伴う左肺摘除術を施行した腺様嚢胞癌の2切除例

小川史洋, 今清水恒太, 矢部三男, 上原浩文, 奥村栄, 中川健, 宮内栄作, 工藤慶太, 岡野義夫, 堀池篤, 大柳文義, 西尾誠人, 宝来威, 濱中和嘉子, 稲村健太郎, 二宮浩範, 元井紀子, 石川雄一

肺癌　48　(3)　239-240　2008/06
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
Phase I-II study of irinotecan (CPT-11) and gefitinib in patients (pts) with gefitinib failure for non-small cell lung cancer (NSCLC)

A. Horiike, F. Ohyanagi, Y. Okano, K. Kudo, E. Miyauchi, K. Kasahara, T. Horai, M. Nishio

JOURNAL OF CLINICAL ONCOLOGY　26　(15)　2008/05

ISSN： 0732-183X
局所切除後再発病変に対して胸膜肺全摘術を行い、その後急速に胸壁再発と多発骨転移を来した限局型悪性胸膜中皮腫(LMM)の1例

矢部三男, 稲垣卓也, 小川史洋, 今清水恒太, 上原浩文, 佐藤之俊, 奥村栄, 中川健, 平松美也子, 二宮浩範, 稲村健太郎, 元井紀子, 石川雄一, 宮内栄作, 工藤慶太, 岡野義夫, 堀池篤, 大柳文義, 西尾誠人, 宝来威

肺癌　48　(1)　76-76　2008/02
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
Notes on "Kichousiwai"(4)

上原浩文, 堀池篤, 大柳文義, 西尾誠人, 宝来威, 元井紀子, 二宮浩範, 稲村健太郎, 石川雄一, 奥村栄, 坂尾幸則, 文敏景, 今清水恒太, 矢部三男, 中川健, 宮内栄作, 工藤慶太

The Journal of the Japan Society for Respiratory Endoscopy　30　(5)　2008
Publisher: The Japan Society for Respiratory Endoscopy
ISSN： 0287-2137

More details Close

『煕朝詩薈』の収録詩を詩人別に定めて整理した。これによって，詩人別の収録詩数，巻別の収録詩数，及び全収録詩数を算出した。併せて，重複して採録された詩，採択上の問題，採択多数の詩人など『煕朝詩薈』の編集状況を検討する資料の一端を得た。もって『煕朝詩薈』の基礎的研究の一とする。
肺カルチノイド切除例の検討

今清水恒太, 佐藤之俊, 奥村栄, 小川史洋, 矢部三男, 上原浩文, 中川健, 宮内栄作, 工藤慶太, 岡野義夫, 堀池篤, 大柳文義, 西尾誠人, 宝来威, 濱中和嘉子, 稲村健太郎, 二宮浩範, 元井紀子, 石川雄一

気管支学　29　(6)　383-384　2007/11
Publisher: (NPO)日本呼吸器内視鏡学会
ISSN： 0287-2137

eISSN： 2186-0149
上葉発生肺癌に対する気管分岐部リンパ節郭清省略の妥当性に関する検討

上原浩文, 佐藤之俊, 小川史洋, 今清水恒太, 矢部三男, 奥村栄, 中川健, 宮内栄作, 工藤慶太, 堀池篤, 岡野義夫, 大柳文義, 西尾誠人, 宝来威, 二宮浩範, 稲村健太郎, 元井紀子, 石川雄一

肺癌　47　(5)　512-512　2007/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
原発性肺癌切除時の開胸時胸腔内洗浄液におけるCEA-mRNAの検出の意義

佐藤之俊, 小川史洋, 今清水恒太, 矢部三男, 上原浩文, 奥村栄, 中川健, 宮内栄作, 工藤慶太, 堀池篤, 岡野義夫, 大柳文義, 西尾誠人, 宝来威, 須貝幸子, 三木義男, 二宮浩範, 稲村健太郎, 元井紀子, 石川雄一

肺癌　47　(5)　526-526　2007/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
非小細胞肺癌におけるProGRP上昇例の臨床および病理学的検討

工藤慶太, 西尾誠人, 宮内栄作, 岡野義夫, 堀池篤, 大柳文義, 矢部三男, 小川史洋, 今清水恒太, 佐藤之俊, 奥村栄, 元井紀子, 石川雄一, 中川健, 宝来威

肺癌　47　(5)　532-532　2007/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
腎細胞癌肺転移切除例の検討

矢部三男, 小川史洋, 今清水恒太, 上原浩文, 佐藤之俊, 奥村栄, 中川健, 工藤慶太, 宮内栄作, 岡野義夫, 大柳文義, 堀池篤, 西尾誠人, 宝来威, 二宮浩範, 元井紀子, 稲村健太郎, 石川雄一

肺癌　47　(5)　574-574　2007/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
精巣腫瘍肺転移切除例の検討

小川史洋, 今清水恒太, 矢部三男, 上原浩文, 佐藤之俊, 奥村栄, 中川健, 宮内栄作, 工藤慶太, 岡野義夫, 堀池篤, 大柳文義, 西尾誠人, 宝来威, 二宮浩範, 稲村健太郎, 石川雄一

肺癌　47　(5)　575-575　2007/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
肺癌骨転移に対するイレッサの効果

岡野義夫, 西尾誠人, 宮内栄作, 工藤慶太, 小川史洋, 今清水恒太, 矢部三男, 上原浩文, 堀池篤, 大柳文義, 佐藤之俊, 奥村栄, 石川雄一, 中川健, 宝来威

肺癌　47　(5)　631-631　2007/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
カルボプラチン併用療法における血液毒性に対するクレアチニンの影響

堀池篤, 西尾誠人, 工藤慶太, 宮内栄作, 大柳文義, 岡野義夫, 小川史洋, 矢部三男, 今清水恒太, 上原浩文, 佐藤之俊, 奥村栄, 石川雄一, 中川健, 宝来威

肺癌　47　(5)　636-636　2007/10
Publisher: (NPO)日本肺癌学会
ISSN： 0386-9628

eISSN： 1348-9992
長期間の心肺補助循環装置の使用にもかかわらず救命できなかった劇症型心筋炎の一例

中嶋壮太, 遠藤秀晃, 相澤健太郎, 佐藤貴子, 宮内栄作, 武田智, 深堀耕平, 伏見悦子, 高橋俊明, 関口展代, 木村啓二, 林雅人, 齊藤昌宏

秋田県農村医学会雑誌　53　(1)　68-68　2007/07
Publisher: (一財)秋田県農村医学会
ISSN： 0002-368X
Streptococcus oralisが原因と考えられた劇症型連鎖球菌感染症の1例

中村敦, 高橋俊明, 久米正晃, 斎藤良太, 村松聡士, 佐藤広規, 庄田三希子, 中嶋壮太, 村上康司, 相澤健太郎, 佐藤貴子, 宮内栄作, 遠藤秀晃, 深堀耕平, 武田智, 伏見悦子, 関口展代, 西村勇人, 荻原忠, 田畑雅央, 木村啓二, 林雅人

秋田県農村医学会雑誌　53　(1)　70-70　2007/07
Publisher: (一財)秋田県農村医学会
ISSN： 0002-368X
当科で経験した血栓性血小板減少性紫斑病の2例

佐藤広規, 久米正晃, 菅谷岳広, 西村勇人, 小作裕則, 村松聡士, 森田隆弘, 三浦孝行, 庄田三希子, 中村敦, 宮内栄作, 佐藤貴子, 相澤健太郎, 遠藤秀晃, 武田智, 深堀耕平, 田畑雅央, 伏見悦子, 高橋俊明, 関口展代, 荻原忠, 木村啓二, 林雅人

秋田県農村医学会雑誌　53　(1)　71-71　2007/07
Publisher: (一財)秋田県農村医学会
ISSN： 0002-368X
肺癌と鑑別を要したサルコイドーシスの1例

中村敦, 木村啓二, 田畑雅央, 斎藤良太, 村松聡士, 佐藤広規, 庄田三希子, 中嶋壮太, 村上康司, 相澤健太郎, 佐藤貴子, 宮内栄作, 遠藤秀晃, 深堀耕平, 武田智, 高橋俊明, 伏見悦子, 関口展代, 西村勇人, 久米正晃, 荻原忠, 林雅人

秋田県農村医学会雑誌　53　(1)　75-75　2007/07
Publisher: (一財)秋田県農村医学会
ISSN： 0002-368X
18年経過している若年発症の肺腺癌の一例

宮内栄作, 木村啓二, 田畑雅央, 相澤健太郎, 佐藤貴子, 遠藤秀晃, 深堀耕平, 武田智, 西村勇人, 久米正晃, 伏見悦子, 高橋俊明, 関口展代, 荻原忠, 林雅人

秋田県農村医学会雑誌　53　(1)　75-75　2007/07
Publisher: (一財)秋田県農村医学会
ISSN： 0002-368X
検診にて発見された気管支動脈肺動脈瘻(気管支動脈蔓状血管腫)の一例

田畑雅央, 木村啓二, 関口展代, 高橋俊明, 伏見悦子, 武田智, 深堀耕平, 遠藤秀晃, 荻原忠, 久米正晃, 西村勇人, 相澤健太郎, 宮内栄作, 佐藤貴子, 村上康司, 中村敦, 照山和秀, 岩間孝英, 大久保俊治, 林雅人

秋田県農村医学会雑誌　52　(2)　47-47　2007/02
Publisher: (一財)秋田県農村医学会
ISSN： 0002-368X
22歳で発症した肺腺癌の一例

宮内栄作, 木村啓二, 田畑雅央, 相澤健太郎, 佐藤貴子, 遠藤秀晃, 深堀耕平, 武田智, 西村勇人, 久米正晃, 伏見悦子, 高橋俊明, 関口展代, 荻原忠, 林雅人

秋田県農村医学会雑誌　52　(2)　48-48　2007/02
Publisher: (一財)秋田県農村医学会
ISSN： 0002-368X
僧帽弁狭窄、動脈管開存、心室中隔欠損、高度肺高血圧を合併した18トリソミーの1例

宮内栄作, 伊藤忠彦, 多賀谷貴史, 小暮敦史

秋田県農村医学会雑誌　52　(2)　52-52　2007/02
Publisher: (一財)秋田県農村医学会
ISSN： 0002-368X
頸動脈内に血栓を認めたバルサルバ洞破裂の1例

佐藤貴子, 伏見悦子, 相澤健太郎, 宮内栄作, 武田智, 高橋俊明, 関口展代, 林雅人

Circulation Journal　70　(Suppl.III)　1132-1132　2006/10
Publisher: (一社)日本循環器学会
ISSN： 1346-9843

eISSN： 1347-4820
シメジ栽培者に認められた過敏性肺臓炎の一例

木村啓二, 田畑雅央, 白戸崇, 高橋識志, 金澤義丈, 高橋康平, 小澤政豊, 加藤雄平, 佐藤貴子, 中西渉, 宮内栄作, 西村勇人, 竹内雅治, 斎藤公基, 伏見悦子, 高橋俊明, 関口展代, 荻原忠, 林雅人, 高橋さつき, 斎藤昌宏

秋田県医師会雑誌　55　(2)　144-145　2005/05
Publisher: (一社)秋田県医師会
ISSN： 0286-7656
特別養護老人ホームにおける看取りの検討第2報施設内死亡に至る経過と成立の要因

荻原忠, 田畑雅央, 斎藤公基, 宮内栄作, 中西渉, 佐藤貴子, 加藤雄平, 高橋康平, 小澤政豊, 金澤義丈, 白戸崇, 高橋識志, 西村勇人, 竹内雅治, 伏見悦子, 高橋俊明, 関口展代, 木村啓二, 林雅人

秋田県農村医学会雑誌　50　(2)　23-23　2005/02
Publisher: (一財)秋田県農村医学会
ISSN： 0002-368X
反復性多発軟骨炎の1例

白戸崇, 木村啓二, 田畑雅央, 高橋識志, 金澤義丈, 高橋康平, 小澤政豊, 加藤雄平, 佐藤貴子, 中西渉, 宮内栄作, 西村勇人, 竹内雅治, 齋藤公基, 伏見悦子, 高橋俊明, 関口展代, 荻原忠, 林雅人, 高橋さつき, 斎藤昌宏

秋田県農村医学会雑誌　50　(2)　41-41　2005/02
Publisher: (一財)秋田県農村医学会
ISSN： 0002-368X

Show all ︎Show first 5

Books and Other Publications 4

Expert's Choice

2022/03
呼吸器病レジデントマニュアル第6版

医学書院　2021/03
肺癌診療Q&A

中外医学社　2017
腫瘍内科ゴールデンハンドブック

南江堂　2010/07

Research Projects 4

EGFR遺伝子変異陽性非小細胞肺がんにおける薬剤治療耐性メカニズムの検討

Offer Organization: 日本ベーリンガーインゲルハイム株式会社

System: 共同研究

Institution: 日本ベーリンガーインゲルハイム株式会社

2019/12 - 2022/11
Development of new treatment strategy focusing on immunotherapy resistance of lung cancer patients with EGFR mutation

Miyauchi Eisaku

Offer Organization: Japan Society for the Promotion of Science

System: Grants-in-Aid for Scientific Research

Category: Grant-in-Aid for Early-Career Scientists

Institution: Tohoku University

2019/04/01 - 2021/03/31

More details Close

We conducted gut microbiome analysis and metabolome analysis, and metabolome analysis for patients with non-small cell lung cancer. We collected fecal microbiome samples and characterized their gut microbiomes and metabolite status using shotgun metagenomic sequencing. As a result, we found the differences in microbial components between EGFR mutant and wild-type. Besides, we found the presence of different metabolite statuses in EGFR-mutant.
血漿・尿を用いたサルコイドーシスの診断・活動性の指標となる新規バイオマーカーの基盤研究

Offer Organization: GSKジャパン

System: 研究助成

Institution: GSKジャパン

2017/04 - 2018/03
小細胞肺がんの個別化治療の試み

Offer Organization: がん研究推進財団

System: がん研究助成

Institution: 公益財団法人がん研究推進財団

2012/04 - 2013/03

Teaching Experience 6

Graduate School of Dentistry “Special Training Course on Cancer Oral Care” Frontiers of Lung Cancer Treatment　Graduate School of Dentistry, Tohoku University
Bronchoscopy
Lung cancer
Lung cancer
inflammatory lung disease
Lung cancer

Show all Show first 5

Social Activities 10

New evidence in treatment for lung cancer 2022

2022/05/28 - 2022/05/28
リレーフォーライフジャパンみやぎオンラインセミナーFight Back（立ち向かう）「肺がん治療の最新の話題」

2020/09/25 - 2020/09/25
Relay for Life JAPAN Miyagi

2019/08/31 - 2019/09/01
Relay for Life JAPAN Miyagi photo exhibition

2019/08/01 - 2019/09/01
がんアドボケートセミナー（ドリームキャッチャー養成講座第９期）

患者力を高めるためのアドボケート活動

2019/07/07 - 2019/07/07
Lung Cancer Update

2019/06/16 - 2019/06/16
進行がんでもあきらめないでー肺癌免疫療法の最新の話題ー

市民公開講座

2019/02/03 - 2019/02/03
Relay for Life JAPAN Miyagi

2018/09/30 - 2018/09/30
期待が高まる最新の肺癌治療

肺の日市民公開講座

2017/08/01 - 2017/08/01
肺がんの予防と治療の最前線

東北大学病院つながる健康講座 in しろいし（市民公開講座）

2019/06/16 -

Show all Show first 5

Media Coverage 3

リレーフォーライフジャパンみやぎオンラインセミナーFight Back（立ち向かう）

2020/09

Type: Internet
Relay for Life JAPAN in Sendai

Relay for Life JAPAN

2019/08/31

Type: Other
Relay for Life JAPAN in Sendai

Relay for Life JAPAN

2018/09/29

Type: Other